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SUMMARY
12/15-LOX is suspected to be involved in inflammatory disorders such as atherosclerosis but 
the exact mechanism of its action is unclear. Novel esterified products called 12- and 15- 
H(p)ETE-PEs were recently identified in murine macrophages and human monocytes 
respectively, which may at least partially account for the effects of 12/15-LOX (Maskrey et 
al, 2007).
In this thesis the generation and metabolism of 12- and 15-H(p)ETE-PEs was characterised in 
murine macrophages and human monocytes. 12- and 15-H(p)ETE-PEs increased by 15 
minutes following cell activation and were metabolised by three hours. However, endogenous 
12- and 15-HETE-PEs increased then remained stable. Novel lipids believed to be precursors 
of 15-HETE-PEs, called 15-KETE-PEs, were identified in human monocytes. 15-KETE-PEs 
increased by 15 minutes and were metabolised by three hours and may therefore account for 
the temporal generation pattern of 15-H(p)ETE-PEs . [14C] radiolabelled products of 15-LOX 
were generated and characterised in human monocytes. Detection of the [14C] radiolabel in 
activated monocytes suggested that products of 15-LOX may form Michael adducts with 
proteins by three hours post activation. This may account for the 15-KETE-PE decrease in 
time-course samples.
A method was developed to synthesise 15-H(p)ETE-PE standards, to use in a new assay for 
their direct quantification following MS analysis. The 15-HETE-PE standard was also used to 
investigate its pro- versus anti-inflammatory effect on LPS-stimulated human monocytes. 15- 
HETE-PE down-regulated IL-ip, TNF-a, IL-6 and G-CSF generation, suggesting that 
products of 15-LOX are anti-inflammatory in human monocytes. 12-H(p)ETE-PEs were 
externalised in activated WT macrophages, which may be important for cell-cell interactions 
and re-structuring the cell membrane.
EM analysis indicated that 12/15-LOX"7' macrophages have a lysosomal storage disease, 
symptoms included the presence of lysosomal storage bodies, vacuoles and damaged 
mitochondria. This may be caused by detected raised levels of PE, PS, PG and PI 
phospholipids and cholesterol esters in 12/15-LOX'7" macrophages.
The data described herein provides a platform to further investigate the function of esterified 
products generated by 15- and 12/15-LOX.
(v)
ABBREVIATIONS
homozygous knockout (genotype)
A23187 Calcium ionophore
AA Arachidonic Acid
AA-PEs Arachidonyl-phosphatidylethanolamine phospholipids
BDMA Dimethy lbenzylam ine
BEL Bromoenol lactone
BSA Bovine serum albumin
C Carbon
Ca2+ Calcium
CID Collision-induced-decomposition
COX Cyclooxygenase
cpm counts per minute
CREB cAMP response element binding
CRB CREB-bonding protein
DDSA Dodecenyl succinic anhydride
dH20 Distilled water
DICE Differentiation control elements
DMPA Dimyristic phosphatydic acid
DMPC Dimyristic phosphatidylcholine
DMPE Dimyristic phosphatidylethanolamine
DMPG Dimyristic phosphatidylglycerol
DMPS Dimyristic phosphatidyl serine
DNA Deoxyribonucleic acid
DODE 9,12-dioxo-dodecenoic acid
DPPC 1,2-Dipalm itoy l-sn-glycero-3 -phosphochol ine
EET Epoxyeicosatetraenoic acid
ELISA Enzyme-linked immunosorbent assay
EM Electron microscopy
EMS Electrospray mass spectrometry
F (amino acid) Phenylalanine
FBS Foetal bovine serum
Fe2+ Ferrous ion
Fe3+ Ferric ion
G-CSF Granulocyte cell stimulating factor
GM-CSF Granulocyte macrophage cell stimulating factor
GPX Glutathione peroxidase
HEDE Hydoxyeicosadienoic acid
HETE Hydroxyeicosatetraenoic acid
HETE-d8 deuterated hydroxyeicosatetraenoic acid
HETrE Hydroxyeicosatrienoic acid
hnRNPs Heterogeneous nuclear ribonucleoproteins
HODE Hydroxyoctadecadienoic acid
HpODE Hydroperoxyoctadecadienoic acid
HpETE Hydroperoxyeicosatetraenoic acid
H(p)ETE A combination of hydroperoxyeicosatetraenoic acid, hydroxyeicosatetraenoic 
acid and other eicosanoids or lipids that form hydroxyeicosatetraenoic acid 
following reduction.
(vi)
HPLC High performance liquid chromatography
IFNy Interferon-y
IL Interleukin
H Hydrogen
H (amino acid) Histidine
HNE 4- hydroxynonenal
HnRNPs Heterogeneous nuclear ribonucleoproteii
HUVECs Human vein endothelial cells
HxA Hepoxilin
Hz Hertz
I (amino acid) Isoleucine
IFNy interferon-y
i.p. intra peritoneal
JAK Janus kinase
KETE Ketoeicosatetraenoic acid
L (amino acid) Leucine
LA Linoleic acid
LAMP Lysosome associated membrane protein
LBP LPS binding protein
LC Light chain
LOX Lipoxygenase
LPS bacterial lipopolysacchraride
LSD Lysosomal storage disorder
LTA* Leukotriene A4
ltb4 Leukotriene B4
ltc4 Leukotriene C4
ltd4 Leukotriene D4
lte4 Leukotriene E4
LXAt Lipoxin A4
lxb4 Lipoxin B4
Lys Lysine
M (amino acid) Methionine
MAFP Methyl arachidonyl fluorophosphate
MAPK Mitogen-activated protein kinase
mCD4 membrane bound CD4
MCP Monocyte chemotactic protein
M-CSF Macrophage cell stimulating factor
MDA Malondialdehyde
MRM Multi reaction monitoring
mRNA Messenger ribonucleic acid
MS Mass spectrometry
m/z Mass to charge ratio
NFkB Nuclear factor Kappa-B
NMR Nuclear magnetic resonance
NO Nitric oxide
NP-HPLC Normal phase- HPLC
o 2 Oxygen
•OH Hydroxyl radical
OOEPC Oleyloxyethyl phosphorylcholine
(vii)
Ox-PAPE oxidised 1 -palmitoyl-2-arachidonyl-sn-glycero-3 -phosphatidylethanolamine
Ox-PLPC Oxidised 1 -palm itoyl-2-linoleoyl-glycery 1-phosphatidylcholine
Ox-PLs Oxidised phospholipids
P Phosphorus
P450 Cytochrome P450
PA Phosphatidic acid
PACOCF3 Palmityl trifluoromethyl ketone
PC Phosphatidylcholine
PE Phosphatidylethanolamine
PG Phosphatidylglycerol
PI Phosphatidylinositol
PKC8 Protein kinase C8
PLA Phospholipase A
PMNL polymorphonuclear leukocytes
RNA Ribonucleic acid
PPAR Peroxisome proliferator-activated receptor
PS Phosphatidylserine
R (amino acid) Arginine
RAG-2 Recombinase activator gene-2
RANTES Regulated on activation normal T expressed and secreted
RO Alkoxyl radical
RP-HPLC Reverse phase HPLC
SAPE Stearoyl- arachidonyl-phosphatidylethanolamine
STATs signal transducers and activators of transcription
SD Standard deviation
SDS-PAGE Sodium dodecyl sulfate polyacrylamide gel electrophoresis
SE Standard error
S.epi Staphylococcus Epidermidis
SES Staphylococcus Epidermidis supernatant
siRNAs Short interfering ribonucleic acids
TGF Transforming growth factor
TLR Toll-like receptor
TNF Tumor necrosis factor
TYK Tyrosine kinase
UV Ultraviolet
W (amino acid) Tryptophan
WT Wild type
Y (amino acid) Tyrosine
CONTENTS
DECLARATION j
STATEMENT 1 i
STATEMENT 2 i
ACKNOWLEDGEMENTS ii
DEDICATION Hi
PUBLICATIONS iv
ABBREVIATIONS v
CONTENTS ix
LIST OF FIGURES xv
LIST OF SCHEMES xxi
LIST OF TABLES xxiii
CHAPTER 1 - GENERAL INTRODUCTION
1.1 Phospholipids 1
1.2 Lipoxygenase enzymes 6
1.2.1 History and classification o f LOX 6
1.3 Synthesis of 12/15-LOXs 11
1.4 Regulation of 12/15-LOX expression 13
1.5 12/15-LOX structure 16
1.6 Phospholipid and fatty acid oxidation by 12/15-LOX 18
1.6.1 Hydrogen abstraction 20
1.6.2 Oxygen incorporation 23
1.6.3 Product dissociation and suicidal inactivation o f 12/15-LOX 27
1.7 Effects of 12/15-LOX products 28
1.7.1 H(p)ETEs andH(p)ODEs 29
1.7.2 Leukotrienes 31
1.7.3 Lipoxins 31
(ix)
1.7.4 Hepoxilins 32
1.7.5 Oxidised products o f esterified AA 33
1.8 Biological roles of 12/15-LOX 33
1.8.1 LOX and atherosclerosis 34
1.8.2 LOX and cell maturation, differentiation and restructuring o f the cell 36
membrane
1.8.3 LOX and cancer 37
1.8.4 LOX and asthma 37
1.8.5 LOX & inflammation 37
1.9 The synthesis of oxidised phospholipids by 12/15-LOX 39
1.10 Electrospray mass spectrometry 40
CHAPTER 2 -  MATERIALS AND METHODS
2.1 Materials 50
2.1.1 Chemicals 50
2.1.2 General buffers and solutions used 51
2.2 Methods 53
2.2.1 Mass spectrometry analysis 53
2.2.1.1 HETE quantitation by LC/MS/MS 53
2.2.1.2 Phospholipid quantification by LC/MS/MS 54
2.2.2 Synthesis and purification o f 18:0a/15-HETE-PE and 18:0a/15-HpETE-PE 59
2.2.2.1 Structural analysis of compounds by MS 67
2.2.3 Extraction o f lipids 67
2.2.4 Chromatographic analysis o f 18:0a/15-HETE-PE 68
2.2.4.1 Normal phase HPLC-UV of phospholipid classes 68
2.2.4.2 HETE isomer determination 68
2.2.4.3 Chiral analysis of HETE isomers for enantiomer determination 69
2.2.5 NMR 69
2.2.6 Isolation and activation o f human monocytes 69
2.2.6.1 Isolation of monocytes ffom human buffy coats 69
2.2.6.2 Activation of human monocytes to generate LOX-derived esterified and 70
free eicosanoids
(x)
2.2.7 Isolation and activation o f murine macrophages 71
2.2.8 Phospholipid profiling o f WT and 12/15-LOX/' murine macrophages 72
2.2.9 Cholesterol ester profiling in WT and 12/15-LOXmurine macrophages 81
2.2.10 Investigation o f cytokine production in response to 15-HETE-PE 81
2.2.10.1 Generation of DPPC and 15-HETE-PE liposomes 81
2.2.10.2 Cellular uptake of 15-HETE-PE 83
2.2.10.3 Cytokine production by human monocytes in response to LPS and 15- 83 
HETE-PE
2.2.11 Investigating association o f HETE-PEs with proteins 84
2.2.11.1 Generation of radiolabelled HETE-PEs 84
2.2.12 Transmission electron microscopy o f WT and 12/15-LOXcells 86
2.2.12.1 Sample Preparation 86
2.2.12.2 Cutting and sectioning of resin pellets 86
2.2.12.3 Development of EM pictures 87
2.2.13 Statistical Analysis 87
CHAPTER 3- SYNTHESIS. PURIFICATION AND CHARACTERISATION 
OF 18:0a/15-HETE-PE AND 18:0a/15-HpETE-PE
3.1 Introduction 8 8
3.1.1 Method development for the synthesis o f 15-HpETE-PE and 15-HETE-PE 89
3.1.2 Aims 90
3.2 Results 92
3.2.1 Structural characterisation o f 18: Oa/15-HpETE-PE and 18:0a/15-HETE-PE 92
3.2.1.1 UV analysis 92
3.2.1.2 Mass spectrometry analysis 92
3.2.1.3 ' H,31P and l3C NMR analysis of 15-HETE-PE 92
3.2.1.4 Analysis of 15-HETE-PE by chromatographic techniques 97
3.2.2 Product yield o f 15-HETE-PE and 15-HpETE-PE 97
3.2.3 Synthesised 18:0a/15-H(p)ETE-PE standards have the same elution time as 103 
18:0a/15-H(p)ETE-PEs from human monocytes.
3.2.4 Development o f an assay for phospholipid quantification by MS. 103
33 Discussion 109
(xi)
CHAPTER 4- CHARACTERISATION OF 15-HETE-PE METABOLISM
FOLLOWING ACTIVATION OF 15-LOX
4.1 Introduction 114
4.1.1 Aims 115
4.2 Results 116
4.2.1 15-H(p)ETE-PEs increase following monocyte activation and are metabolised 116
by 3 hours following their synthesis.
4.2.2 15-H(p)ETE-PE metabolism does not involve hydrolysis o f 15-H(p)ETE, 116
conversion o f the PE head group to PC or elongation o f 15-H(p)ETE.
4.2.3 Products o f 15-LOX are not all endogenously reduced to 15-HETE-PEs. 128
4.2.4 15-HpETE-PEs are unlikely to be the precursors o f 15-HETE-PEs that are 130
metabolised in time-course samples.
4.2.5 15-KETE-PEs are formedfollowing 15-LOX activation and are metabolised to 130
unknown products.
4.2.6 18:0a/15-HpETE-PE forms 18:0a/15-KETE-PE following its addition to 135
monocytes.
4.2.7 15-KETE-PEs are metabolised to unknown products by three hours following 142
their generation.
4.2.8 15-H(p)ETE-PEs are principally retained by monocytes while free 15- 145
H(p)ETE
is secreted following cellular activation.
43 Discussion 147
CHAPTER S - INCORPORATION OF I14C1 INTO PRODUCTS OF 15-LOX
5.1 Introduction 153
5.1.1 Aims 159
5.2 Results I6 0
5.2.1 Monocytes treated with [i4CJ-ethanolamine hydrochloride generated more 160
[14C] - 7 5-H(p)ETE-PEs, in comparison to monocytes incubated with [I4C]-AA 
or [,4C]-SAPE.
(xii)
5.2.2 [,4C]-treated monocytes generate [uC\-AA-PEs and [uC)-15-H(p)ETE-PEs. 163
5.2.3 [ 14C]-ethanolamine hydrochloride is specifically incorporated into PE 167
phospholipids.
5.2.4 Preliminary investigations support the association o f proteins with [14CJ- 167
radiolabelled lipids synthesised by 15-LOX.
5.2.4.1 [,4C]-radiolabelled lipid products of 15-LOX are likely to covalently bind 169
with
proteins following cell activation.
S3 Discussion 172
CHAPTER 6  - CHARACTERISATION OF ESTERIFIED PRODUCTS 
GENERATED BY MURINE MACROPHAGE 12/15-LOX
6.1 Introduction 17 9
6.1.1 Aims 180
6.2 Results 181
6.2.1 12-H(p)ETE-PEs generated basally are cell-associated in peritoneal lavages. 181
6.2.2 l2-H(p)ETE-PEs increase in activated peritoneal lavages. 181
6.2.3 12-H(p)ETE-PEs are primarily retained by macrophages following cellular 181 
activation.
6.2.4 12S-H(p)ETE is present in the PE phospholipidfraction. 185
6.2.5 12-H(p)ETE-PEs are formed by direct oxidation o f membrane phospholipids. 185
6.2.6 12-H(p)ETE-PEs are metabolised within 3 hours to unknown products. 190
6.2.7 12-H(p)ETE-PEs are externalised in the plasma membrane o f WT 193 
macrophages
following activation.
6  3  Discussion 196
CHAPTER 7 - CELLULAR UPTAKE OF 15-HETE-PE. ITS EFFECT ON
CYTOKINE GENERATION AND ITS SYNTHESIS DURING 
HUMAN BACTERIAL INFECTION
7.1 Introduction 203
(xiii)
7.1.1 Aims 208
12 Results 209
7.2.1 Synthesis o f liposomes containing 15-HETE-PE 209
7.2.2 The addition o f 15-HETE-PE in methanol achieved the largest 214
Incorporation into human monocytes
7.2.3 Incorporation o f 15-HETE-PE into human monocytes is dose-dependent 216
7.2.4 Cytokine generation is dose-dependently reduced by 15-HETE-PE. 216
7.2.5 Levels o f 15-HETE-PEs in control and bacterial-infected human peritoneal 227
lavages are variable.
73 Discussion 230
CHAPTER 8  - ULTRA-STRUCTURAL ANALYSIS AND PHOSPHOLIPID
PROFILING OF PERITONEAL MACROPHAGES FROM WT 
AND 12/15-LOX''' MICE
8.1 Introduction 238
8.1.1 Aims 239
8.2 Results 240
8.2.1 Peritoneal macrophages from 12/15-LOX^ mice show ultra-structural 240
abnormalities consistent with a lysosomal storage disease
8.2.2 Statistical analysis suggests that glycerophospholipidprofiles ofW T and 240
12/15-
LOX' macrophages may account for their structural differences.
8.2.3 Combined levels o f cholesterol esters are higher in 12/15-LOX' peritoneal 244
macrophages.
83 Discussion 253
CHAPTER 9 -  GENERAL DISCUSSION 261
BIBLIOGRAPHY 269
(xiv)
LIST OF FIGURES
Figure 1.1 Structure of glycerophospholipids 2
Figure 1.2 Location of glycerophospholipid hydrolysis by phospholipases 3
Figure 1.3 Metabolism of arachidonic acid 5
Figure 1.4 Scheme of LOX reaction 7
Figure 1.5 AA can be metabolised by LOX to form specific hydroperoxy 9
eicosanoids known as HpETEs 
Figure 1.6 Localisation of human LOX chromosomal genes 10
Figure 1.7 Phylogenetic tree of representative animal LOXs 12
Figure 1.8 Mechanism of 12/15-LOX induced expression by IL-4 and IL-13 14
Figure 1.9 Three dimensional structure and schematic view of rabbit 15-LOX 17
Figure 1.10 12/15-LOX can metabolise esterified and free AA. 19
Figure 1.11 Alignment of arachidonic acid at the 15-LOX active site 21
Figure 1.12 LOX reactions centre on the ability of the iron atom to transfer 22
between a ferrous and ferric and state 
Figure 1.13 Interactions between 12/15-LOX and AA 24
Figure 1.14 Movement of oxygen within rabbit 15-LOX 25
Figure 1.15 Illustration of four hypotheses for oxygenation control in LOX 26
catalysis
Figure 1.16 Signal transduction pathways mediated by H(p)ETEs and 30
H(p)ODEs
Figure 1.17 Precursor scanning identifies four ions, that contain HETE, which 41
are elevated following A23187 activation of human monocytes 
Figure 1.18 Proposed structures for four HETE-containing products of LOX 42
in activated human monocytes 
Figure 1.19 Schematic diagram of a mass spectrometer 44
Figure 1.20 Basic illustration of direct injection (A) and HPLC separation (B) 45
prior to MS analysis
Figure 1.21 Illustration of a Q1 scan (A), product ion spectrum (B) and 46
precursor scanning (C) by MS.
Figure 3.1 Products of SAPE oxidation by LOX have an absorbance maxima 93 
at 235 nm, confirming the presence of a conjugated diene
(xv)
94
95
96
98
99
100
101
102
104
105
106
107
117
118
120
121
124
126
127
129
18:0a/15-HETE-PE and 18:0a/15-HpETE-PE separates from 
SAPE during RP-HPLC
18:0a/l5-HETE-PE was free from contaminants and its structure 
was confirmed
18:0a/15-HpETE-PE was free from contaminants and its structure 
was confirmed 
H NMR of 15-HETE-PE 
I3C-Pendant NMR of 15-HETE-PE 
3,P NMR of 15-HETE-PE 
Synthesised lipid contains only 15-HETE 
Synthesised 15-HETE-PE contains largely 15S-HETE 
Human monocyte 18:0a/15-HETE-PE has the same retention time 
as a 18:0a/l 5-HETE-PE standard.
18:0a/15-HpETE-PE from human monocytes has the same 
retention time as the 18:0a/15-HpETE-PE standard. 
Representative chromatograms of synthesised 15-HETE-PE, 15- 
HpETE-PE and DMPE standards.
Representative standard curve for 15-HETE-PE and 15-HpETE- 
PE.
15-H(p)ETE-PEs are metabolised to unknown products by 3 
hours.
15-H(p)ETE remains stable following synthesis 
15-HETE-dg is not esterified into phospholipids of human 
monocytes
15-H(p)ETE-PEs are not metabolised by PLA2 or PAF-AH 
enzymes
18:0a/15-H(p)ETE-PC standard was successfully synthesised 
Metabolism of 15-H(p)ETE-PE is unlikely to involve conversion of 
the PE head group to PC
Metabolism of 15-H(p)ETE-PE is unlikely to involve chain 
elongation of H(p)ETE
Products of 12/15-LOX are not all endogenously reduced to 15- 
HETE-PE
131
132
133
134
136
137
138
139
140
143
145
146
161
164
165
166
168
171
175
16:0p/15-HpETE-PE is unlikely to be the 16:0p 15-HETE-PE 
precursor that is metabolised by 3  hours.
18:1 p/15-HpETE-PE is unlikely to be the 18:lp 15-HETE-PE 
precursor that is metabolised by 3 hours.
18:0p/15-HpETE-PE is unlikely to be the 18:0p 15-HETE-PE 
precursor that is metabolised by 3 hours.
18:0a/15-HpETE-PE is unlikely to be the 18:0a 15-HETE-PE 
precursor that is metabolised by 3 hours.
LC/MS/MS trace and product ion spectrum of 18:0a/15-KETE-PE 
LC/MS/MS trace and product ion spectrum of 18:0p/15-KETE-PE 
LC/MS/MS trace and product ion spectrum of 18:lp/15-KETE-PE 
LC/MS/MS trace and product ion spectrum of 16:0p/15-KETE-PE 
15-KETE-PEs are generated following activation of 15-LOX 
18:0a/l5-HpETE-PE can be converted to 18:0a/15-KETE-PE by 
monocytes
15-KETE-PEs are not metabolised to 15-HETrE-PEs or di-HETE- 
PEs
15-H(p)ETE-PEs are retained by monocytes following their 
generation while free 15-H(p)ETE is secreted 
Comparison of different strategies used to generate [l4C]-15- 
HETE-PEs
There is no statistical difference in 15-HETE-PE generated by 
activated human monocytes following incubation with and without 
[14C]-ethanolamine hydrochloride
[14C]-AA-PEs are detected following incubation of monocytes with 
[14C]-ethanolamine hydrochloride.
[14C]-15-HETE-PEs are detected in activated monocytes following 
incubation with [14C]-ethanolamine hydrochloride. 
[14C]-ethanolamine hydrochloride is exclusively incorporated into 
the PE phospholipids.
Radiolabelled lipid products of 15-LOX bind with proteins 
following cell activation.
The isolation of proteins using biotinylated-PLPC
182
183
184
186
187
191
192
194
195
201
204
205
207
210
211
212
213
215
217
219
220
Basal 12-H(p)ETE-PEs are cell-associated 
12-H(p)ETE-PEs increase following activation in peritoneal 
lavages.
12-H(p)ETE-PEs are primarily cell-associated following activation 
12-H(p)ETE is the main product in the PE fraction according to 
the peak apex.
12/15-LOX synthesises predominantly 12S-H(p)ETE 
12-H(p)ETE-PEs are formed by direct oxidation of AA-PEs 
12-H(p)ETE-PEs are metabolised by three hours to unknown 
products
Endogenous 12-HETE remains stable following activation 
12-H(p)ETE-PEs are externalised following activation in 
macrophage plasma membrane 
Schematic representation of the lipid whisker model 
12-HETE-PEs decrease in SES peritonitis during inflammation, 
then recover by day 7
12-HETE-PEs decrease in live bacterial peritonitis, but are 
elevated in Ova lung allergy
Liposomes are vesicles of bilayer phospholipids used to transport 
various substances
Confirmation that synthesised liposomes contain DPPC 
Confirmation that synthesised liposomes contain 15-HETE-PE 
Negative and positive product ion spectra confirm peak identity as 
DPPC
Negative product ion spectra confirm peak identity as 18:0a/15- 
HETE-PE
The addition of 15-HETE-PE in methanol resulted in the largest 
incorporation
Incorporation of 15-HETE-PE is dose-dependent
LPS stimulated G-CSF is dose-dependently reduced by 15-HETE-
PE
LPS stimulated IL-ip is dose-dependently reduced by 15-HETE- 
PE
Figure 7.12 
Figure 7.13
Figure 7.14 
Figure 7.15
Figure 7.16
Figure 7.17 
Figure 7.18
Figure 7.19
Figure 8.1 
Figure 8.2
Figure 8.3
Figure 8.4
Figure 8.5
Figure 8 . 6  
Figure 8.7 
Figure 8 . 8
Figure 8.9
LPS stimulated IL- 6  is dose-dependently reduced by 15-HETE-PE 
LPS stimulated TNF-a is dose-dependently reduced by 15-HETE- 
PE
LPS stimulated IL-10 is not specifically reduced by 15-HETE-PE 
IL- 8  generation decreases following the addition 15-HETE-PE to 
unstimulated monocytes
MCP-1 generation decreases following the addition 15-HETE-PE 
to unstimulated monocytes..
RANTES is not affected by the addition of LPS or 15-HETE-PE 
15-HETE-PE may be generated in response to infection by 
particular gram-positive bacteria.
Locations where LPS signaling may be inhibited by oxidised 
phospholipids
EM analysis of WT peritoneal macrophages
Analysis of 12/15-LOX'7' peritoneal macrophages suggests the
presence of LSD
Close inspection of macrophages suggest the presence of LSD in 
12/15-LOX''- mice
Differences between the PE phospholipid profiles of WT and 
12/15-LOX'7' macrophages are significant following ANOVA 
analysis.
Differences between the PC phospholipid profiles of WT and 
12/15-LOX 7' macrophages are significant following ANOVA 
analysis
Differences between the PS phospholipid profiles of WT and 12/15- 
LOX-7' macrophages are significant following ANOVA analysis. 
There are few significant differences between the PI phospholipid 
profiles of WT and 12/15-LOX'7' macrophages.
Differences between the PG phospholipid profiles of WT and 
12/15-LOX'7' macrophages are significant following ANOVA 
analysis.
There are few significant differences between the PA phospholipid 
profiles of WT and 12/15-LOX"7" macrophages.
221
222
223
224
225
226 
228
234
241
242
243
245
246
247
248
249
250
(xix)
Figure 8.10 Differences between the cholesterol ester profiles of WT and 12/15- 252
LOX*7- macrophages are significant following ANOVA analysis.
Figure 8.11 The endocytic pathway, lysosomes and autophagy 254
Figure 8.12 Fragmentation of mitochondria in LSDs 256
(xx)
LIST OF SCHEMES
Scheme 2.1 Structures and m/z of 15-HETE-PEs 55
Scheme 2.2 Structures and m/z of 12-HETE-PEs 56
Scheme 23  Structures and m/z of 5-HETE-PEs 5 7
Scheme 2.4 Structures and m/z of phospholipid standards 58
Scheme 2.5 Structures and m/z of AA-PEs 60
Scheme 2.6 Structures and m/z of 15-HETE-PCs 61
Scheme 2.7 Structures and m/z of 15-HETE-PE following C2H4 elongation 62
Scheme 2.8 Structures and m/z of 15-HpETE-PEs 63
Scheme 2.9 Structures and m/z of 15-KETE-PEs 64
Scheme 2.10 Example structures and m/z of di-HETE-PEs, those shown are of 5, 65 
15- of di-HETE-PEs
Scheme 2.11 Structures and m/z of 15-HETrE-PE 6 6
Scheme 2.12 Structures and m/z of cholesterol esters 82
Scheme 3.1 Method for the synthesis and purification of 15-HpETE-PE and 91
15-HETE-PE
Scheme 3.2 Synthesis of d9-l-steroyl, 2-archidonyl-sn-glycero-3-PC 111
hydroperoxide (-OOH) and alcohol (-OH) internal standards 
Scheme 4.1 Conversion of the phospholipid head group from 122
phosphatidylethanolamine to phosphatidylcholine 
Scheme 4.2 Conversion of the phospholipid head group from 123
phosphatidylethanolamine to phosphatidylserine 
Scheme 4.3 Formation of carbonyl following the decomposition of a peroxyl 141
group
Scheme 4.4 The formation of 15-HpETE by 15-LOX-l 150
Scheme 5.1 Positions in 15-KETE-PE susceptible to nucleophilic attack that 154
form Schiff bases
Scheme 5.2 Positions in 15-KETE-PE susceptible to nucleophilic attack that 155
can form Michael adducts 
Scheme 5.3 Mechanism of imine (Schiff base) formation by reaction of a 156
primary amine group with an aldehyde/ ketone 
Scheme 5.4 Mechanism of Michael adduct formation by reaction of a primary 157
amine group with an a, P-un saturated ketone
(xxi)
Scheme 5.5 Incorporation of [14C]-ethanolamine hydrochloride into 162
phosphatidylethanolamine 
Scheme 6.1 Synthesis of 12-HpETE-PE by direct oxidation 188
Scheme 6.2 Synthesis of 12-HpETE-PE and 12-HpETE-180  -PE by re- 189
esterification of 12-HpETE or 12-HpETE- lsO respectively
(xxii)
LIST OF TABLES
Table 2.1 Parent and daughter m/z and MS conditions for analytes 54
Table 2.2 PE Phospholipid profiling transitions 73
Table 23  PC Phospholipid profiling transitions 75
Table 2.4 PI Phospholipid profiling transitions 77
Table 2.5 PA Phospholipid profiling transitions 78
Table 2.6 PS Phospholipid profiling transitions 79
Table 2.7 PG Phospholipid profiling transitions 80
Table 5.1 Metabolites of AA implicated in the formation of Schiff bases 177
(xxiii)
CHAPTER 1
INTRODUCTION
1.1 Phospholipids
Phospholipids are considered to be the building blocks of cellular membranes, and are present 
in all organisms, including archae-bacteria, plants and humans (Hanahan DJ, 1997, Vance & 
Vance, 2002). They are involved in diverse functions, including compartmentalisation of 
cytoplasm, intercellular adhesion, cytoskeletal support and are precursors of lipids mediators 
(Small DM, 1986, Henson & Murphy, 1989). Among the most abundant phospholipids in 
eukaryotic cells are glycerophospholipids, molecules that consist of a glycerol backbone 
(three carbon sugar), with three functional groups. The first is a phosphate ester group (polar 
head group) by which glycerophospholipids are classified (Figure 1.1). The second and third 
components are either two fatty acids or a fatty acid and an alkyl hydrocarbon (Berg et al, 
2002, Pulfer & Murphy, 2003). The fatty acid present at the snl position can be linked to a 
phospholipid via an acyl, plasmalogen or ether bond, while sn2 fatty acids are attached via an 
acyl bond. A diverse range of fatty acid species can be present at the snl or sn2 positions, all 
of which vary in carbon chain length and degree of un-saturation. Such fatty acids include 
arachidonic acid (AA) and linoleic acid (LA), which are important precursors of many lipid 
mediators. These fatty acids can be cleaved from phospholipids by phospholipases, in 
particular, phospholipase Aj (PLAj) and A2 (PLA2) specifically hydrolyse at the snl and sn2 
positions respectively (Figure 1.2).
In mammals, the sn2 fatty acid is usually polyunsaturated and is therefore prone to oxidation 
by enzymes (Spiteller G, 2006). This results in the formation of biologically active molecules 
(Marathe et al, 1999, Subbanaounder et al, 2000, Murphy RC, 2001). Oxidation of free fatty
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Figure 1.1. Structure of glycerophospholipids. Glycerophospholipids have fatty acyl, 
fatty ether or fatty vinyl ether substituents at snl, a fatty-acyl substituent at sn2, and a 
polar head group at the sn3 position of glycerol (reproduced from Pulfer & Murphy, 
2003, with permission (12/11/2010)).
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Figure 1.2. Location of glycerophospholipid hydrolysis by phospholipases.
Glycerophospholipids are targeted at specific locations for hydrolysis by 
phospholipase enzymes, as indicated. The denoted letters apply to the phospholipase 
classification (adapted from Gunstone et al, 2007, with permission (16/11/2010)).
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acids is carried out by cyclooxygenase (COX), cytochrome P450 (CyP450s) and 
lipoxygenase (LOX) enzymes (Figure 1.3). However, a specific LOX isoform, the 12/15- 
LOX, is reported to oxidise both free and esterified fatty acids (Maskrey et al, 2007). The 
main focus of this work will be oxidised lipid products of 12/15-LOX, in particular, products 
derived from phosphatidylethanolamine (PE) phospholipids that contain AA.
Cellular membranes are composed of bilayers with each leaflet containing a different 
composition of phospholipids. This asymmetric arrangement is integral to membrane 
function (Bevers et al, 1998). The inner leaflet of a bi-layer membrane is highly enriched in 
phosphatidylethanolamine (PE) and phosphatidylserine (PS). Their extemalisation to the 
outer membrane leaflet can alter membrane fluidity and change how a cell is perceived by 
neighbouring cells. Translocation of PS and PE to the outer plasma membrane leaflet of 
macrophages is an important event in apoptosis. Their extemalisation acts as a signal for 
macrophages to carry out phagocytosis and promote programmed cell death in targeted cells 
(Fadok et al, 2001). The types of phospholipid classes present in membranes is important 
since a change in composition has been noted in particular disease conditions such as 
Alzheimer’s (Han et al, 2001). The oxidation of phospholipids by LOX alters the properties 
of a membrane, and is reported to play a role in events such as apoptosis and cell migration 
(Maccarrone et al, 1999 & 2000, Miller et al, 2001). In this thesis, phospholipid products that 
may be responsible for the immunological effects exerted by LOX are characterised and their 
biological effects are investigated.
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Figure 1.3. Metabolism of arachidonic acid. Arachidonic acid (AA) can be metabolised to 
a variety of products by LOX, COX and P450 enzymes to the indicated products 
(reproduced from Murphy et al, 2005, with permission (12/11/2010)).
Abbreviations: COX, Cyclooxygenase; LOX, lipoxygenase; Cyp450, cytochrome P450; 
HpETE, hydroperoxyeicosatetraenoic acid; HETE, hydroxyeicosatetraenoic acid; KETE, 
ketoeicosatetraenoic acid; PG, prostaglandin; TX, thromboxane; LT, leukotriene; LX, 
lipoxin; EET, epoxyeicosatetraenoic acid; HETrE, hydroxyeicosatrienoic acid.
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1.2 Lipoxygenase enzymes
LOXs are a class of non-heme iron enzymes that stereo-specifically incorporate molecular 
oxygen onto the carbon chain of esterified or free polyunsaturated fatty acids (Brash AR,
1999, Kuhn et al, 2002, Feussner & Wastemack, 2002, Furstenberger et al, 2006). Oxidation 
by LOX is bimolecular, requiring the presence of both oxygen and a fatty acid or lipid 
substrate (Kuhn & O’Donnell, 2006). This reaction consists of three key steps (Figure 1.4): 
firstly, hydrogen is abstracted from a particular carbon (determined by the isoform of LOX), 
followed by delocalisation of the radical. Next, oxygen is inserted, which forms a peroxyl 
radical then the fatty acid is reduced, forming a peroxide (Kuhn & O’Donnell, 2006). This 
process is described in greater detail in Section 1.6.
1.2.1 History and classification o f LOX
LOX enzymes have been identified in a variety of organisms, including higher animals, 
plants, lower marine life forms and a small number of bacteria (Hawkins & Brash, 1987, 
Brash et al, 1996, Grechkin A, 1998, Kuhn & Thiele, 1999, Porta & Rocha-Sosa, 2001, 
Vance et al, 2001). Only three bacterial microbes have been found to contain genes encoding 
LOX, namely, Pseudomonas aeruginosa, Anabaena (cyanobacterium) and Nitromonas 
europaea (chemolithoautotroph). In addition, Nostoc punctiforme (cyanbacterium) and 
Sorangium cellulosum (soil bacterium) contain LOX-like sequences (Porta & Rocha-Sosa, 
2001, Zheng et al, 2008). As so few bacteria contain genes for LOX, their presence may be 
the result of horizontal gene transfer from eukaryotic microorganisms (Porta & Rocha-Sosa, 
2001). However, basic eukaryotes such as yeast (e.g. Sacharomyces cerevisiae) do not 
contain genes for LOX, suggesting that these enzymes were introduced at later stages of 
organism evolution, followed by horizontal transfer to bacteria (Kuhn & O’Donnell, 2006).
Abstraction of hydrogen
H
Insertion of oxygen
Figure 1.4. Scheme of LOX reaction. LOXs are lipid peroxidising enzymes that 
stero- and regio-specifically incorporate molecular oxygen into the hydrocarbon 
chain of polyunsaturated fatty acids. The reaction consists of three key steps as 
indicated (adapted from Kuhn & O’Donnell, 2006, with permission (06/12/2010)).
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Much of the knowledge regarding the structure and enzymatic mechanism of LOX is derived 
from studies investigating soybean LOX-1, some of which date back to the 1940s (Theorell et 
al, 1947, Kuhn et al, 2002). At first, LOX was thought not to exist in animal cells. However, 
in 1974, experiments showed that 12-HETE was formed following the incubation of AA with 
human platelets, marking the discovery of mammalian LOX (Hamberg & Samuelsson, 1974). 
This was followed by detection of a rabbit reticulocyte LOX which was purified for 
characterization and biological studies (Schewe et al, 1975, Rapoport et al, 1979).
Currently, LOXs are categorized according to the position that oxygen is incorporated in one 
of their primary substrates, AA, forming hydroperoxyeicosatetraenoic acid (HpETE) (Figure 
1.5) (Kuhn & Thiele 1999, Cathcart & Folcik, 2000, Walther et al, 2001, Kuhn & O’Donnell, 
2006, Mahipal et al, 2007). The LOX isoforms present in mammals include: 5-LOX, 8 -LOX, 
12-LOX and 15-LOX (Kuhn & O’Donnell, 2006). This method of classification has become 
more complicated as the same peroxide products are generated by several isoforms of 
mammalian LOX, which are encoded by different genes and are expressed in different cell 
types (Figure 1.6) (Schewe et al, 1986, Kuhn & O’Donnell, 2006). For example, in humans 
there are two isoforms of 15-LOX, a leukocyte/reticulocyte 15-LOX (15-LOX 1) and an 
epidermal type (15-LOX2) (Schewe et al, 1975, Brash et al, 1997). In this case, the method 
of classification used above is misleading, as while both enzymes produce the same products, 
their phylogenetic relatedness is low (Bryant et al, 1980). Indeed, the sequence homology of 
15-LOX1 bears a greater similarity to the murine leukocyte 12S-LOX (12/15-LOX) (85% 
homology) than to 15-LOX2 (35% homology) (Brash AR, 1997, Kuhn & O’Donnell, 2006). 
There are also four isoforms of murine 12-LOX enzymes. As with the 15-LOXs, leukocyte 
12S-LOX bears little phylogenetic relatedness to the platelet type 12S-LOX (58-65%
8
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15-LOX
OOH
12-HpETE 15-HpETE
Figure. 1.5. AA can be metabolised by LOX to form specific hydroperoxy eicosanoids known as HpETEs. Individual LOX 
isomers are denoted according the location of oxygen insertion on AA (blue). The red arrows indicate the location of hydrogen 
abstraction (reproduced from McGinley & van der Donk, 2003, with permission (16/11/2010)).
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Figure. 1.6. Localisation of human LOX chromosomal genes. All human LOX genes 
(except for 5-LOX) lie on the short arm of chromosome 17. Multiple genes for LOX 
may be a consequence of gene duplication. The genes most closely related in terms of 
sequence homology lie closest to one another (reproduced from Kuhn & O’Donnell, 
2006, with permission (06/12/2010)).
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homology) or to the epidermal 12S- and 12R-LOXs (Chen et al, 1994, Brash et al, 1997). 
Therefore, a second method of classification has been proposed where mammalian LOXs are 
sorted according to their phylogenetic relatedness, rather than position of AA peroxidation 
(Kuhn & Thiele, 1999). According to this system of classification, there are four LOX sub­
families: leukocyte 12/15-LOXs, 5-LOXs, platelet-type 12-LOX and the epidermal type 
LOXs (Kuhn & Thiele, 1999, Kuhn & O’Donnell, 2006). In addition to the murine 12-LOX 
and human 15-LOX found in leukocytes, functionally equivalent leukocyte 12/15-LOXs have 
been identified in rats (12-LOX), pigs (12-LOX) and rabbits (15-LOX), and all share a high 
degree of phylogenetic relatedness (Figure 1.7) (Yoshimoto et al, 1991, Watanabe et al, 
1993, Chen et al, 1994, Kuhn & Thiele, 1999). In humans, there is no gene for leukocyte 12- 
LOX, however, genes for leukocyte 15-LOX and 12-LOX have been identified in rabbits. As 
the sequence of both enzymes bear a high degree of sequence homology, it is likely that they 
have evolved as a result of gene duplication (Berger et al, 1998, Kuhn et al, 2002).
1.3 Synthesis of 12/15-LOXs
12/15-LOX is constitutively expressed by resident peritoneal macrophages in mice, while 
human 15-LOX 1 is expressed by immature red blood cells, eosinophils, airway epithelial 
cells and mast cells derived from the umbilical cord blood (Sigal et al, 1988, Nadel et al, 
1991, Heydeck et al, 1998, Conrad DJ, 1999, Gulliksson et al, 2007). In addition, low 
expression of 15-LOX 1 has been reported in alveolar macrophages, polymorphonuclear 
leukocytes, atherosclerotic lesions, vascular cells, the uterus and in the male reproductive 
system (Valone et al, 1980, Shannon et al, 1991, Natarajan et al, 1993 & 2002, Cheon et al, 
2002, Sutovsky et al, 2004, Kuhn & O’Donnell, 2006). Alternatively, particular cell types
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Figure 1.7 Phylogenetic tree of mammalian LOXs. LOXs were sorted according to 
their phylogenetic relatedness tree (reproduced from Brash AR, 1999, with permission 
(12/ 11/2010)).
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can be induced to express 12/15-LOX. For example, leukocytes such as peripheral blood 
monocytes (human or mouse) do not express 12/15-LOX, however, expression is induced 
following treatment with interleukin-4 (IL-4) or IL-13 (Conrad et al, 1992, Levy et al, 1993, 
Heydeck et al, 1998, Chaitidis et al, 2005). Similarly, 15-LOX 1 is up-regulated by this 
method in a human lung carcinoma cell line, A549 (Conrad et al, 1992, Brinckmann et al,
1996). In contrast, several prominent human (Mono-Mac-6 , THP 1 , U937, HL-60) and 
murine (J774A.1, P388.DI) monocytic cell lines do not express 12/15-LOX following 
treatment with IL-4 (Brinckmann et al, 1996).
1.4 Regulation of 12/15-LOX expression
Several aspects of the signalling cascade leading to the expression of 12/15-LOX have been 
identified. This process is initiated by IL-4 and IL-13, via the IL-4/IL-13 receptors 
(Brinckmann et al, 1996). The receptor complex for IL-4 has two sub-units, IL-4Ra and IL- 
4Ry, while IL-13 binds to a receptor complex containing IL-13Ral and IL-4Ra (Figure 1.8) 
(Aman et al, 1996, Letzelter et al, 1998, Ogata et al, 1998, Nelms et al, 1999, Roy et al, 
2002, Kuhn & O’Donnell, 2006). The binding of IL-13 and IL-4 to their respective receptor 
complexes results in auto-phosphorylation of members of the janus kinase (JAK) family, 
JAK2 and TYK2, which are bound to IL-4Ra and IL-13Ral respectively (Musso et al, 1995, 
Murata et al, 1996, Brinckmann et al, 1996, Roy & Cathcart, 1998, Nelms et al, 1999, Roy et 
al, 2002). Once phosphorylated, the JAK proteins in turn phosphorylate the receptor chains to 
which they are attached (Ihle et al, 1994, Kuhn et al, 2002). This leads to recruitment of 
signal transducers and activators of transcription (STATs), specifically STAT6  for IL-4 and 
STAT proteins la, 3, 5A, 5B or 6  for IL-13 (Heydeck et al, 1998, Cathcart & Folcik, 2000, 
Kuhn et al, 2002, Roy et al, 2002, Bhattachaijee et al, 2006). JAKs then phosphorylate a
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Figure 1.8. Mechanism of 12/15-LOX induced expression by IL-4 and IL-13. In
response to the binding of IL-4 (A) and IL-13 (B) to their receptor complexes, JAK kinases 
(JAK2 and TYK2) autophosphorylate, followed by phosphorylation of the receptor chains 
and further signalling by STATs. The signalling cascade is made up of three steps: (1) 
Phosphorylation of STATs, leading to their activation; (2) Acetylation of activated STATs 
and nuclear histones; (3) Binding of STAT dimers to DNA promoter regions, activating 
transcription of 12/15-LOX (adapted from Roy et al, 2002, and Kuhn & O’Donnell, 2006, 
with permission (06/12/2010)). 14
tyrosine residue in the C-terminal of STATs, allowing STATs to form hetero/homo-dimers 
(Ihle et al, 1994, Roy et al, 1998). STATs then translocate to the nucleus and are acetylated 
by activated histone acetyl transferase CREB-binding protein (CBP/p300) (Conrad et al, 
1992, Ihle et al, 1994, Roy et al, 1998, Kamitani et al, 2001). Simultaneously, nuclear 
histones are also acetylated, which de-masks the DNA promoter sequence for 12/15-LOX, 
allowing STATs to bind and activate gene transcription (Conrad et al, 1992, Heydeck et al, 
1998, Conrad & Lu, 2000, Kamitani et al, 2001, Shankaranarayanan et al, 2001, Xu et al, 
2003). Other regulatory elements are involved in the activation of 15-LOX, for example, 
following cell induction by IL-13, P38 MAPK is up-regulated, which mediates the 
phosphorylation of STATI and STAT3 (Xu et al, 2003). Protein kinase C5 (PKC5) and PI3- 
kinase are also involved in this process and are required for the activation of 15-LOX (Xu et 
al, 2003 & 2004, Coffey et al, 2004, Battachaijee et al, 2006).
Studies involving STAT6 '7' and recombinase activator gene-2‘7‘ (RAG-2 7 ) mice indicate that 
IL-4 and IL-13 may not be the only cytokines capable of inducing 12/15-LOX production in- 
vitro (Sendobry et al, 1991, Heydeck et al, 1998). Therefore, many cytokines have been 
investigated in terms of their ability to induce 12/15-LOX expression. It is not up-regulated 
by IL-6 , IL-10, interferon-y (IFNy) or granulocyte macrophage-cell stimulating factor (GM- 
CSF) (Conrad et al, 1992, Chaitidis et al, 2005). Studies investigating the tissue expression of 
murine 12/15-LOX have shown that it is primarily generated by peritoneal macrophages, 
with little or no expression in macrophages from other locations (Huo et al, 2004). This 
suggests that 12/15-LOX is selectively up-regulated following the entry of peripheral 
monocytes into the peritoneum (Kuhn & O’Donnell, 2006). A potential cytokine involved in 
this process, and is therefore implicated in the induction of 12/15-LOX is fractalkine
15
(CX3CR1), which can trigger migration and differentiation of monocytes to resident 
peritoneal macrophages (Geissmann et al, 2003).
The activity of human 15-LOX1 is under strict regulation, albeit post-transcriptional, and/or 
post-translational (Kuhn et al, 1999b). Post-translational regulation of 15-LOX has been 
reported in young rabbit reticulocytes where the messenger ribonucleic acid (mRNA) of 15- 
LOX is expressed but no functional enzyme is present (Thiele et al, 1982). Similarly, mRNA 
of 15-LOX 1 is expressed in human vein endothelial cells (HUVECs) following treatment 
with IL-4, however, no protein is detected (Lee et al, 2001b). Such negative regulation has 
been shown in-vitro by differentiation control elements (DICE), which bind to repetitive 
sequences in the 3’ translational region of 15-LOX mRNA, thus preventing translation 
(Ostareck-Lederer et al, 1994). In addition, regulatory proteins such as heterogeneous nuclear 
ribonucleoproteins (hnRNPS) K and Ei and short interfering RNAs (siRNAs) can prevent 
translation of 15-LOX (Ostareck et al, 1997, Li et al, 2005). 15-LOX is also regulated post- 
translational ly by nitric oxide (NO), which is believed to interact with the catalytic iron 
center of LOX (Wiesner et al, 1996, Holzhtttter et al, 1997). Furthermore, the association of 
15-LOX to the membrane is dependent on calcium (Brinckmann et al, 1998).
1.5 12/15-LOX structure
The crystal structure of rabbit reticulocyte-type 15-LOX was completed to a resolution of 2.4 
A in 1997, seven years after its crystallization (Figure 1.9) (Sloane et al, 1990, Gillmor et al,
1997). The amino acid sequences of mammalian and plant LOXs are somewhat different, 
however, the 3D structures of the two enzyme types bear a close resemblance (Gillmor et al, 
1997, Kuhn et al, 2005). Rabbit 15-LOX is a 75 kDa fatty acid made up of a single 
polypeptide chain folded into two domains (Kuhn et al, 1993, Carrol et al, 1993, Gilmor et
16
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Figure 1.9. Three dimensional structure and schematic view of rabbit 15-LOX. (A) The
3D structure of rabbit 15-LOX shows the N-terminal (3-barrel domain (yellow); Non-heme 
iron (dark yellow); catalytic domain (green), amino acids 210, 211, 601, 602 and 177-187 
have not been defined (white). (B) A schematic view of rabbit 15-LOX, its shape resembles 
an elliptic cylinder (reproduced from Gillmor et al, 1997 and Kuhn et al, 2005, with 
permission, 04/12/2010)). 1 7
al, 1997). The N-terminus (110 amino acids) consists of two four-stranded anti-parallel 13- 
sheets that interfaces with two long helices of the C-terminus via a peptide (amino acids 1 1 1 - 
124) (Gillmor et al, 1997, Kuhn et al, 2005). Within the C-terminus (550 amino acids), is a 
catalytic domain containing 18 helices, separated by a small (3-sheet sub-domain (Gillmor et 
al, 1997, Kuhn et al, 2002, Kuhn O’Donnell, 2006). The overall shape is an elliptical 
cylinder, with a boot shaped substrate binding cleft that is accessible from the protein surface 
(Figure 1.9B) (Gillmor et al, 1997, Kuhn et al, 2005). The catalytic domain contains the non­
heme iron and at its core are two long helices where particular residues take on a 7t-helix 
conformation (residues 360-366 and 537-543) (Gilmor et al, 1997). Within the 7c-helixes are 
four of the six ligands that associate with iron, namely, H361, H366, H541 and H454. The 
fifth is 1663 which resides in the C-terminal and the sixth (required for Fe3+ state) is a water 
molecule (Minor et al, 1996, Gilmor et al, 1997). The ferric centre and its associated ligands 
are pivotal for enzyme activity. Specifically, the changeable ionisation state of iron, from 
Fe2+ to Fe3+ is central to the ability of LOX to carry out hydrogen abstraction (McGinley & 
van der Donk, 2003, Kuhn et al, 2005).
1.6 Phospholipid and fatty acid oxidation by 12/15-LOX
12/15-LOX, induced by IL-13 and/or IL-4, remains predominantly dormant in cells as
product generation requires direct activation of the enzyme (Kuhn & O’Donnell, 2006).
When cells are treated with A23187, 12/15-LOX translocates from the cytosol to intracellular
membranes, to metabolise phospholipids or free fatty acids liberated by PLA2 (Figure 1.10)
(Brinckmann et al, 1998, Christmas et al, 1999, Miller et al, 2001, Coffey et al, 2004, Kuhn
et al, 2005, Maskrey et al, 2007). Following activation, LOX becomes associated with the
plasma membrane, via calcium-dependent mechanisms (Maccarrone et al, 2001). During this
process, both electrostatic and hydrophobic interactions take place between the hydrophobic
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Figure 1.10 15-LOX can metabolise esterified and free AA. Increases in [Ca2+] 
result in translocation of 15-LOX to cellular membranes, where it metabolises free 
and esterified AA . The same mechanism also applies to 12/15-LOX where AA is 
oxidised at C-12.
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tail of a fatty acid and particular amino acids exposed in the binding pocket of LOX (Y15, 
F70 and L71) (Walther et al, 2002 & 2004, Kuhn & O’Donnell, 2006). Site directed 
mutagenesis studies have shown that specific amino acids are sequence determinants of 
membrane binding, namely, Y15, F70 and L71 (located in the p-barrel domain of the N- 
terminal) and W181 and LI95 (in the catalytic domain) (Walther et al, 2002 & 2004, Kuhn et 
al, 2005). Structural studies suggest that there are two calcium binding sites on the enzyme, 
one in the p-barrel domain of the N-terminus, and the second in the catalytic domain (Kuhn et 
al, 2005). Calcium is also thought to increase substrate binding by promoting the formation 
of salt-bridges between acidic amino acids on the surface of 12/15-LOX and the negatively 
charged phospholipid head group (Rapoport et al, 1982, Walther et al, 2002 & 2004, Kuhn et 
al, 2005). A fatty acid substrate enters the active site with its methyl group, once inside the 
binding cleft, substrate alignment is aided by hydrophobic interactions between the methyl 
group and amino acids F353, 1418 and 1593 (Figure 1.11) (Kuhn et al, 1990, 1999 & 2002, 
Sloane et al, 1991, Chen & Funk, 1993, Gan et al, 1996, Bomgraber et al, 1996 & 1999, 
Funk & Loll, 1997, Gillmor et al, 1997). This is also facilitated by ionic interactions between 
R403 and the substrate carboxyl group (Kuhn et al, 2002 & 2005, Gan et al, 1996, Gilmor et 
al, 1997). Studies involving site directed mutagenesis have indicated that particular residues 
are important in the activity and mechanism of LOX. For example, substitution of R403 for 
an uncharged amino acid decreases catalytic activity (Gan et al, 1996). Furthermore, in rabbit 
15-LOX, the side chains of F353, 1418, M419 and 1593 dictate the depth of the substrate 
binding pocket and thus determine where the fatty acid is oxidised (Figure 1.11) (Sloane et 
al, 1990 & 1991, Bomgraber et al, 1996 & 1999, Kuhn et al, 2000 & 2005, Feussner & 
Wastemack, 2002, Kuhn and O’Donnell, 2006).
1.6.1 Hydrogen abstraction
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Figure. 1.11 Alignment of arachidonic acid at the 15-LOX active site. The
methyl end enters first and interacts with 1418,1593 and F353 while the carboxyl 
terminal interacts with R403 (reproduced from Kuhn et al, 2002, with 
permission (04/12/2010)).
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Figure 1.12. LOX reactions centre on the ability of the iron atom to transfer 
between a ferrous and ferric and state. Following enzyme activation, the non­
heme iron becomes oxidised to a ferric state (Fe3+). Hydrogen abstraction from AA 
reduces the iron, to the ferrous form (Fe2^ . Loss of hydrogen associated with Fe2+ 
results in a return of iron to a ferric state, in preparation for another round of enzyme 
activity (reproduced from McGinly & van der Donk, 2003, and Kuhn & O’Donnell, 
2006, with permission (12/11/2010 and 04/12/2010).
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Raised intracellular [Ca2+] and low levels of basally generated HpETEs are required for LOX 
activation, which involves the oxidation of the ferrous iron (Fe2+) within LOX, to the ferric 
(Fe3+) form (Figure 1.12) (Scarrow et al, 1994, Coffey et al, 2004, Schneider et al, 2007, 
Conrad et al, 1992). This is the catalytically active species that can abstract hydrogen from 
unsaturated lipids. Initially, hydrogen is abstracted from a methylene located at C-13 or C-10, 
to form 15-HpETE and 12-HpETE respectively (Kuhn et al, 1990 & 2005, Walther et al, 
2001). Removal of hydrogen produces a free radical, oxygen is then added regio-selectively, 
forming a peroxyl radical on the opposite side of the fatty acid substrate, which is finally 
reduced to a hydroperoxide (Figure 1.12) (Maas & Brash, 1983, Rickert & Klinman, 1999, 
Kuhn et al, 2005, Schneider et al, 2007). The abstraction of hydrogen from a bisallylic 
methylene is the rate limiting step of oxidation by 12/15-LOX (Egmond et al, 1973). If the 
catalytic iron is located between two bisallylic methylene groups, hydrogen abstraction is 
possible from two locations, such dual specificity makes 12/15-LOX unique from other LOX 
isoforms (Figure 1.13) (Bryant et al, 1982, Kuhn et al, 1990 & 2005, Walther et al, 2001).
1.6.2 Oxygen incorporation
The specificity of oxygen incorporation is, in part, dependent on the location of the bisallylic
methylene from the methyl end of the fatty acid (Hamberg & Samuelsson, 1967, Kuhn et al,
1990a). However, the mechanism by which molecular oxygen is incorporated is yet to be
fully characterised. Kinetic studies have concluded that oxygen is not bound to the iron of
12/15-LOX prior to the initial abstraction of hydrogen (Knapp & Klinman, 2003, Schneider
et al, 2007). Furthermore, free diffusion of oxygen into the active site is unlikely, because of
the high degree of stereo-selectivity and the depth and hydrophobic nature of the substrate
pocket (Figure 1.14) (Kuhn et al, 2005). There are several hypotheses speculating on the
nature of how oxygenation is carried out by LOX. The first is via steric shielding, where the
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Figure 1.13 Interactions between 12/15-LOX and AA. (A) The binding forces involved contributing to substrate 
alignment: (i) hydrophobic interactions between amino acid side chains of 15-LOX and the substrate (double ended 
arrows), (ii) ionic interactions between R403 of LOX and the substrate carboxyl-terminal, and (iii) 7t-electron interactions 
between the aromatic residues of 15-LOX and double bonds within the substrate. (B) The alignment of substrates at the 
active site of 12-, 15- and 12/15-Lipoxygenase (Reproduced from Kuhn et al, 2005, with permission (04/12/2010)).
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Figure 1.14 Movement of oxygen within rabbit 15-LOX. The suspected path of 
oxygen diffusion was studied by the use of MD simulation experiments. The yellow 
dots represent the path that oxygen is thought to take if entering the enzyme by 
diffusion, from the enzyme surface to the active site. The non-heme iron is green and 
the oxygen is represented by the red double spheres (Reproduced from Kuhn et al, 
2005, with permission (04/12/2010)).
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Figure 1.15. Illustration of four hypotheses for oxygenation control in LOX catalysis. (A)
Steric shielding: All parts of the substrate are blocked, apart from the reactive center of the 
pentadiene radical. (B) Oxygen channeling: oxygen is directed from the outside to the 
pentadiene radical. (C) Selective peroxyl radical trapping: oxygen can react at all sites of the 
pentadiene; A hydrogen donor is strategically placed and traps the desired product by reducing, 
forming a hydroperoxide. (D) Radical localization: oxygen is induced by the enzyme to rotate 
around a carbon bond. It becomes trapped, leaving one carbon to react with oxygen 
(Reproduced from Schneider et al, 2007, with permission (12/11/2010)).
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structure of LOX restricts the accessibility of the fatty acid to particular areas within the 
binding pocket (Figure 1.15 A). As a targeted methylene is rotated towards the iron during 
hydrogen abstraction, the face of the fatty acid may be hidden and confined. Therefore, 
oxygen stored in a pocket within the active site is incorporated onto the opposite face to 
hydrogen abstraction, forming a peroxyl radical (Gilmor et al, 1997, Schneider et al, 2007). 
The existence of an oxygen channel leading molecular oxygen directly from the cytoplasm to 
the site of oxygenation has also been suggested, which would ensure positional specificity 
during incorporation (Figure 1.15 B) (Schneider et al, 2007). However, research investigating 
the structure of LOX has not shown that such a channel exists (Boyington et al, 1993, Minor 
et al, 1996, Gillmor et al, 1997, Knapp et al, 2001, Kuhn et al, 2005). Rather than stereo­
selectiveness being dependent on oxygen insertion, in an alternative hypothesis the peroxyl 
radical is trapped following interactions with a hydrogen donor that has been strategically 
placed by LOX. As a result, only the ‘trapped’ product can be reduced to the hydroperoxide 
(Figure 1.15 C) (Schneider et al, 2007). Lastly, in a process named radical localization, the 
radical is rotated by the enzyme and forced around a particular carbon bond where it is 
trapped, leaving only one carbon for oxygen to react with (Figure 1.15 D) (Schneider et al, 
2007). For the latter hypothesis, the peroxyl group would travel on and off ‘incorrect’ carbons 
before arriving at the correct location. This is therefore unlikely because of the time involved 
for it to take place. However, this process may be important in keeping the peroxyl group 
trapped at a selected location for the formation of the hydroperoxide (Schneider et al, 2007).
1.6.3 Product dissociation and suicidal inactivation o f 12/15-LOX
Following the metabolism of fatty acids, LOXs undergo suicidal inactivation (Hartel et al,
1982, Kim et al, 1989). This was believed to occur following oxidation of a particular
methionine residue by the hydroperoxy products. However, site directed mutagenesis of this
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methionine does not prevent inactivation (Rapoport et al, 1984, Gan et al, 1995). In rabbit 
15-LOX, this process may be accompanied by covalent linkage of reaction intermediates 
(Rapoport et al, 1984, Schneider et al, 2007, Kishimoto et al, 1996, Weisner et al, 2003, Zhu 
et al, 2003).
1.7 Effects of 12/15-LOX products
LOXs are multifunctional enzymes, having hydroperoxide, leukotriene, lipoxin and hepoxilin 
synthase activities. Human and mouse 12/15-LOXs have a broad range of substrates as they 
can metabolise AA, LA, phospholipids, cholesterol esters, mono-, di- and tri-acylglycerols 
(Kuhn et al, 2002, Arai et al, 1997, Maskrey et al, 2007). Furthermore, rabbit and murine 
12/15-LOX and can oxidise bio-membranes and lipoproteins but so far, this has only been 
shown in-vitro (Schewe et al, 1975, Harkewicz et al, 2008).
The primary activity of LOX is oxygenation, producing hydroperoxy conjugated diene lipids. 
AA is a major substrate for this reaction, resulting in the formation of HpETEs (Figure 1.5), 
alternatively, oxidation of LA produces hydroperoxyoctadecadienoic acid (HpODEs). 
Hydroperoxides can undergo secondary decomposition by homolytic cleavage of the peroxy 
group, forming alkoxyl (RO#) and hydroxyl (*OH) radicals (Nunez-Delicado et al, 1996). 
Self-rearrangement, or reactions with nearby bio-molecules result in the formation of more 
stable secondary peroxidation products, such as alkanes, short chain aldehydes and keto- 
dienes (Salzmann et al, 1984, Glasgow et al, 1986, Yokoyama et al, 1986). Alternatively, a 
rapid reduction of peroxides by glutathione peroxidases (GPXs) forms the corresponding 
hydroxyl group, for example, HETEs and HODEs, for AA and LA, respectively (Ursini et al, 
1995). Hydroperoxides can also be further metabolised, for example 5- and 12/15-LOX can 
convert 5-HpETE and 15-HpETE respectively, to 5,6- and 14,15-epoxy leukotrienes (Figure
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1.3) (Bryant et al, 1985, Denis et al, 1991). These compounds can then be used as substrates 
for the synthesis of more biologically relevant leukotrienes (Denis et al, 1991). Many 
metabolites of LOX are biological mediators and are implicated in inducing gene expression 
by activating transcription factors e.g. the mitogen-activated protein kinase (MAPK) family, 
nuclear factor-icB (NFkB), c-jun and the peroxisome proliferator-activated receptor (PPAR) 
family (Brash AR, 1999, Middleton et al, 2005, Huang et al, 1999). The effects of particular 
products generated by LOX are described below.
1.7.1 H(p)ETEs and H(p)ODEs
H(p)ETEs and H(p)ODEs have been implicated in signalling events such as 
neurotransmission, cell adhesion, differentiation and survival (Piomelli et al, 1987, Tang et 
al, 1996, Yu et al, 1995, Tang & Honn, 1994). They have regulatory properties in several cell 
types, affecting cell adhesion, proliferation, chemotaxis and DNA synthesis (Patricia et al, 
2001, Rao et al, 1994, Reddy et al, 2002, Hedrick et al, 1999, Natarajan et al, 1994, Wen et 
al, 1996). H(p)ETEs and H(p)ODEs regulate these events via PKC, PPARy, PPAR8 , 
MAPKs, CREB, Ras translocation and G-coupled receptors (Figure 1.16) (Beckman JS, 
1990, Liu et al, 1994, Lie et al, 1995, Wilson et al, 1996, Huang et al, 1999, Hsi et al, 2001, 
Shureiqi et al, 2003). 13-HODE and 15-HETE also have chemotactic properties, resulting in 
recruitment of leukocytes, thus propagating inflammatory processes (Higgs et al, 1981, 
Schwenk et al, 1992). However, the anti- versus pro-inflammatory nature of these products 
has not been fully determined, 15-HpETE for example, displays pro-inflammatory properties 
in rabbit skin but has also been reported to down regulate the synthesis of pro-inflammatory 
cytokines, such as TNF-a (Higgs et al, 1981, Fermnte et al, 1997, Ferrante & Ferrante, 2005).
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Figure 1.16 Signal transduction pathways mediated by H(p)ETEs and 
H(p)ODEs. 15-HETE can activate PPARy, however, 13-H(p)ODEs can inhibit 
PPARy via MAP kinase phosphorylation. 15-HETE can also activate MAP 
kinases, Ras, CREB and PKC intracellular signaling pathways (adapted from 
Kuhn & O’Donnell, 2006, with permission, (06/12/2010)).
The effect of esterified 15-HETEs on cytokine generation will be investigated in work for this 
thesis.
1.7.2 Leukotrienes
Leukotrienes are products of 5-LOX that differ from HpETEs and HpODEs as they are 
conjugated trienes, rather than dienes (Figure 1.3) (Murphy et al, 2005). Leukotriene A4 
(LTA4 ) is synthesised following the actions of 5-LOX and 5-lipoxygenase activating protein 
(FLAP) on AA, LTA4 can then be converted to LTB4 and LTC4. LTC4 is further metabolised 
to leukotrienes D4 (LTD4) and E4 (LTE4) (Lam BK, 2003, Murphy et al, 2005, Peters-Golden 
et al, 2007). Leukotrienes are synthesised by many leukocytes, including 
monocytes/macrophages, neutrophils, mast cells, eosinophils, dendritic cells and basophils 
(Peters-Golden et al, 2007). These cells are also regulated by leukotrienes, which stimulate 
their production, growth and recruitment (Peters-Golden et al, 2007). Furthermore, they 
increase cell adhesion and transmigration into damaged tissue and promote leukocyte 
activation and survival, all actions that are consistent with a pro-inflammatory response 
(Ford-Hutchinson et al, 1980, Peters-Golden et al, 2007). Also, leukotrienes often have a pro- 
inflammatory effect in particular diseases, such as asthma, atherosclerosis, cancer and 
rheumatoid arthritis (Coffey & Peters-Golden, 2003, Capra V, 2004, Peters-Golden et al, 
2007, Back M, 2009).
1.7.3 Lipoxins
Lipoxins are conjugated tetraenes and are generated by metabolism of HpETEs and certain
leukotrienes, via the combined actions of 15-LOX 1 and 5-LOX, or 5-LOX and 12-LOX from
platelets (Serhan et al, 1984a, 1984b & 2005, Kuhn et al, 1987, Papayianni et al, 1995).
There are two ways of forming LXA4 , the first involves the metabolism of 15-HpETE by 5-
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LOX followed by a non-enzymatic addition of water (Serhan et al, 1990 & 1999, Pace- 
Asciak et al, 1999, McMahon et al, 2001, Murphy et al, 2005). Secondly, LTA4 can be 
converted to LXA* and/or LXB4 by the action of 12-LOX and addition of water at C- 6  or C- 
14 (Serhan et al, 1990, Pace-Asciak et al, 1999, McMahon et al, 2001). The synthesis of 
lipoxins is proposed to require the interaction of several LOX isoforms, therefore, the 
presence of different cell types is necessary. In-vitro, human monocyte-derived dendritic cells 
incubated with IL-4 and TGF-pl, express both 15-LOX 1 and 5-LOX, but they do not 
produce lipoxins in-vivo (Spanbroek et al, 2001). Lipoxins are generated in various tissues 
during in-vivo cell-cell interactions and have both pro- and anti-inflammatory properties 
(Serhan et al, 2005). In particular, lipoxins have anti-inflammatory effects towards 
neutrophils, such as inhibiting their migration, adhesion, chemotaxis and generation of 
superoxide (Grandordy et al, 1990, Colgan et al, 1993, Serhan et al, 1994, Stenke et al, 1994, 
Papaiyanni et al, 1996, Fiore & Serhan, 1996, Filep et al, 1999). In addition, lipoxins down- 
regulate the response of monocytes, dendritic cells, eosinophils and natural killer cells 
(Ramstedt et al, 1987, Stenke et al, 1994, Maddox et al, 1998, Bandeira-Melo et al, 2000). In 
animal models of various inflammatory conditions, such as cystic fibrosis and 
glomerulonephritis, lipoxins interfere with host defence by hindering leukocyte rolling and 
tissue infiltration and prevent tissue damage that is mediated by neutrophils (Munger et al, 
1999, Leonard et al, 2002, Serhan et al, 2003, Karp et al, 2004).
1.7.4 Hepoxilins
12-LOX in human platelets and rat and/or porcine 12/15-LOX can catalyse the isomerisation 
of 12(S)-HpETE, to form hepoxilins A3 and B3 (HxA3 and HXB3) (Nigam et al, 2004). These 
compounds contain an epoxide group, making them chemically and biologically unstable,
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thus investigating their in-vivo function is difficult (Pace-Asciak CR, 2009). Similar to the 
other products of 12/15-LOX, hepoxilins are involved in signalling. For example, they 
increase intracellular calcium concentration, promote secretion of glucose-induced insulin 
from pancreatic islet cells, open potassium channels in platelets and are involved in neuronal 
signalling (Pace-Asciak & Martin, 1984, Piomelli et al, 1987, Belardetti et al, 1989, Dho et 
a l  1990).
1.7.5 Oxidised products o f esterified AA
Following the discovery of a reticulocyte LOX in 1974, experiments were carried out to 
explore its function. Investigations revealed that this LOX can oxidise PE and PC 
phospholipids isolated from rat liver mitochondria, as well as lysing both outer and inner 
mitochondrial membranes in-vitro (Schewe et al, 1975). Human and murine 12/15-LOX is 
reported to oxidise AA esterified to PC and PE phospholipids (Kuhn et al, 1990b, Maskrey et 
al, 2007). In particular, 15-HETE and 12-HETE esterified to PE-phospholipids (15-HETE- 
PEs and 12-HETE-PEs) have been detected in human monocytes and murine peritoneal 
lavages respectively (Maskrey et al, 2007). Furthermore, endogenous 12-HETE and 5-HETE 
esterified to both PE and PC have been detected in human platelets and PMN leukocytes 
respectively (Thomas et al, 2010, Clark et al, in preparation). To support, studies have shown 
that exogenously added 5-HETE is esterified primarily to triacylglycerols, followed by PC 
and PE phospholipid classes (Arai et al, 1997). However, the role of LOX in generating ox- 
PLs in cells is not well studied and the biological function of HETE-PEs and -PCs has not 
been investigated. Thus, in this thesis, the generation and potential function of these novel 
phospholipids are investigated.
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1. 8 Biological roles of 12/15-LOX
The biological role of 12/15-LOX is not folly determined since the known products do not 
folly account for the biological activities of the enzyme. Our group recently found that 12- 
HETE is not responsible for the biological effects of 12/15-LOX in murine macrophages, 
particularly in the stimulation of cytokines (Dioszeghy et al, 2008). Therefore, other products 
of 12/15-LOX, such as the 12-HETE-PEs, may be involved.
1.8.1 LOX and atherosclerosis
Many groups have investigated the role of LOX isoforms and their products in 
atherosclerosis. The function of 12/15-LOX in this disease model is not folly understood and 
conflicting evidence has been reported regarding its anti- or pro-atherosclerotic role (Kuhn & 
Chan, 1997, Feinmark & Comicelli, 1997, Comicelli & Trivedi, 1999, Cathcart & Folcick, 
2000, Witter & Hersberger, 2007). In humans, 12/15-LOX has been detected in 
atherosclerotic lesions, macrophage foamy lesions and within smooth muscle cells (Hiltunen 
et al, 1995, Hugoe et al, 1995, Yla-Herttuala et al, 1999). Studies investigating the role 
12/15-LOX in rodent models suggest that the enzyme is pro-atherosclerotic. In support, LDL 
oxidised by LOX is atherogenic as its continual up-take by macrophages and smooth muscle 
cells (via scavenger receptors such as CD36) cause the formation of lipid foam cells (Bird et 
al, 1999, Boullier et al, 2000, Stocker & Keaney, 2004, Wittwer & Hersberger, 2007). 
Several observations have lead to the belief that 12/15-LOX is pro-atherogenic:
(i) in-vitro studies show that 12/15-LOX oxidises LDL, a reaction suggested to be of central 
importance in atherosclerosis (Kuhn et al, 1994b).
34
(ii) During the oxidation of LDL, secondary reactions take place that cause the oxidation of 
proteins such as apolipoprotein B, which alters their function (Neuzil et al, 1998).
(iii) Disrupting the gene for murine 12/15-LOX leads to reduced oxidation of LDL and 
decreased formation of atherosclerotic lesions in apoE A or LDL receptor7' mice (Sun & 
Funk, 1996, Cyrus et al, 1999, George et al, 2001).
(iv) Consistent with a pro-atherosclerotic effect, transgenic mice that over-express 15-LOX 
and are deficient of the LDL receptor, became more susceptible to atherosclerosis (Harats et 
al, 2 0 0 0 ).
(v) Finally, 15-LOX inhibitors prevent the formation of atherosclerotic lesions in cholesterol 
fed rabbits (Sendobiy et al, 1996, Bocan et al, 1998).
There is also conflicting evidence to that stated above, implicating 12/15-LOX in an anti­
atherogenic role. For example, trans-genic rabbits that over-express 15-LOX are protected 
from atherosclerosis (Shen et al, 1996). Similarly, in a macrophage cell line J774A.1 over­
expressing 12-LOX, less cholesterol esters were deposited in intra-cellular stores in 
comparison to mock transfected controls (Belkner et al, 2005). Products of 15-LOX also have 
anti-atherogenic effects such as down-regulating the binding of platelets to the endothelium 
(Buchanan et al, 1985). Furthermore, 15-HETE inhibits the de-granulation of PMN and the 
synthesis of superoxide and also prevents PMN migration across the endothelium in-vitro 
(Smith et al, 1993, Takata et al, 1994a).
Of interest, many of the studies showing that 12/15-LOX is pro-atherogenic were carried out 
in mice, while studies investigating rabbit 15-LOX suggest that the enzyme is anti­
atherogenic. Such opposing evidence may due to the different product isomers synthesised by
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LOXs in the two animal models. As previously stated, murine 12/15-LOX predominantly 
oxidises C-12 of AA while rabbit 15-LOX oxidises at C-15. As a result, the different 
products isomers may have diverse, or even opposing biological properties.
1.8.2 LOX and cell maturation, differentiation and restructuring o f the cell membrane
15-LOX was first discovered in rabbit reticulocytes, where expression coincides with a key 
step in their maturation, the degradation of mitochondria (Grullich et al, 2001). However, in 
experiments where 15-LOX was inhibited, the process of maturation was slowed but not 
averted. Therefore, 15-LOX may be involved with other metabolic processes that take place 
during reticulocyte maturation. For example, its expression is also associated with triggering 
ATP-dependent proteolysis (Rapoport et al, 1982, Schewe et al, 1986). Products of 15-LOX, 
in particular 15-HETE, regulate the proliferation of particular cells, such as Friend 
erythroleukemia cells (Postoak et al, 1990, Beckman et al, 1990).
12/15-LOX may also be involved in cell-cell interactions prior to phagocytosis. Evidence to 
support this includes enzyme translocation from the cytosol to the plasma membrane of 
murine peritoneal macrophages where they come into contact with apoptosing thymocytes 
(Miller et al, 2001). Furthermore, inhibiting 12/15-LOX reduces both actin polymerisation 
and the ability of macrophages to phagocytose apoptotic cells (Miller et al, 2001). 15-LOX is 
also suggested to play a role in apoptosis as it can oxidise bio-membranes (Schewe et al, 
1975). In addition, the apoptosis of neuroblastoma and erythroleukemia cells is induced 
following LOX activation (Maccarrone et al, 1999 & 2000). These actions strongly support a 
role for 12/15-LOX in the regulation of events that require membrane re-structuring, 
including of cell differentiation, maturation, phagocytosis and apoptosis.
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1.8.3 LOX and cancer
15-, 12/15-, 5- and platelet 12-LOX have all been implicated in cancer, but their specific roles 
have not been fully determined. Eicosanoid products of LOX are thought to exert their effects 
via PPARs (Hunter et al, 1985, Holtzman MJ, 1992, Shureiqi et al, 2003, Michalik et al, 
2004). For particular cancers, studies show either up- or down-regulatory effects by different 
isomers of LOX. The role of LOX in this disease is complex due to the multiple numbers of 
LOX genes and therefore, the resulting number of different LOX isoforms (Firstenberger et 
al, 2003). A general consensus is that human and murine 12/15-LOX and the epithelial LOXs 
(15-LOX2 and 8 -LOX), are anti-carcinogenic, present in healthy tissue and benign tumours, 
but are absent in carcinomas such as lung, breast, prostate, skin, colon and bladder tissue 
(Shureiqi et al, 1999, Shappell et al, 1999, Gonzalez et al, 2004, Subbarayan et al, 2005). In 
contrast, 5- and platelet 12-LOX are up-regulated in several cancers including skin, lung, 
esophageal, pancreatic and prostate (Krieg et al, 1995, Gao et al, 1999, Gupta et al, 2001, 
Jiang et al, 2003, Ohd et al, 2003, Hennig et al, 2005).
1.8.4. LOX and asthma
A growing number of studies indicate that 15-LOX plays a role in asthma. 15-LOX is 
detected in human airways and is raised in severe asthma, as is the generation of 15-HETE 
(Hunter et al, 1985, Sigal et al, 1991, Holtzman et al, 1992, Profita et al, 2000, Chu et al, 
2002, Zhao et al, 2009). Deficiency of 12/15-LOX increases the secretion of IgA and is 
reported to protect mice from allergic airway inflammation (Hajek et al, 2008). 15-LOX is 
also up-regulated in human bronchial endothelial cells and in nasal epithelia, with higher
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expression in people who smoke, suggesting a modulatory role in airway function 
(Jayawickreme et al, 1999).
1.8.5 LOX & inflammation
Products of LOX are frequently linked to inflammatoiy regulation. 15-HETE and 13-HODE 
are raised in particular inflammatory conditions, for example, 15-HETE is raised in human 
proctocolitis and inflammatory bowel disease (Donoiwitz M, 1985, Zijlstra et al, 1991). LOX 
also has a complicated role in hypertension and vascular damage as different products have 
opposing effects. In particular, 12-HETE and LTA4 are pro-inflammatory. Their effects 
include the constriction of renal blood vessels and glomerular mesangial cells, decreasing 
renal blood flow and increasing the permeability of glomerular and peritubular capillaries 
(Navar et al, 1996, Imig J, 2000, Yiu et al, 2003, Natarajan et al, 2004 Imig J, 2006). 
Conversely, lipoxins and 15-HETE have anti-inflammatory effects in this disease (Badr et al, 
1984, Fischer et al, 1992, Badr & Lakkis, 1994, Munger et al, 1999, Leonard et al, 2002, 
Kieran et al, 2004). There is additional evidence supporting that 12/15-LOX derived 
eicosanoids have anti-inflammatory effects. For example, metabolic products of AA increase 
in the cornea following injury, particularly lipoxins, which promote wound healing (Bazan et 
al, 1985, Gronert et al, 2005a & 2005b, Kenchgowda et al, 2010).
In mice, 12/15-LOX is largely expressed by resident peritoneal macrophages, which play a
key role in peritoneal inflammation. In comparison to macrophages from WT mice,
macrophages devoid of 12/15-LOX show increased generation of IL-1, IL-3, granulocyte
macrophage cell stimulating factor (GM-CSF), and IL-17, but less RANTES (Dioszeghy et
al, 2008, Miller et al, 2001, Huang et al, 1999, Zhao et al, 2002). Furthermore, during
infection by Staphylococcus epidermidis (S.epi) (a bacterium largely responsible for
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peritonitis), 12/15-LOX 7' macrophages generate more GM-CSF but less RANTES, IL-12p40 
and IL-12p70 than WT cells (Dioszeghy et al, 2008). Importantly, infecting mice with 
Staphylococcus epidermidis also alters the synthesis of products by 12/15-LOX (Morgan et 
al, 2009). This evidence implies that 12/15-LOX is involved in regulating inflammation. In 
support, the function of 12/15-LOX 7' macrophages is altered, for example, they show a 
decreased ability to carry out phagocytosis of apoptotic cells. Thus, 12/15-LOX is involved in 
regulating inflammation, but the exact mechanism of its action is unclear.
Other anti-inflammatory events promoted by LOX, in particular by 15-HETE, include 
inhibiting the formation and release of superoxide from PMN leukocytes (Smith et al, 1993). 
Also, 15-HETE reduces the synthesis of LTB4, a pro-inflammatory eicosanoid involved in 
experimental arthritis (Herlin et al, 1990, Takata et al, 1994b). 12/15-LOX also down- 
regulates the expression of NFkB, a pro-inflammatory transcription factor (Nakajima et al, 
2001, Yuan et al, 2005, Appel et al, 2005). Thus, the reported evidence suggests that 12/15- 
LOX can have both pro- and/or anti-inflammatory effects during inflammation.
1.9 The synthesis of oxidised phospholipids by 12/15-LOX
A lack of methods sensitive enough to detect and quantify oxidised phospholipids has 
delayed work in this area until recent years. However, due to the increased availability of new 
generation mass spectrometers, this technique is proving to be invaluable for research 
investigating oxidised phospholipids. Yet, much is still unknown regarding the biological and 
immunological impact of specific molecular species of oxidised phospholipids.
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Until recently, free H(p)ETEs were believed to be the sole products synthesised by LOX 
following the metabolism of AA. However, with the aid of mass spectrometry (MS), four 
novel lipids synthesised by 12/15-LOX were identified and characterised in IL-4-treated 
human monocytes (Figure 1.17) (Maskrey et al, 2007). These phospholipids consist of 15- 
HETE attached to phosphatidylethanolamine (PE), and were identified as 18:0a/15-HETE- 
PE, 18:0p/l 5-HETE-PE, 18:1 p/15-HETE-PE and 16:0p/15-HETE-PE (Figure 1.18). They are 
generated by direct oxidation of arachidonate-containing PEs (AA-PEs) (Maskrey et al, 
2007). Levels of 15-HETE-PEs increased following cellular activation, indicating that they 
are generated enzymatically. Furthermore, 12-HETE-PEs were identified in human platelets 
and murine peritoneal macrophages (Maskrey et al, 2007).
Studies using 12/15-LOX’7 mice indicated that the enzyme is involved in regulating 
inflammation (Maskrey et al, 2007, Dioszeghy et al, 2008). Specifically, 12/15-LOX 
modulates immune cell function, however, it does so in the absence of free H(p)ETEs, 
suggesting that alternative products, such as HETE-PEs, may be involved (Huang et al, 1999, 
Miller et al, 2001, Shappell et al, 2001, Zhao et al, 2002, Shankaranarayanan & Nigam, 
2003). Recent studies have indicated that 12/15-LOX may act in a pro-resolving manner 
during inflammation (Gonert et al, 2005, Middleton et al, 2006, Zhao et al, 2009). Therefore, 
it is important to determine whether 15-HETE-PEs have anti-inflammatory effects. However, 
studies investigating the metabolism and biological importance of 15-HETE-PEs in 
inflammatory conditions have not been carried out.
1.10 Electrospray mass spectrometry
The study by Maskrey et al (2007) forms the basis of this thesis as it describes the
identification of 15-HETE-PEs in human monocytes and 12-HETE-PEs in murine peritoneal
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Figure 1.17 Precursor scanning identified four ions, that contain HETE, which are elevated following A23187 
activation of human monocytes. Precursor scanning for HETE {m/z 319) identified four major parent ions: m/z 
738.5, 764.5, 766.5 and 782.5 [M-H]' (Reproduced from Maskrey et a /, 2007, with permission (18/11/2010)).
OH
18:0a/15-HETE-PE [M-H]-= 782.5.
O OH
18:0p/15-HETE-PE [M-H]- = 766.5.
OH
‘CH
CH
18:1 p/15-HETE-PE [M-H]- = 764.5.
O OH
OH
16:0p/15-HETE-PE [M-H]- = 738.5.
Figure 1.18 Proposed structures for four HETE-containing products of LOX 
in activated human monocytes. Based on comparison with synthesis standards, 
four 15-HETE-PEs were identified. Similar compounds were identified in 
platelets where 15-HETE is replaced by 12-HETE (Maskrey et al, 2007).
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macrophages. The primaiy method of analysis utilized by Maskrey et al (2007) was 
electrospray mass spectrometry (EMS), which was also used for the studies described herein. 
The mass spectrometer used throughout these investigations was an Applied Biosystems 
4000 Q-Trap, a schematic representation of which is shown in Figure 1.19. Liquid samples 
are introduced either by direct injection or following HPLC separation (Figure 1.20). Within 
the mass spectrometer, the sample is fed through a hypodermic needle at a high voltage, 
which causes its evaporation into an ‘electrospray’ (Mann et al, 2001, Fenn et al, 1989). 
Molecules within the electrospray are then ionised in atmosphere (Mann et al, 2001). The 
ability of an analyte to form a negative [M-H]' or positive [M+H]+ ion is critical for its 
detection, and for this to occur it must be sufficiently polar (Mann et al, 2001). After 
ionisation, charged molecules travel through three quadrapoles (Ql, Q2 and Q3) to a detector. 
These consist of four rods, to which an oscillating electric field is applied (Mann et al, 2001). 
Ql and Q3 act as mass filters, and only let stable masses through to the detector. If required, 
charged molecules can be contained in Q2 and undergo collision-induced-decomposition 
(CID) using inert gas (Maskrey & O’Donnell, 2008). The fragments then pass through Q3 to 
the detector. A mass spectrum can be acquired by scanning the amplitude of the electric field 
and recording the ions at the detector (Mann et al, 2001). Due to the structural arrangement of 
the mass spectrometer, it can be used in different ways to analyse molecules, some of which 
are described below.
For the investigations described herein, EMS was used in various modes. For example, 
purified infusions of lipid were injected directly into the mass spectrometer in order to 
investigate its contents; this is known as a Ql scan (Figure 1.21 A) (for example, Figure 3.3). 
During this analysis, only molecules that are both ionised and on a stable trajectory are 
detected. Mass spectrometry (MS) can also be used to investigate the fragmentation pattern of
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Figure 1.19 Schematic diagram of a mass spectrometer. An Applied Biosystems Q-trap 4000 mass spectrometer was used 
as a diagnostic tool for the work described herein. The scheme represents the general structure of this instrument 
(Reproduced with permission from Applied Biosystems, (16/11/2010).
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a specific analyte detected during a Ql scan. A compound of interest can selectively undergo 
CID in the collision cell, the products are then released into Q3 and travel through to the 
detector (Figure 1.21 B) (Maskrey & O’Donnell, 2008). This is known as a product ion 
spectrum, an example of which can be seen in Figure 3.3 (inset). Alternatively, MS has been 
used in ‘fishing’ experiments, searching for the m/z of a particular structure(s) that can be 
fragmented into smaller molecules of known m/z. This mode is known as precursor scanning 
(Figure 1.21 B). An example is described by Maskrey et al (2007), where precursor scanning 
was used to investigate compounds that contain HETE (m/z 319). Lipids extracted from 
human monocytes were separation by liquid chromatography, followed by precursor 
scanning for m/z 319. As seen in Figure 1.17, four compounds contained this fragment, which 
were identified as 15-HETE-PEs. In addition to the methods described above, samples can be 
analysed for numerous compounds simultaneously that have specific parent and daughter m/z, 
which are consequently detected in Ql and Q3 respectively, known as multiple reaction 
monitoring (MRM) transitions (Maskrey & O’Donnell, 2008, Yin et al, 2010). This method 
of analysis is known as MRM scanning (MS//MS). The use of HPLC preceding MS/MS 
(LC/MS/MS) has meant that individual compounds can be separated followed by their 
sensitive identification. Combining the known parent to daughter m/z transition with time of 
elution can be very specific to individual compounds. Thus, LC/MS/MS is a very efficient 
technique for phospholipid analysis.
MS has been used extensively in proteomics and its use in lipidomics, is also proving to be
invaluable. MS is efficient since, multiple compounds can be analysed simultaneously and
due to its sensitivity and specificity, small changes such as oxidation (a m/z increase of 16),
can be monitored easily (Pitt & Spickett, 2008). For this reason, MS is likely to be used by
many groups investigating protein or lipid oxidation. MS has been used for many purposes,
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for example, to understand the mechanisms and products derived from lipid oxidation (Pulfer 
& Murphy, 2003, Yin et al 2010, Yin et al, 2009, Yin & Porter, 2007). Furthermore, novel 
compounds, as well as amino acid modifications, have been identified by MS in both research 
and clinical samples (Pitt & Spickett, 2008, Maskrey et al, 2007, Greenberg et al, 2006. 
Podrez et al, 2002a &b, von Schliffen et al, 2009, Williams et al, 2007, Fermandis & Wenk, 
2009, Walther & Mann, 2010). Thus MS is a suitable technique for the investigations 
described herein.
The identification of H(p)ETE-PEs by Maskrey et al (2007) meant an assay was required for 
their direct quantification. As a soybean LOX was available that oxidises AA at C-15, 
existing methods were adapted in orderused to synthesise and purify a H(p)ETE-PE standard, 
for use in a new quantification assay. Maskrey et al (2007) characterised the synthesis of 15- 
H(p)ETE-PEs by 15-LOX but they did not characterise how 12-H(p)ETE-PEs are made by 
murine 12/15-LOX. Therefore, using MS and traditional chromatographic techniques, I 
aimed to characterise the synthesis of 12-H(p)ETE-PEs by 12/15-LOX in murine 
macrophages. The immunological effects of 12/15-LOX may be exerted by 12- and 15- 
H(p)ETE-PEs, therefore, studies were required to determine how the H(p)ETE-PEs are 
metabolised. Thus, the generation and metabolism of 15- and 12-H(p)ETE-PEs was 
investigated in human monocytes and murine macrophages respectively.
Studies in this thesis investigated whether 15- and 12-H(p)ETE-PEs may be involved in 
inflammatory processes. In particular, the pro- versus anti-inflammatory effect of 15- 
H(p)ETE-PEs was assessed by adding a synthesised 18:0a/15-H(p)ETE-PE standard to 
human monocytes. Also, membrane extemalisation of PE and PS is believed to regulate 
events that require re-structuring of the membrane, such as phagocytosis. Thus, studies herein
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describe whether 12-H(p)ETE-PEs were externalised in murine macrophages. Also, analysis 
of WT and 12/15-LOX7" peritoneal macrophages by electron microscopy showed whether 
their ultra-structure is affected by the absence of 12/15-LOX, which may aid in determining 
the function of this enzyme. Briefly, the work in this thesis has attempted to characterise the 
synthesis and metabolism of 12- and 15-H(p)ETE-PEs generated by 12/15-LOX in murine 
macrophages and human monocytes, and has discussed how they may be involved in 
inflammatory responses.
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CHAPTER 2 
MATERIALS AND METHODS
2.1 Materials.
2.1.1 Chemicals.
15(,S)-hydroxy-[S-(E,Z,Z,Z)]-5,8,11,13-eicosatetraenoic acid (15-HETE), 15(5)-hydroxy- 
1 lZ,13E-eicosadienoic acid (15-HEDE) and 15(«S)-hydroxy-[S-(E,Z,Z,Z)]-5,8,ll,13- 
eicosatetraenoic acid-d8  (15-HETE-dg) were from Alexis Chemicals Ltd. (Nottingham, UK). 1- 
stearoyl-2-arachidonyl-sn-glycero-3-phosphoethanolamine (SAPE), 1 -stearoyl-2-arachidonyl- 
sn-glycero-3-phosphocholine (SAPC), 1,2-dimyristoyl-s«-glycero-3-phosphoethanolamine
(DMPE), 2-dimyristoyl-s«-glycero-3-phosphocholine (DMPC), 1,2-dimyristoyl-s«-glycero-3- 
phospho-L-serine (DMPS), 1,2 -dimyristoyl-s?7-glycero-3 -phospho-(l '-rac-glycerol) (DMPG) 
and 1,2-dimyristoyl-src-glgbycero-3-phosphate (DMPA) were from Avanti Polar Lipids inc. 
(Alabaster, Alabama, USA). Human recombinant interleukin 4 (hrIL-4) was from Promega 
(Southampton, Hampshire, UK). Lymphoprep was from Axis Shield (Oslo, Norway). 
Lipopolysaccharide was from Calbiochem, (Beeston, Nottingham,UK). Bovine serum albumin 
was from USB (Staufen, Germany). Glutaldehyde, sodium cacodylate, osmium tetroxide, 
urianyl acetate, propyl oxide, araldyte CY212, dodecenyl succinic anhydride (DDSA) and 
dimethylbenzylamine (BDMA) were all from Agar Scientific (Stansted, Essex, UK). Kodak D- 
19 developer and Ilford Hypam fixer were from Piccadilly Photographic (Cardiff, Wales, UK). 
All other reagents were from Sigma-Aldrich company Ltd (Poole, Dorset, UK) unless otherwise 
stated. All Solvents used were from Fisher (Loughborough, Leicestershire, UK).
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2.1.2 General buffers and solutions used.
Krebs Ringer buffer
50 mM HEPES, 120 mM NaCl, 4.71 mM KC1, 1.2 mM MgS04, 2.5 mM CaCl2, 1.2 mM 
KH2P04,26.8 mM NaHCOs, 10 mM Glucose, pH 7.4
Phosphate buffered Saline (PBS)
137 mM NaCl, 2.7 mM KC1, 8.1 mM Na2HP04 , 1.47 mM KH2P04, pH 7.4 
Citrate-PBS
137 mM NaCl, 2.7 mM KC1, 8.1 mM Na2HP04, 1.47 mM KH2P0 4 0.4% (w/v) trisodium citrate, 
pH 7.4
Dextran-Citrate-PBS
137 mM NaCl, 2.7 mM KC1, 8.1 mM Na2HP04, 1.47 mM KH2P0 4 ,0.8% (w/v) trisodium citrate, 
2% (w/v) Dextran, pH 7.4
Monocyte media
RPMI media, 10% (v/v) foetal bovine serum, 100 pg/ml penicillin, 100 pg/ml streptomycin, 2 
mM glutamine.
Extraction Solvent
1 M acetic acid:2-propanol:hexane (2:20:30 (v/v/v))
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Wash buffer
0.05% Tween-20 in PBSF 
Tris buffered saline
20 mM Trizma Base, 150 mM NaCl (pH 7.4)
Reagent diluent 
1 % BSA in PBS buffer
TNFa blocking buffer
1 % BSA, 5 % Sucrose in PBS with 0.05 % NaN3 
TNFa reagent diluents
0.1 % BSA, 0.05 % Tween-20 in Tris buffered saline 
Carbonate buffer
0.1 M sodium carbonate buffer (8.4 g NaHCC>3 and 3.56 g Na2CC>3 in 1 L H2O), pH 9.5 
Cacodylate buffer
0.2 M sodium cacodylate trihydrate in H2O, pH 7.
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Embedding Resin
Epoxy resin (Araldyte CY212); Dodecenyl succinic anhydride (DDSA); Dimethylbenzylamine 
(BDMA). Ratio of 1:1:0.03 (w/w/w)
Reynold's lead citrate
Lead Nitrate 1.33 g, Sodium Citrate 1.76 g, H2O 30 ml
Acetic acid stop bath 
Acetic acid; H2O. Ratio of 1:60
2.2 Methods
2.2.1 Mass spectrometry analysis.
2.2.1.1 HETE quantitation by LC/MS/MS.
Fatty acids were separated on a C l 8  Spherisorb ODS2, 5 pm, 150 x 4.6 mm column (Waters Ltd, 
Elstree, Hertfordshire, UK). The gradient used was 50 - 90% B over 20 minutes at 1 ml/min (A= 
water:acetonitrile:acetic acid at 75:25:0.1; B= methanol:acetonitrile:acetic acid at 60:40:0.1). 
Products were quantified by LC/ESI/MS/MS on a 4000 Q-Trap (Applied Biosystems, Foster 
City, California, USA) using specific parent to daughter transitions of [M-H]~ m/z 319.2 (HETE) 
219 (15-HETE), 179 (12-HETE) and 115 (5-HETE), 327.2 226 (15-HETE-dg), 327.2 ->
184 (12-HETE-dg) and 323.2 -> 223 (15-HEDE) in a negative ion mode (Figure 2.1). The 
collision energies and de-clustering potentials for each analyte are below in Table 2.1. Products 
were quantified using 15-HETE-dg, 12-HETE-dg or 15-HEDE as internal standards run in 
parallel under the same conditions. Standard curves with purified HETEs versus 15-HETE-dg
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and 12-HETE-dg were constructed for eicosanoid quantification, allowing for detection of 
approximately 1 to 1 0  pg of each eicosanoid.
Table 2.1 Parent and daughter m/z and MS conditions for analytes
Analyte Q1 Mass 
(amu)
Q3 Mass 
(amu)
Declustering 
Potential (V)
Collision Energy 
(V)
15-HETE-d8 327 226 -65 -16
12-HETE-d8 327 184 -85 - 2 0
15-HEDE 323 223 -105 -28
15-HETE 319 219 -45 - 2 0
12-HETE 319 179 -85 - 2 0
5-HETE 319 115 -80 - 2 2
15-KETE 317 113 -40 -24
AA 303 259 -75 - 2 0
2.2.1.2 Phospholipid quantification by LC/MS/MS.
Phospholipids were separated using a Luna 3 pm C l8  150 x 2 mm column (Phenomenex Ltd., 
Macclesfield, Cheshire, UK) based on the hydrophobicity of the snl fatty acid. The gradient used 
was 50-100 % B over 10 minutes then 100 % B for 30 minutes at 200 pl/min (A= 
methanol:acetonitrile:water at 6:2:2 with 1 mM ammonium acetate; B= methanol with 1 mM 
ammonium acetate). Products were quantified by LC/ESI/MS/MS on a Q-Trap (as above) using 
the specific parent to daughter transitions of m/z 782.5, 766.5, 764.5 and 738.5 -> 219 (15- 
HETE-PEs) (Scheme 2.1) or 179 (12-HETE-PEs) (Scheme 2.2) or 115 (5 -HETE-PEs) (Scheme 
2.3) and 634 -> 227 (DMPE) (Scheme 2.4) (all [M-H]'). The collision energy for the HETE-PEs 
was -140 V and the declustering potential, -45 V. Standard curves with either purified 15-HETE- 
PE (generated and purified in 2.2.3) or an isomer mixture of HETE-PEs versus DMPE were 
constructed for lipid quantification, allowing for detection of approximately 1 to 1 0  pg of each 
phospholipid. These will be fully described in Chapter 3.
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Scheme 2.1 Structures and m/z of 15-HETE-PEs
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The following parent to daughter transitions were followed for arachidonate-containing PEs 
(AA-PEs): m/z 766, 750, 748 and 722 -» 303 ([M-H]') (Scheme 2.5). 15-HETE-PCs: m/z 826.6,
808.6, 810.6 and 782.6 -> 184 ([M+H]+); 810.6, 794.6, 792.6 and 766 319 ([M-CH3]') and
860.6, 844.6, 842.6 and 816.6 ->319 ([M+Cl]") (Scheme 2.6). The following parent to daughter 
ion transitions were followed for the addition of C2H4 to HETE-PEs: 810, 794, 792 and 766 -> 
347 ([M-H]') (Scheme 2.7). The following parent to daughter transitions were followed for the 
15-HpETE-PEs: 756.6, 780.6, 782.6 and 798.6 ->317 ([M-H] ) (HpETE following a loss of 
H2O), (Scheme 2.8). The parent to daughter transitions followed for 15-KETE-PEs were 736.6,
762.6, 764.6 and 780.6 -> 317 ([M-H]') (Scheme 2.9). The parent to daughter transitions 
followed for di-HETE-PEs were 756.6, 780.6, 782.6 and 798.6 -> 335 ([M-H]') (Scheme 2.10). 
The parent to daughter transitions followed for hydroxyeicosatrienoic acid-PEs (HETrE-PEs) 
were 766.6, 792.6, 794.6 and 810.6 ^  321 ([M-H]') (Scheme 2.11).
TW
All MS data was analysed using Analyst software.
2.2.2 Synthesis and purification o f  18:0a/15-HETE-PE and 18:0a/15-HpETE-PE.
1 mM l-stearoyl-2-archidonyl-sn-glycero-3-PE (18:0-20:4 PE) (SAPE) in 10 mM deoxycholate/ 
0.2 M borate (pH 9) was oxidized using 8 KU/ml soybean 15-lipoxygenase for 30 minutes at RT 
(Brash et al, 1987). For synthesis of 15-HETE-PE, the hydroperoxides were reduced to their 
corresponding alcohols by adding 1 mM SnCh for 10 minutes at RT. Lipids were extracted as 
described below in section 2.2.3.
Purification of 15-HpETE-PE and 15-HETE-PE was carried out by reverse phase high 
performance liquid chromatography (RP-HPLC) using a 5 pm spherisorb ODS2 C l8, 4.6 x 150
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16:0p/15-KETE-PE, [M-H]- = 736.6
Scheme 2.9 Structures and of 15-KETE-PEs
o 18:0a/5,15-DiHETE-PE, [M-H]- = 798.6
OH OH
18:0p/5,15-DiHETE-PE, [M-H]- = 782.6
18:1 p/5,15-DiHETE-PE, [M-H]-= 780.6.
16:0p/5,15-DiHETE-PE, [M-H]- = 754.6.
Scheme 2.10 Example structures and m/z of di-HETE-PEs, those 
shown are of 5,15- of di-HETE-PEs
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18:0a/15-HETrE-PE, [M-H]- = 810.6
c
D s
O OH
18:0p/15-HETrE-PE, [M-H]- = 794.6
O OH
18:1 p/15-HETrE-PE, [M-H]- = 792.6
O OH
OH
16:0a/15-HETrE-PE, [M-H]- = 766.6
Scheme 2.11 Structures and m/z of 15-HETrE-PEs
mm column (Waters Ltd, Elstree, Hertfordshire, UK.). The mobile phase consisted of a gradient 
of (A) 50:50 methanol:water, 1 mM ammonium acetate going to 100 % methanol, 1 mM 
ammonium acetate over 15 minutes then remaining at 100 % B for 20 minutes, running at 1 
ml/min. The crude mixture containing 15-H(p)ETE-PE was injected onto the column; relevant 
peaks were collected, combined, dried down under N2 gas, then re-suspended in methanol.
2.2.2.1 Structural analysis of compounds by MS.
Dilutions of the sample were introduced at 10 (il/min in methanol using a hamilton syringe. 
Compounds were analysed using the ion trap mode of the Q-trap. The de-clustering potential and 
collision energy were -140 V and -45 V, respectively. Q1 scans were carried out in negative 
mode out to determine overall purity of compounds, spectra were obtained from m/z 500 to 1000 
amu over 12 seconds, with 10 scans acquired and averaged. Product ion spectra of our 
compounds of interest were acquired using the ion trap mode. Spectra were obtained from m/z 
100 to 800 amu over 12 seconds, with 10 scans acquired and averaged.
2.2.3 Extraction o f lipids.
Lipids were extracted using a solvent mixture of 1 M acetic acid:2-propanol:hexane (2:20:30) 
containing an internal standard (10 ng/ml sample volume), followed by the addition of hexane, 
all at a ratio of 2.5:1 (solvent mixture:sample) as described by Zhang et al (2002). Briefly, 
following the addition of samples to extraction mixture, they were mixed vigorously by vortex 
then centrifuged for 5 minutes and the upper organic layer was removed into clean glass vials. A 
second extraction step was carried out by the addition of hexane at a ratio of 2.5:1 (solvent
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mixture:sample). The organic layers were pooled and dried under N2 flow or under vacuum, re­
suspended in methanol and stored at -70 °C.
2.2.4 Chromatographic analysis o f  18:0a/15-HETE-PE.
2.2.4.1 Normal phase HPLC-UV of phospholipid classes.
Phospholipid classes were isolated from samples by normal phase HPLC (NP-HPLC). Lipid 
extracts re-suspended in normal phase solvents (50:50 of solvents A:B (A, hexane:2-propanol, 
3:2; B, solvent A:H20, 94.5:5.5)) were separated on a Spherisorb S5W 4.6 x 150-mm column 
(Waters Ltd, Elstree, Hertfordshire, UK) using a gradient of 50-100 % B over 25 minutes (A, 
hexane:2-propanol, 3:2; B, solvent A:H20, 94.5:5.5) at a flow rate of 1.5 ml/min (Dugan LL, 
1986). Absorbance was monitored at 205 nm, and products were identified by retention time by 
comparison with to a mixture of standard phospholipids. The PE phospholipids eluted at around 
5 minutes and were collected. Samples were dried down under N2 , then re-suspended in 
methanol.
2.2.4.2 HETE isomer determination.
The PE fraction collected from NP-HPLC was subjected to base-hydrolysis. The samples were 
dried under N2 and re-suspended in 1.5 ml propan-2-ol. An equal volume of 0.2 M NaOH was 
added to the samples followed by incubation for 30 minutes at 60 °C under N2 . The samples were 
acidified to pH 3.0 and then the fatty acids extracted twice using 3 ml hexane. The upper organic 
layers were combined, dried under N2 and finally resuspended in methanol. All the HETE 
isomers were analysed by RP- LC/MS/MS as described above in 2.2.2.1.
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2.2A.3 Chiral analysis of HETE isomers for enantiomer determination.
15-HETE and 12-HETE was purified from cell extracts using the method described in 2.2.2.1, 
dried under N2 then re-suspended in the chiral phase mobile phase (hexane:2 -propanol:acetic 
acid, 100:5:0.1), and injected onto a Chiralcel OD 0.46 x 25-cm column (Chiral Technologies 
Ltd, Exton, PA) with isocratic separation at 1 ml/min with absorbance monitored at 235 nm. 
HETE chirality was identified by comparison with 12- and 15- R and S HETE standards 
(Cayman Chemical, Michigan, USA).
2.2.5 NMR.
NMR analysis of 15-HETE-PE was carried out in collaboration with Dr Michaela Serpil and 
Professor Chris McGuigan, School of Pharmacy, Cardiff University. 1H-NMR, 31P-NMR and 13C 
Pendent -NMR were recorded at 500, 200 and 125 MHz respectively on a Bruker Avance 500 
spectrometer using CD3OD 21s the solvent. Chemical shifts are reported in parts per million (ppm, 
5 units) and J  values are given in Hertz (Hz).
2.2.6 Isolation and activation o f  human monocytes.
2.2.6.1 Isolation of monocytes from human buffy coats.
All blood donations were with approval from the Cardiff University Research Ethics Committee. 
Isolation of human monocytes was carried out under sterile conditions. 50 ml buffy-coat blood 
obtained from the Welsh Blood Service, was diluted 1:1 with Dextran-Citrate-PBS. The red cells 
were left to sediment for 1 - 2  hours then the upper plasma layer removed and under-layered with 
Lymphoprep at a ratio of 2:1 (supematant:Lymphoprep) and centrifuged at 800 g for 20 minutes 
at 4 °C. The interface (containing monocytes) was collected and diluted 1:1 with chilled
69
PBS/citrate (0.4 % w/v citrate, pH 7.4), then centrifuged at 400 g for 10 minutes at 4 °C. The 
pellet was washed with citrate-PBS, centrifuged at 400 g for 5 minutes at 4 °C, discarding the 
supernatant to remove contaminating platelets. This was repeated five times. Following the final 
spin, the pellet was re-suspended in 2 ml monocyte medium (RPMI 1640 (Invitrogen, Paisley, 
UK), containing 10 % FCS, 100 U/ml penicillin, 100 pg/ml streptavidin, 2 mM glutamine). Cells 
were counted by trypan blue exclusion on a haemocytometer. The cell stock was diluted to 108 
cells/ml with monocyte medium, 108 cells were seeded per T75 flasks (Nunc Brand, Fisher 
Scientific UK, Loughborough, Leicestershire, UK). The monocytes were allowed to adhere by 
incubating the flasks at 37 °C for 2 hours, 5 % CO2. The cells were washed with RPMI 1640 
then fresh monocyte media and 700 pM human recombinant interleukin 4 (hrIL-4) (Promega, 
Southampton, Hampshire, UK) was added prior to a second 72 hour incubation. Monocytes were 
harvested by removing and combining the monocyte containing medium from flasks and 
centrifuging at 500 g for 5 minutes, 4 °C, then re-suspended in Krebs buffer. Cells were counted 
by trypan blue exclusion then diluted to 4 x 106 cells/ml for use in experiments.
2.2.6.2 Activation of human monocytes to generate LOX-derived esterified and free eicosanoids. 
Monocytes were activated with 10 pM A23187 at 37 °C and incubated for various time periods 
depending on the experiment in question. All samples underwent lipid extraction, some 
following reduction by adding 1 mM SnCL for 10 minutes at room temperature (RT). In some 
experiments, cells and supernatant were separated by centrifugation at 290 g for 5 minutes (4 
°C). For some experiments, cells were spiked with 170 ng 15-HETE-dg or 15-HETE-PE or 15- 
HpETE-PE prior to activation. The effect of PLA2 inhibitors (50 nM bromoenol lactone (BEL), 
10 pM palmityl trifluromethyl ketone (PACOCF3), 2 pM oleyloxyethyl phosphorylcholine
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(OOEPC)) and PAF-AH inhibitor (150 pM methylarachidonyl-fluorophosphonate (MAFP)) on 
15-HETE-PE synthesis was investigated by the addition of PLA2 inhibitors 10 minutes prior to 
activation. For some experiments, reduction was carried out using 10 mM NaCNBH3 for 1 hour 
at 37 °C (Hazen et al, 1997) followed by lipid extraction. For all samples, 10 ng per 4 x 106 cells 
of DMPE and 15-HETE-dg and/or 15-HEDE were added as internal standards, following 
reduction.
2.2.7 Isolation and activation o f murine macrophages.
C7567/BL6 wild type and 12/15-LOX"7' mice were culled by Schedule 1 methods using C 0 2 
asphyxiation. Peritoneal lavages were carried out using 2 ml PBS. Lavages from mice were 
pooled (unless otherwise specified), pelleted by centrifugation at 500 g for 5 minutes at 4 °C, re­
suspended in monocyte medium. Cells were counted by trypan blue exclusion and either used 
directly or and seeded in flasks at 100 x 106 cells/ml to isolate the macrophages by adhesion. For 
this, cells were incubated for 2 hours at 37 °C, 5 % C02. The monocyte medium was removed 
and the adhered macrophages washed once with RPMI media, fresh monocyte medium was 
added to the flasks and the macrophages released by gentle scraping. Macrophages were pelleted 
as described above, washed and pelleted in PBS, re-suspended in Krebs buffer, counted, and 
diluted to 4 x 106 cells/ml for experiments. Cells were activated with 10 pM A23187 at 37 °C 
and incubated for time periods depending on the experiment in question. All samples underwent 
lipid extraction, some following reduction by adding 1 mM SnCl2 for 10 minutes at RT. In some
1 oexperiments, cells were re-suspended in Krebs buffer made using H2 O, rather than regular 
Krebs prior to activation. In several experiments, control and activated cells were incubated with 
1 mg/ml Sulfo-NHS-Biotin (Pierce Ltd, Rockford, USA) for 10 minutes, at RT; unbound Sulfo-
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NHS-Biotin was removed by centrifuging samples at 550 g for 5 minutes, followed by re- 
suspending the cell pellets in Krebs buffer, reduction and lipid extraction. In other experiments, 
cells were pelleted using a micro-centrifuge by spinning at 290 g for 5 minutes (4 °C), the 
supernatant was then subjected to ultracentrifugation at 100,000 g for 1 hour (4 °C) in a 
Beckman L8-60M (SW55TI rotor). All pellets were re-suspended in PBS, reduced, and lipids 
extracted. For all samples, 10 ng per 4 x 106 cells of DMPE and 12-HETE-dg were added as 
internal standards, following reduction.
2.2.8 Phospholipid profiling ofW T and 12/15-LOX/' murine macrophages.
Macrophages from WT and 12/15-LOX’7' mice were isolated as described above. Harvested 
macrophages were re-suspended in 0.5 ml Krebs buffer and the lipids were extracted. PE, PC, PI, 
PA and PG phospholipids were profiled by LC/ESI/MS/MS on a 4000 Q-Trap as described in 
2.22.2, using the specific parent to daughter transitions shown in Tables 2.2. to 2.7. Relative 
levels of lipids were determined by comparison to internal standards with the following parent to 
daughter transitions m/z 634 -> 227 (DMPE) [M-H]’, 678 -> 184 (DMPC) [M+H]+, 591 -> 227 
(DMPA) [M-Na]' and 665 -> 227 (DMPG) [M-Na]' (Scheme 2.4). PS-phospholipid profiling was 
carried out by flow injection using the phospholipid solvent system (as described in 2.22.2) 
running at 50:50 A:B, 1 ml/min for 6  minutes. Products were profiled using an internal standard, 
with parent to daughter transition of m/z 678 -> 227 (DMPS) [M-Na]'.
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Analysed Transition 
[M-H]-
PE
Phospholipid Structure
Fatty acid analysed 
by MS
662/255 30:0 (16:0/14:0-PE) 16:0
688/255 32:1a (16:0/16:1-PE) 16:0
690/255 32:0a (16:0/16:0-PE) 16:0
698/279 34:2p (18:2/14:0-PE) 18:2
700/281 34:lp (18:1/16:0-PE) 18:1
702/281 34:le (18:1/16:0-PE) 18:1
702/283 34:0p (18:0/16:0-PE) 18:0
714/281 34:2a (18:1/16:1-PE) 18:1
714/255 34:2a (16:0/18:2-PE) 16:0
716/281 34:1a (18:1/16:0-PE) 18:1
718/255 34:0a (16:0/18:0-PE) 16:0
722/303 36:4p (16:0/20:4-PE) 20:4
726/281 36:2p (18:1/16:0-PE) 18:1
728/281
36:lp (18:1/18:0-PE) or 
36:2e(18:l/18:l-PE) 18:1
730/283 36:0p(l 8:0/18:0-PE) 18:0
730/281 36:le(18:l/18:0-PE) 18:1
738/303 36:4a (16:0/20:4-PE) 20:4
740/255 36:3a (16:0/20:3-PE) 16:0
742/281 36:2a (18:1/16:0-PE) 18:1
744/281 36:1a (18:1/18:0-PE) 18:1
746/327 38:6e (16:0/22:6-PE) 2 2 : 6
746/283 36:0a (18:0/18:0-PE) 18:0
748/303 37:6 (17:2/20:4-PE) 20:4
748/327 38:6e (16:0/22:6-PE) 2 2 : 6
748/329 38:5p (16:0/22:5-PE) 22:5
750/303 38:4p (18:0/20:4-PE) 20:4
750/331 38:5e (16:l/22:4-PE) 22:4
752/307 38:3p (18:l/20:2-PE) 2 0 : 2
752/303 38:4e (20:4/18:0-PE) 20:4
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Analysed Transition 
[M-H]-
PE
Phospholipid Structure
Fatty acid analysed 
by MS
754/309 38:2p (18:1/20:1-PE) 2 0 : 1
754/307 38:3e (18:l/20:2-PE) 2 0 : 2
756/309
38: lp, (18:0/20:1-PE or 
38:2e (18:1/20:1-PE) 2 0 : 1
758/311 38:0p (18:0/20:0-PE) 2 0 : 0
762/327 38:6a (16:0/22:6-PE) 2 2 : 6
762/283 38:6a (18:0/20:6-PE) 18:0
764/281 38:5a (18:l/20:4-PE) 18:1
764/255 38:5a (16:0/22:5-PE) 16:0
766/303 38:4a (18:0/20:4-PE) 20:4
768/305 38:3a (18:0/20:3-PE) 20:3
768/281 38:3a (18:l/20:2-PE) 18:1
770/281 38:2a (18:1/20:1-PE) 18:1
772/327 39:8 (17:2/22:6-PE) 2 2 : 6
772/283 38:1a (18:0/20:1-PE) 18:0
774/283 38:0a (18:0/20:0-PE) 18:0
774/327 40:6p (18:0/22:6-PE) 2 2 : 6
776/329 40:5p (18:0/22:5-PE) 22:5
776/327 40:6e (18:0/22:6-PE) 2 2 : 6
778/303 40:4p (20:0/20:4-PE) 20:4
778/331
40:4p (18:0/22:4-PE) or 
40:5e (18:l/22:4-PE) 22:4
788/327 40:7(18: l/22:6-PE) 2 2 : 6
790/327 40:6a (18:0/22:6-PE) 2 2 : 6
792/303 40:5a (20:l/20:4-PE) 20:4
794/331 40:4a (18:0/22:4-PE) 22:4
810/327 42:8 (20:2/22:6-PE) 2 2 : 6
812/327 42:9 (20:3/22:6-PE) 2 2 : 6
814/327 42:8 (20:2/22:6-PE) 2 2 : 6
818/327 42:6a (20:0/22:6 -PE) 2 2 : 6
Table 2.2 continued (PE Phospholipid profiling transitions)
Analysed Transition 
TM+H1+
PC
Phospholipid Structure
Fatty acid also analysed 
by MS in 
negative mode
678/184 28:0 -
692/184 32:0a _
701/184 - -
703/184 - -
704/184 30:1a (14:0/16:1-PC) 14:0
706/184 30:0a (14:0/16:0-PC) 14:0 & 16:0
717/184 32:0p -
718/184
32:0p (14:0/18:0-PC) or 
32:le (14:0/18:1-PC) 14:0
720/184 32:0e (16:0/16:0-PC) 16:0
727/184 - -
729/184 - -
730/184 32:2a (16:1/16:1-PC) 16:1
731/184 - -
732/184 32a: 1 (16:0/16:1-PC) 16:0 & 16:1
734/184 32a:0 (16:0/16:0-PC) 16:0
735/184 - -
736/184 - -
744/184 34:2e (16:0/18:2-PC) 18:2
746/184 34:1 e (16:0/18:1 -PC) 18:1
748/184 34:0e (16:0/18:0-PC) 18:0
758/184 34:2e (16:0/18:2-PC) 16:0 & 18:2
760/184 34:1a (16:0/18:1-PC) 16:0 & 18:1
762/184 34:0a (16:0/18:0-PC) 16:0 & 18:0
763/184 - -
764/184 - -
772/184 36: lp or 36:2e -
774/184 36:le (18:0/18:1-PC) 18:1
782/184 36:4a (16:0/20:4-PC) 16:0 & 20:4
784/184 36:3a (16:0/20:3-PC) 16:0 & 20:3
785/184 - -
786/184 36:2a (18:1/18:1-PC) 18:1
788/184 36:1a (18:0/18:1-PC) 18:0 & 18:1
790/184
36:0a (18:0/18:0-PC) or 
38:6p (18:0/20:6-PC) 18:0
792/184 38:5p or 38:6e -
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Analysed Transition 
[M+H1+
PC
Phospholipid Structure
Fatty acid analysed MS 
in
negative mode
806/184 38:6a (16:0/22:6-PC) 16:0 & 2 2 : 6
807/184 _ .
808/184 38:5a (16:0/22:5-PC) 16:0 & 22:5
810/184 38:4a (18:0/20:4-PC) 18:0 & 20:4
811/184 _ _
812/184 38:3a (18:l/20:2-PC) 18:1 & 2 0 : 2
814/184 38:2a (18:1/20:1-PC) 18:1 & 2 0 : 1
816/184 38:1a (18:l/20:0-PC) 18:1 & 2 0 : 0
818/184 40:6p (18:0/22:6-PC) 18:0 & 2 2 : 6
820/184 40:5p (18:0/22:5-PC) 22:5
832/184 40:0e (20:0/20:0-PC) 2 0 : 0
834/184 40:6a (18:0/22:6-PC) 18:0 & 2 2 : 6
835/184 _ _
836/184 40:5a (20:l/20:4-PC) 20:1 & 20:4
839/184 _ _
862/184 42:6a (20:0/22:6-PC) 2 0 : 0  & 2 2 : 6
Table 2 3  Continued (PC Phospholipid profiling transitions)
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Analysed Transition 
[M-H]-
PI Phospholipid 
structure
Fatty acid analysed 
by MS
857/303 36:4 (16:0/20:4-PI) 20:4
859/305 36:3 (16:0/20:3-PI) 20:3
863/283 36:1 (18:0/18:1-PI) 18:0
881/327 38:6 (16:0/22:6-PI) 22:6
883/329 38:5 (16:0/22:5-PI) 22:5
885/283 38:4 (18:0/20:4-PI) 18:0
887/281 38:3 (18:l/20:2-PI) 18:1
909/283 40:6 (18:0/22:6-PI) 18:0
Table 2.4 PI Phospholipid profiling transitions
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Analysed Transition 
[M-HT
PA Phospholipid 
Structure
Fatty acid analysed by 
MS
591/227 28:0 (14:0/14:0-PA) 14:0
597/283 29:4 (18:0/11:4-PA) 18:0
619/227 32:0 (14:0/18:0-PA) 14:0
645/253 32:1 (16:0/16:1-PA) 16:1
647/255 32:0 (16:0/16:0-PA) 16:0
667/303 34:4 (14:0/20:4-PA) 20:4
671/279 34:2 (16:0/18:2-PA) 18:2
673/281 34:1 (16:0/18:1-PA) 18:1
675/283 34:0 (16:0/18:0-PA) 18:0
695/303 36:4 (16:0/20:4-PA) 20:4
699/281 36:2 (18:1/18:1-PA) 18:1
701/281 36:1 (18:0/18:1-PA) 18:1
703/283 36:0(18:0/18:0-PA) 18:0
719/327 38:6 (16:0/22:6-PA) 2 2 : 6
723/303 38:4 (18:0/20:4-PA) 20:4
727/309 38:2 (18:1/20:1-PA) 2 0 : 1
729/303 39:8 (19:4/20:4-PA) 20:4
747/327 40:6 (18:0/22:6-PA) 2 2 : 6
749/303 40:5 (20:l/20:4-PA) 20:4
751/303 40:4 (20:0/20:4-PA) 20:4
Table 2.5 PA Phospholipid profiling transitions
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Analysed Transition
[M-Hl-
PS Phospholipid 
Structure
Fatty acid analysed 
by MS
760/281 34:1 (16:0/18:1-PS) 18:1
782/303 36:4 (16:0/20:4-PS) 20:4
784/305 36:3 (16:0/20:3-PS) 20:3
786/281 36:2 (18:1/18:1-PS) 18:1
788/281 36:1 (18:0/18:1-PS) 18:1
788/283 36:1 (18:0/18:1-PS) 18:0
790/283 36:0(18:0/18:0-PS) 18:0
806/327 38:6 (16:0/22:6-PS) 2 2 : 6
808/329 38:5 (16:0/22:5-PS) 22:5
810/283 38:4 (18:0/20:4-PS) 18:0
810/303 38:4 (18:0/20:4-PS) 20:4
812/307 38:3(18: l/20:2-PS) 2 0 : 2
814/281 38:2 (18:1/20:1-PS) 18:1
816/309 38:1 (18:0/20:1-PS) 2 0 : 1
818/311 38:0 (18:0/20:0-PS) 2 0 : 0
834/327 40:6 (18:0/22:6-PS) 2 2 : 6
836/303 40:5 (20:l/20:4-PS) 20:4
838/303 40:4 (20:0/20:4-PS) 20:4
840/305 40:3 (20:0/20:3-PS) 20:3
842/307 40:2 (20:0/20:2-PS) 2 0 : 2
844/309 40:1 (20:0/20:1-PS) 2 0 : 1
846/311 40:0 (20:0/20:0-PS) 2 0 : 0
862/327 42:6 (20:0/22:6-PS) 2 2 : 6
864/329 42:5 (20:0/22:5-PS) 22:5
866/331 42:4 (20:0/22:4-PS) 22:4
Table 2.6 PS Phospholipid profiling transitions
Analysed Transition 
(M-H)-
PG Phospholipid 
Structure
Fatty acid followed 
by MS
667/303 29:6 (9:2/20:4-PG) 20:4
671/279 27:4 (9:2/18:2-PG) 18:2
675/283 29:2(18:0/11:2-PG) 18:0
703/283 31:2 (18:0/13:2-PG) 18:0
719/283 32:1 (18:0/14:1-PG) 18:0
721/255 32:0 (16:0/16:0-PG) 16:0
749/255 34:0 (16:0/18:0-PG) 16:0
773/281 36:2 (18:1/18:1-PG) 18:1
793/327 38:6 (16:0/22:6-PG) 2 2 : 6
797/303 38:4 (18:0/20:4-PG) 20:4
Table 2.7 PG Phospholipid profiling transitions
2.2.9 Cholesterol ester profiling in WT and 12/15-LOX ' murine macrophages.
Precursor mass spectra were obtained operating in positive mode. Samples were introduced at 10 
pl/min in methanol using a hamilton syringe. The de-clustering potential and collision energy 
were -140 V and -45 V respectively. Spectra were obtained from m/z 100 - 1000 atomic mass 
units over 12 seconds with 10 MCA scans acquired. Cholesterol esters were then detected by 
LC/MS/MS, having adapted a method described by Ferreira et al (2009). Cholesterol esters were 
separated on a C l8  ODS2, 5 pm, 150 x 4.6 mm column (Waters Ltd, Elstree, Hertfordshire, UK) 
using an isocratic method with mobile phase propan-2 -ol:acetonitrile:ammonium acetate 
(60:40:4) at 1 ml/min. Products were profiled by LC/ESI/MS/MS using the specific parent to 
daughter transitions of m/z 6 6 8 , 6 6 6 , 682, 690, 706, 642, 640, 670 708, 714 and 730 -> 369.1 
(cholesterol) ([M+NFLi]*) (Scheme 2.12). The collision energy for cholesterol esters was -33 V 
and the declustering potential, -91 V.
2.2.10 Investigation o f  cytokine production in response to 15-HETE-PE.
2.2.10.1 Generation of DPPC and 15-HETE-PE liposomes.
10 mM DPPC, and lpM 15-HETE-PE was prepared in chloroform. The sample was dried down 
under N2 flow then incubated under vacuum at room temperature for 1 hour. Lipids were re­
hydrated to their original concentration by the addition of RPMI media. To create liposomes the 
sample was freeze-thawed 10 times using liquid N2 and warm water. Liposomes with diameters 
of above 100 nm were excluded from the lipid emulsion using a Lipofast™ (Avestin, Toronto, 
Canada) extruder.
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R=
16:0- [M+NHJ+ = 642.8
16:1- [M+NH4]+ = 640.8
18:0- [M+NH4]+ = 670.8
18:1- [M+NH4]+ = 668.8
18:2- [M+NHJ+ = 666.8
18:201-1- [M+NH4]+ = 682.8
20:4- [M+NH4]+= 690.8
20:4OH- [M+NHJ+ = 706.8
22:6- [M+NH4]+= 714.8
22:60H- [M+NH4]+= 730.8
Scheme 2.12 Structures and m/z of cholesterol esters
82
2.2.10.2 Cellular uptake of 15-HETE-PE.
Human monocytes were isolated from buffy coats as described above, 5 x 107 leukocytes in 
monocyte medium were seeded in 24-well plates and incubated for 2 hour at 37 °C, 5 % 
humidity. The adhered monocytes were washed once with RPMI medium, then fresh RPMI 
medium (0.5 ml) was added to each well. Cells were incubated with 1 pM 15-HETE-PE, 
introduced either in methanol, in liposomes or in BSA solution (2 mg/ml BSA dissolved in 
RPMI), for various time points. At each time point, the supernatant from each well was removed 
into extraction buffer. To recover the adhered cells fresh RPMI medium was added to the wells, 
which were gently scraped then the medium was removed into extraction buffer. Following 
extraction, samples were re-suspended in methanol.
2.2.10.3 Cytokine production by human monocytes in response to LPS and 15-HETE-PE. 
Following human leukocyte isolation 5 x 107 cells were adhered to 24-well plates. Monocytes 
were cultured with 10 ng/ml LPS, with and without 20 or 40 pg (50 or 100 pM) SAPE or 15- 
HETE-PE for 24 hours. Supernatant was removed and centrifuged at 290 g. Cytokine levels were 
measured using enzyme linked immunosorbent assay (ELISA) kits from R&D (Abingdon, UK) 
and BD Biosciences (Oxford, UK).
Briefly, for R&D kits, DYNEX Immulon 4HBX 96 well plates (Fisher Scientific, 
Loughborough, Leicestershire, UK) were coated overnight with a capture antibody in PBS buffer 
overnight at either RT or 4°C. Plates were washed then blocked for one hour at RT with either 1 
or 5% BSA in PBS (or for TNFa, TNFa blocking buffer was used). Following washing, a
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standard curve of the appropriate cytokine and each sample, suitably diluted in reagent diluent 
(TNFa reagent diluent was used for TNFa) were added to plates and incubated at RT for 2 hours. 
Plates were washed, followed by the addition of the detection antibody, in reagent diluent for 2 
hours at RT. Following washing, wells were incubated with avidin-horseradish peroxidase 
conjugate in reagent diluent for 20 minutes a RT, plates were washed again and SureBlue TMB 
microwell peroxidase substrate (KPL Inc., Gaithersburg, Maryland, USA) was added and 
allowed to develop. Substrate development was stopped by acid addition, then plates were 
analysed using a multiskan spectrum plate reader (Thermolabsystems, Thermo Fisher Scientific 
Inc., Waltham, MA. USA).
Briefly, for BD Bioscience kits, Immulon plates were coated overnight with a capture antibody 
in carbonate buffer overnight at 4 °C. Plates were washed then blocked for one hour at RT with 
5% BSA in PBS. Following washing, a standard curve of the appropriate cytokine and each 
sample, suitably diluted in reagent diluent were added to plates and incubated at RT for 2 hours. 
Plates were washed, followed by the addition of the detection antibody and avidin-horseradish 
peroxidase conjugate, in reagent diluent for 1 hour at RT. Plates were washed again and 
SureBlue TMB substrate was added and allowed to develop. Substrate development was stopped 
by acid addition, then plates were analysed using a multiskan spectrum plate reader 
(Thermolabsystems, Thermo Fisher Scientific Inc., Waltham, MA. USA).
2.2.11 Investigating association o f  HETE-PEs with proteins.
2.2.11.1 Generation of radiolabelled HETE-PEs.
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Following the isolation of human monocytes as described above, the adhered monocytes were 
incubated with hrIL-4 at 37 °C for 48 hours. Following incubation, cells were scraped, counted 
by trypan blue exclusion then separated into two flasks. 700 pM hrIL-4 was added to one flask 
and to the other, 700 pM hrIL-4 and either 100 pM 14C-ethanolamine hydrochloride (13.8 
mCi/mmol) (Moravek Biochemicals Inc., Brea, CA, USA), 1 pM 14C-SAPE (56 mCi/mmol) 
(ARC UK LTD, Cardiff, UK), or 0.5 pM 14C-arachidonic acid (57 mCi/mmol) (GE Healthcare, 
Little Chalfont, Buckinghamshire, UK). Following 24 hours cells were scraped, then washed 
twice with PBS. The cells were counted by trypan blue exclusion and each was diluted to 4 x 106 
cells/ml in Krebs buffer. Using A23187, the cells were activated for 15 minutes or 3 hours. 
Following each time-point, lipids from samples were either immediately extracted or were 
reduced prior to extraction, using 1 mM SnCL for 10 minutes (RT) or 10 mM NaCNBH3 for 1 
hour at (37 °C). Lipids were then extracted using hexane, both the organic and aqueous phases 
were kept for analysis, the organic layers were dried under N2 flow then re-suspended in 
methanol. To determine their 14C radioactive content, samples were analysed for 10 minutes on a 
Tri-Carb 2100 TL liquid scintillation analyser (Packard, Global Medical Instrumentation Inc, 
Ramsey, Minnesota, USA).
The organic fraction underwent LC/MS/MS analysis as described above in section 2.2.2.2, 30 
second fractions were collected over times corresponding to the elution of the HETE-PEs and 
their parent compounds, which were then subject to scintillation counting. To investigate which 
of the phospholipid classes contained the 14C radiolabel, the organic fraction was also analysed 
by NP- HPLC, 1 minute fractions were collected and subject to scintillation counting. 
Alternatively, proteins from the aqueous samples were precipitated by incubating with 10 %
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TCA for 30 minutes, on ice, followed by a centrifugation at 17,500 g for 15 minutes at 4 °C. 
Supernatant was removed and pellet was re-suspended in Krebs buffer. Both pellet and 
supernatant was analysed by scintillation counting.
2.2.12 Transmission electron microscopy ofW T and 12/15-LOX ' cells.
2.2.12.1 Sample Preparation.
Wild type and 12/15-LOX"7' mice were sacrificed and peritoneal lavages were carried out with 
PBS. Lavage cells, pelleted in eppendorfs, were submerged in cacodylate buffer containing 2.5 
% glutaldehyde and stored at 4 °C overnight. Samples were washed twice for 15 minutes with 
0.1 M cacodylate buffer then re-suspended in 1% osmium tetroxide in 0.2 M cacodylate buffer 
and incubated at room temperature for 1 hour. Samples were washed four times for 15 minutes 
with H2O followed by staining with 0.5 % urianyl acetate in dfhO for 1 hour at RT. All samples 
were dehydrated by re-suspending in a series of solutions containing increased percentage of 
ethanol, each for 15 minutes: 50 %, 70 %, 80 %, and 90 % followed by 3 times with 100 % 
ethanol. Samples were transferred to glass vials and re-suspended in propyl oxide. Resin 
infiltration was carried out by re-suspending samples in 1:1 pre-mixed embedding resin and 
propyl oxide overnight, at room temperature, leaving the vials open to allow evaporation of the 
propyl oxide. Cell samples were immersed further with fresh embedding resin and transferred 
into plastic moulds. Cell/tissue pellets were allowed to settle to the bottom of the moulds, 
following 2 hours at RT, samples were transferred to an oven set at 60 °C where they were left 
for approximately 48 hours.
2.2.12.2 Cutting and sectioning of resin pellets.
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90 nm sections were cut from 3 different pellet locations using a Reichert-Jung Ultracut E 
microtome. Sections were then mounted onto naked grids. Grids were stained using 2 % urianyl 
acetate for 10 minutes, washed twice with distilled water followed by staining with Reynold’s 
lead citrate for 5 minutes and an additional two washes with dE^O. Samples were dried on filter 
paper then analysed by transmission electron microscopy, on a Philips EM208.
2.2.12.3 Development of EM pictures.
Kodak EM 2289 film (Agar Scientific, Stansted, Essex, UK) was developed for 3.5 minutes, at 
20 °C in Kodak D-19 developer, diluted 1:2 with H2O. Films were then fixed by incubating for 
30 seconds in an acetic acid stop bath, followed by 4 minutes in Ilford Hypam fixer, diluted 1:3 
with H2O. Films were washed under running water for 20 minutes then dried.
2.2.13 Statistical Analysis.
Data is presented as the mean +/- SEM. of three independent experiments. Statistical analysis of 
differences was carried out by Students t-test or by one-way ANOVA with a Tukey post hoc test 
to compare all pairs of data sets. A p-value of less than 0.05 was considered to be significant.
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CHAPTER 3
SYNTHESIS, PURIFICATION AND CHARACTERISATION OF 18:0a/15-HFTE-PE
AND 18:0a/15-HpETE-PE
3.1 Introduction
The availability of oxidised phospholipid standards is key to investigating their biological 
function and equally important is the ability to quantify these lipids. Many studies have been 
carried out using mixtures of oxidised phospholipids (Ox-PLs), generated either by air 
oxidation or by exposure to reactive nitrogen species (Watson et al, 1997, Podrez et al, 1999, 
Podrez et al, 2002, Von Schlieffen et al, 2009, Cherepanova et al, 2009, Walton et al, 2003, 
Leitinger et al, 1999). The use of crude phospholipid mixtures is a major weakness in the 
experiments described in these studies, as it is difficult to determine which phospholipid 
oxidation product is the cause of an exerted effect. Thus, when investigating the effect of a 
particular phospholipid on cell function, it is important that it is free of contaminants, such as 
additional bio-active lipids.
In the studies listed above, no individual molecular species of Ox-PL were quantified.
However, the total amount of Ox-PLs was evaluated by calculating the amount of total lipid
peroxide products, or by estimation, based on how much substrate was used. Alternatively,
Ox-PLs were quantified using microphosphorus assays (Gao et al, 2006, Chen et al, 2008).
The importance of knowing the quantity and concentration of specific lipids used in an
experiment cannot be overlooked. Using estimated or inaccurate concentrations may lead to
experiments being carried out under non-physiological conditions and consequently result in
incorrect or misleading data. Thus far, a lack of oxidised phospholipid standards has meant
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that their direct quantification by MS has not been possible. Up to now, Ox-PLs were 
indirectly quantified in our studies by calculating the amount of eicosanoids, following their 
release from phospholipids by base hydrolysis (Maskrey et al, 2007). The structures of Ox- 
PLs are more complex and unstable than the un-oxidised lipid substrates, as a result, Ox-PLs 
are more challenging to study.
To enable the quantification of 15-HpETE-PEs and 15-HETE-PEs, purified forms of these 
lipids are required as standards. In 1987, a study was published describing the use of soybean 
LOX to oxidise fatty acids esterified to PC (Brash et al, 1987). As soybean LOX is 
commercially available, the method described by Brash et al was adapted to generate our 
own phospholipids of interest, specifically, PEs containing 15-HETE at the sn2 position (Van 
Os et aU 1981).
3.1.1 Method development for the synthesis o f 15-HpETE-PE and 15-HETE-PE.
The structures of 15-HETE-PEs previously detected in human monocytes are shown in 
Scheme 2.1 (Maskrey et al, 2007). 15-HpETE-PEs differ by the presence of a peroxyl group 
at C-15, rather than a hydroxide (Scheme 2.8). The four 15-HETE-PEs differ from each other 
by the identity of their snl fatty acid or by the type of bond by which they are connected to 
the phospholipid. One is attached via a diacyl bond (Scheme 2.1 A), while the remaining 
three are plasmalogens (Scheme 2.1 B-D). To generate the diacyl 15-H(p)ETE-PE, 15-LOX 
can be used to oxidise l-stearoyl-2-arachidonyl-sn3-phosphatidylethanolamine (SAPE) 
(Scheme 2.5 A), available from Avanti as a pure lipid. However, the substrates for the three 
plasmalogen lipids are only available as a mixture of ‘brain plasmalogen PEs . Therefore, 
while all four lipids can be synthesised, the plasmalogens would require additional
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purification. Attempting to isolate particular lipids from a complex mixture would be a far 
greater challenge than synthesising and isolating one product from a single substrate. Scheme
3.1 describes the proposed method for the synthesis of 18:0a/15-HpETE-PE and 18:0a/15- 
HETE-PE. Before a synthesised compound is used, its identity must be thoroughly 
established by structural characterisation. It must also be analysed to ensure that it is free of 
contaminants, which could potentially interfere with the biological activity of the lipid.
The discovery of four 15-H(p)ETE-PEs in human monocytes made it a requirement to have a 
pure standard to enable direct quantification of these esterified lipids by MS and also, for use 
in experiments investigating their biological function (Maskrey et al, 2007). As described in 
Chapter 1, cellular LOX enzymes generate HpETEs that are rapidly reduced to the 
corresponding hydroxyl compounds (HETEs) by glutathione peroxidases (Ursini & Bindoli, 
1987). As a result, both 15-HpETE-PE and 15-HETE-PE standards were required.
3.1.2 Aims
• To synthesise 18:0a/15-H(p)ETE-PE of a pure quality for use as a standard for 
quantification and biological studies.
• To confirm the structure of the product using a combination of techniques, including 
NMR, MS and traditional chromatographic techniques.
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18:0a/20:4-PE, [M-H]- =766.6
Oxidation of SAPE by 15-Lipoxygnease 
(Soybean Type V)
18:0a/15-H pETE-PE, [M-H]- = 7 9 8 .6
Reduction by SnCI2*
18:0a/15-H ETE-PE, [M-H]- = 78 2 .5 .
Removal of lipids by hexane extraction
v
Purification of 15-HpETE-PE /
15-HETE-PE from crude lipid mixture by RP-HPLC
v
Evaporation o f  h e x a n e  by drying under N2
i
R e -su sp e n s io n  into a known vo lum e of m ethanol
/  \
A nalysis  by MS Calculation of am ount
by UV
* For the sy n th e s is  of 15-H ETE-PE only
Scheme 3.1. Method for the synthesis and purification of 
15-HpETE-PE and 15-HETE-PE
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3.2 Results
3.2.1 Structural characterisation of 18:0a/15-HpETE-PE and 18:0a/15-HETE-PE.
3.2.1.1 UV analysis
Following the oxidation of SAPE by LOX, the reaction products were extracted and analysed 
by UV. Products had a A,-max at 235 nm, indicating the presence of a conjugated diene 
chromophore (Figure 3.1). 15-HpETE-PE and 15-HETE-PE contain a conjugated diene while 
SAPE does not, thus the results show that SAPE was successfully oxidised. Next, 15-HETE- 
PE and 15-HpETE-PE were purified by reverse phase HPLC, monitoring elution at a 
wavelength of 235 nm. As indicated, both oxidised products eluted at approximately 21 
minutes, clearly separating from the substrate lipid, SAPE (Figure 3.2).
3.2.1.2 Mass spectrometry analysis
Following purification, the products were analysed by MS, a single ion with m/z of 782.6 or 
798.6 [M-H]‘ were seen for the hydroxy and hydroperoxy phospholipids respectively (Figures
3.3 and 3.4). The figure insets show the product ion spectra of the phospholipids, 
demonstrating daughter ions diagnostic of 15-HETE at m/z 219 and 175, the daughter ions of 
15-HpETE were at 317 and 219. The fragment with m/z of 283 corresponds to stearic acid, 
present at the snl position.
3.2.1.3 'H,31? and ,3C NMR analysis of 15-HETE-PE
To confirm the structure of 15-HETE-PE using an additional method, the purified lipid was
analysed by multinuclear NMR. The result of these analyses was consistent with the
18:0a/l 5-HETE-PE structure. ]H-NMR analysis identified the protons adjacent to the
conjugated diene, specifically, the double doublet at 8 6.56 (1H, J  — 15.02 and 11.02 Hz)
(labelled as HA), the triplet at 5 6.02 (1H, J= 10.55 Hz) (HB) and the double doublet at 5 5.68
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Figure 3.1 Products of SAPE oxidation by LOX have an absorbance maxima at 235 
nm, confirming the presence of a conjugated diene. SAPE was oxidised using 
soybean LOX followed by SnCl2 reduction. The lipid products were extracted then 
analysed using a UV spectrometer prior to purification.
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Figure 3.2. 18:0a/15-HETE-PE and 18:0a/15-HpETE-PE separates from SAPE during 
RP-HPLC. 15-HpETE-PE was synthesised by oxidising SAPE using soybean LOX, followed 
by SnCl2 reduction to generate 15-HETE-PE. Both lipids were extracted then underwent 
purification and analysis by UV-RP-HPLC. A) UV-RP-HPLC purification of 15-HETE-PE. B) 
UV-RP-HPLC purification of 15-HpETE-PE.
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Figure 3.3 18:0a/l 5-HETE-PE was free from contaminants and its structure was 
confirmed. 18:0a/l 5-HETE-PE was generated by soybean LOX oxidation of SAPE 
followed by SnCl2 reduction. The lipid was purified by RP-HPLC then analysed by MS 
Q1 scans in negative mode, the major component present was then analysed by product 
ion spectra (inset).
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Figure 3.4 18:0a/l5-HpETE-PE was free from contaminants and its structure was 
confirmed. 18:0a/l 5-HpETE-PE was generated by soybean LOX oxidation of SAPE. 
The lipid was purified by RP-HPLC then analysed by MS Q1 scans in negative mode, 
the major component present was then analysed by product ion spectra (inset).
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(1H, J = 14.8 Hz and 6.75 Hz) (Hc) (Figure 3.5). For 13C-NMR, signals at 6 138.07, 130.53, 
130.05, 129.94, 129.55, 129.47, 128.80, and 126.21 confirm the presence of the alkene bonds 
and the conjugated diene (Figure 3.6). However, the signals corresponding to the carbonyl 
groups were not detected, probably due to the very low concentrations of the sample. The 
31P-NMR spectrum showed that 15-HETE-PE was free of phosphorus containing 
contaminants such as detergents (Figure 3.7). Importantly, NMR analysis confirmed the 
presence of the conjugated diene which is formed during oxidation. As synthesis of 15- 
HpETE-PE only differs to that of 15-HETE-PE by excluding the reduction step, 15-HpETE- 
PE was not analysed by NMR.
3.2.1.4 Analysis of 15-HETE-PE by chromatographic techniques
To confirm the positional isomer of HETE present in the synthesised lipid, traditional 
chromatographic techniques were used. Purified 15-HETE-PE underwent saponification to 
release the fatty acids and the extracted products were analysed by LC/MS/MS for all HETE 
transitions. The HPLC traces confirm that the only HETE isomer present is 15-HETE (Figure 
3.8). 15-HETE was then collected during RP-HPLC separation and its chirality was 
determined by separation on a Chiralcel OD column (as described in section 2.2.4.3). The 
sample was compared to 15R- and 15S-HETE standards and found to contain mainly the S- 
isomer, as expected from the enantiomeric specificity of soybean 15-LOX (Figure 3.9).
3.2.2 Product yield o f 15-HETE-PE and 15-HpETE-PE.
To synthesise 18:0a/l 5-HETE-PE and 18:0a/15-HpETE-PE, SAPE was oxidised using 
soybean LOX (Type V), with or without reduction by SnCb respectively. From 20 mg of 
SAPE substrate, there was a product yield of approximately 6 mg of purified 15-HpETE-PE 
and 15-HETE-PE, calculated using UV. This is equivalent to a 30% yield of product.
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Figure 3.5 'H-NMR of 15-HETE-PE. 18:0a/15-HETE-PE was synthesised by 
soybean LOX oxidation of SAPE followed by SnCl2 reduction. The lipid was purified 
by RP-HPLC, dried under gaseous N2 then re-suspended in deuterated chloroform. 15- 
HETE-PE was analysed by ’H-NMR (500 MHz) on a Bruker Avance 500 MHz 
spectrometer at 25 °C. The inset shows the signals that correspond to three hydrogen 
atoms near the conjugated diene (H(A), H(B) and H(C)). 98
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Figure 3.6 l3C-Pendant NMR of 15-HETE-PE. 18:0a/15-HETE-PE was synthesised 
by soybean LOX oxidation of SAPE followed by SnCl2 reduction. The lipid was 
purified by RP-HPLC, dried under gaseous N2 the re-suspended in deuterated 
methanol. 15-HETE-PE was analysed by 13C-Pendant NMR spectroscopy on a Bruker 
Avance 500 MHz at 25 °C.
31P-NMR (202  MHz C D 3OD) 6  -1 .29 .
Figure 3.7 3,P NMR of 15-HETE-PE. 18:0a/15-HETE-PE was synthesised by 
soybean LOX oxidation of SAPE followed by SnCl2 reduction. The lipid was purified 
by RP-HPLC, dried under gaseous N2 then re-suspended in deuterated methanol. 15- 
HETE-PE was analysed by 3IP-NMR (202 MHz) on a Bruker Avance 500 MHz 
spectrometer at 25 °C.
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Figure 3.8 Synthesised lipid contains only 15-HETE. 18:0a/15-HETE-PE was 
synthesised by soybean LOX oxidation of SAPE followed by SnCl2 reduction. The 
lipid was purified by RP-HPLC then underwent base hydrolysis to release the HETE. 
The fatty acids were extracted followed by LC/MS/MS analysis.
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Figure 3.9 Synthesised 15-HETE-PE contains largely 15S-HETE. 15R and 15S- 
HETE were analysed by chiral phase chromatography individually (A). 18:0a/l5- 
HETE-PE was synthesised by soybean LOX oxidation of SAPE followed by SnCl2 
reduction. The lipid was purified by RP-HPLC then underwent base hydrolysis to 
release the HETE. 15-HETE was collected during RP-HPLC then analysed by chiral 
phase HPLC and compared to combined 15R- and 15S-HETE standards (B).
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3.2.3 Synthesised 18:0a/15-H(p)ETE-PE standards have the same elution time as 18:0a/15-
H(p)ETE-PEs from human monocytes.
Prior to their use as standards, LC/MS/MS analysis of the synthesised 18:0a/15-H(p)ETE-PEs 
were compared to that of 18:0a/15-H(p)ETE-PEs derived from human monocytes, to confirm 
that they were the same phospholipids. Human monocytes were activated using A23187 for 
15 minutes followed by lipid extraction either directly, or after SnCl2 reduction. LC/MS/MS 
analysis showed that both human monocyte derived, and the synthesised 18:0a/15-HETE-PE 
and 18:0a/15-HpETE-PE standards have the same retention time. This confirms that they are 
the same lipids (Figures 3.10 and 3.11).
3.2.4 Development o f an assay for phospholipid quantification by MS.
A new method for quantifying phospholipids following MS analysis is required. The assay 
described herein calculates the amount of 15-H(p)ETE-PE in samples by comparing the 
analyte peak area to the peak area of an internal standard. To account for differences in lipid 
recovery during the extraction procedure, an internal standard (Di-myristoyl 
phosphatidylethanolamine (DMPE)) was added to biological samples prior to extraction. 
DMPE was used as an internal standard as it is the closest phospholipid in structure to 15- 
HETE-PEs that is not present in the samples analysed for this thesis. Prior to quantifying 15- 
H(p)ETE-PE in samples, a standard curve was constructed where varying amounts (0 - 
10,000 pg) of 15-HETE-PE, or 15-HpETE-PE, was added to a fixed amount of DMPE (100 
pg). Thus, different ratios of 15-H(p)ETE-PE vs DMPE were present in each sample. 
Following LC/MS/MS analysis, the ratio of the integrated area of 15-H(p)ETE-PE:DMPE 
was plotted against the ratio of pg 15-H(p)ETE-PE:DMPE injected (Figures 3.12 and 3.13). 
A standard curve generated for 15-HETE-PE using a daughter ion of 219 can only be used to 
quantify 15-HETE-PE products (rather than other HETE isomers), as 219 is a fragment
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Figure 3.10. Human monocyte 18:0a/15-HETE-PE has the same retention 
time as a 18:0a/15-HETE-PE standard. Human monocytes were activated for 
15 minutes using A23187, followed by reduction with SnCl2 and lipid extraction. 
Lipids from monocyte samples and a 18:0a/15-HETE-PE standard were analysed 
by LC/MS/MS.
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Figure 3.11.18:0a/15-HpETE-PE from human monocytes has the same retention 
time as the 18:0a/15-HpETE-PE standard. Human monocytes were activated with 
10 pM A23817 for 15 minutes followed by and lipid extraction. Monocyte samples 
and 18:0a/l 5-HpETE-PE standard were analysed by LC/MS/MS.
105
1.8e5
(/>
Q.O
CA
£ 1.0e5
24,00
[M-H]- = 782/219 
18:0a/15-HETE-PE
B
3.0e5
(AQ.o
■|'2.0e5
C0)
1.0e5
0
10
[M-H]- = 798/317 
18:0a/15-HpETE-PE
20 Timo min 30 Time, min
23.82
40 50
10 20 T J m o  m in  3 0Time, min 40 50
2.0e4
(A
Q .O
£
(A 1.0e4 c  d) 
c
o
[M-H]- = 634/227 
DMPE (14:0, 14:0 PE)
24,69
10 20 Time, min 30 40 50
Figure 3.12. Representative chromatograms of synthesised 15-HETE-PE, 15-HpETE- 
PE and DMPE standards. A synthesised and purified 15-HETE-PE (A), 15-HpETE-PE 
(B) and a DMPE standard (C.) were analysed by LC/MS/MS. To generate a standard curve 
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Figure 3.13. Representative standard curve for 15-HETE-PE and 15- 
HpETE-PE. A synthesised and purified 15-HETE-PE and a DMPE standard 
were analysed by LC/MS/MS. To generate a standard curve the ratio of peak 
areas of detected 15-HETE-PE and DMPE is plotted against the known ratio 
of actual quantity injected. The gradient from the standard curve can then be 
used to quantify 15-HETE-PE in test samples. 107
specific to 15-HETE. However, a standard curve formed using a daughter ion of 319 could be 
applied in the quantification of all PE-HETE isomers.
The standard curves were linear over a 200-fold range (50 to 10,000 pg) and the equations for 
the lines of regression were y = 0.3144x for 15-HETE-PE and y = 0.3775x for 15-HpETE- 
PE. In addition, the line slopes did not vary significantly from unity (r2 = 0.9989 to 0.9999 
respectively) (Figure 3.13). The lower limit of detection, determined by a minimum signal to 
noise ratio of approximately 4:1, was approximately 25 pg. The gradient of the generated 15- 
H(p)ETE-PE standard curve can be used to quantify 15-H(p)ETE-PEs in test samples using 
the following formula:
Analyte (ng)
r
Analyte Peak Area v
r
Internal Standard (ng)
Internal Standard Peak Area v. J
A
Gradient from standard curve ^ J
3.3 Discussion
The work described in this chapter illustrates the successful adaptation of a published method 
to synthesise our own lipids of interest (Brash et al, 1987). Furthermore, the structures of the 
generated products were confirmed using techniques comparable to those used in the same 
published article, which included analysis by UV, RP-HPLC, MS, NMR and chiral HPLC.
This chapter has also described a new assay for the quantification of 15-H(p)ETE-PEs, which 
is more accurate than methods used up to now. Previous studies have not calculated amounts 
of individual molecular species of phospholipid products, or they were quantified indirectly 
by calculating the amount of sn2 fatty acids following base hydrolysis (Watson et al, 1997, 
Podrez et al, 1999, Podrez et al, 2002, Von Schlieffen et al, 2009, Cherepanova et al, 2009, 
Walton et al, 2003, Leitinger et al, 1999, Maskrey et al, 2007). Also, the quantification 
methods used in these referenced articles did not take into account the amount of product lost 
during lipid extraction. This is addressed by the new quantification method described in this 
chapter, by adding the internal standard (DMPE) to samples during lipid extraction. 
Furthermore, using the hexane:isopopanol-based extraction solvent the recovery of lipids is 
approximately 76-83%, which is greater than that achieved when using the Bligh and Dyer 
extraction method (60-62%) (Morgan et al, 2010). In publications by Podrez et al (2002a & 
2002b), a similar assay was used. Particular oxidised PC lipids (such as 9-hydroxy-12-oxo- 
10-dodecenoic acid (HODA-PC) and 9-keto-12-oxo-10-dodecenoic acid (KODA-PC)) were 
quantified with the aid of synthesised standards, some of which are available from Avanti. 
However, lipid extraction was carried out using the Bligh and Dyer method, followed by the 
addition of the internal standard. Conversely, adding a known amount of standard to samples 
before lipid extraction (as described in this chapter) ensures that the efficiency of extraction is
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taken into consideration during quantification. Therefore, the amount of lipids present can be 
calculated with greater accuracy.
Currently, DMPE is used as an internal standard as structurally, it is the most similar 
phospholipid to HETE-PEs available that is not present in human monocytes and murine 
macrophages, which are the samples used throughout this thesis. The extraction efficiency of 
DMPE is also at 76-83% using the hexaneiisopropanol based extraction, similar to that of the 
HETE-PEs (Morgan et al, 2010). However, as the structures of DMPE and the HETE-PEs are 
different their extraction efficiency will not be exactly the same. A more suitable standard 
would be a deuterated PE-HETE, which would have an identical extraction efficiency and 
could also be analysed by LC/MS/MS. Previous researchers have synthesised deuterated 
hydroperoxide and hydroxide -PC lipids, (Milne et al, 2005) (Scheme 3.2). This method 
could be adapted to incorporate deuterium onto the amine of a PE head group. Initial 
experiments attempting to synthesise deuterated 15-HETE-PEs have been carried out by 
members of the O’Donnell research group, but were not successful. Nonetheless, efforts to 
synthesise these standards are ongoing through collaboration with members of the research 
group involved in the development of this technique (Milne et al, 2005).
In addition to 15-H(p)ETE-PEs, other phospholipid-HETE isomers require quantification, 
including 12-HETE-PEs detected in murine macrophages and 5-HETE-PEs in neutrophils. 
The 15-HETE-PE standard curve can be generated following MS analysis, using a daughter 
ion of m/z 219 or 319. 219 is a fragment that is specific to 15-HETE, therefore, a standard 
curve generated using this daughter ion can be used specifically to quantify 15-HETE-PEs. 
However, a standard curve generated using a daughter ion of 319 (the m/z of HETE [M-H]') 
could be used to quantify all the HETE isomers. During RP-HPLC analysis of samples, 15-, 
12- and 5-HETE-PEs can be distinguished as they elute at different times, in this order
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Scheme 3.2 Synthesis of d9-l-steroyl, 2-archidonyl-sn-glycero-3-PC hydroperoxide (- 
OOH) and alcohol (-OH) internal standards. The PC head groups were cleaved by 
phospholipase D in the presence of d9-Choline. The phospholipids were oxidised using 
soybean LOX then reduced using triphenylphosphine (reproduced from Milne et al, 2005, 
with permission (06/12/2010)).
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(Morgan et al, in preparation). 12-HETE-PE or 5-HETE-PE can then be selected during MS 
analysis for quantification. However, in some instances, HPLC peaks overlap and on these 
occasions the selected peak area of analytes may not be a true reflection of the actual amount 
present. Analysing each HETE isomer to its specific daughter ion fragment would allow 
greater accuracy during quantification, for example, using daughter ions with m/z of 179 for 
12-HETE-PEs and 115 for 5-HETE-PEs. Quantification by this method would require the 
synthesis of 12- and 5-HETE-PE standards. However, there are no purified LOX enzymes 
that can oxidise efficiently at C-12 and C-5 of AA. A rabbit 15-LOX has been successfully 
isolated and also, a recombinant platelet 12-LOX, but no mammalian 5-LOX. These enzymes 
would not be suitable for synthesising large quantities of lipid standards as mammalian 
isoforms of LOX undergo rapid suicidal inactivation. As a result, veiy little amounts of 
products are synthesised, which are insufficient to use in biological studies (O’Donnell, 
unpublished). A 5-LOX has been isolated from potatoes but results from preliminary 
experiments show that this enzyme also oxygenates at C-15 of AA and only generates a small 
yield of 5-HETE-PEs (Clark et al, unpublished).
Since this method of synthesising 15-H(p)ETE-PE was developed, an alternative method of
synthesising phospholipid standards has established by the O’Donnell research group, by
adapting different published methods (Yin et al, 2008, Milne et al, 2005). This involves the
air oxidation of substrates such as SAPE in the presence of a vitamin E analogue, which
prevents the formation of secondary oxidation products. All HpETE-PE isomers are formed
during this process, specifically a mixture of 5-, 8-, 9-, 11-, 12- and 15-HpETE-PEs
(O’Donnell et al, unpublished). They are reduced using SnCE to form HETE-PEs if required.
The relative proportion of each isomer is determined by separation using a Discovery C-18
column, and the overall UV absorbance is used to calculate the amount of each isomer (Milne
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et al, 2005). Using the mixed HETE isomer standard with the quantification assay described 
in this chapter, standard curves of each HETE isomer are generated. Thus, each HETE-PE 
can be analysed during MS, using its specific daughter ion fragment. Therefore, all esterified 
HETE products can be quantified. This method has also been used to generate HETE-PC 
products, using SAPC as the substrate. In addition, oxidised products of linoleic acid (LA) 
and docosahexaenoic acid (DHA) (both free and esterified) have been synthesised using the 
air oxidation method. Thus, the majority of analytes investigated by the O’Donnell research 
group can now be directly quantified (Morgan et al, 2010).
As a direct result of the experiments described in this chapter, 15-H(p)ETE-PEs can now be 
quantified directly and with greater accuracy. Results will therefore be more reliable in 
comparison to experiments where products were quantified indirectly, or by estimation. 
Greater accuracy during quantification will mean that physiological concentrations of 15- 
H(p)ETE-PEs can be determined and therefore applied during biological experiments. Using 
one oxidised phospholipid in experiments is more specific than using a mixture of oxidised 
phospholipid molecular species. Thus, published results will give a truer account of the 
concentrations and actions of these phospholipids.
The synthesised 15-H(p)ETE-PE standards and the quantification assay described in this 
chapter was used in the subsequent chapters of this thesis. Specifically, 15-H(p)ETE-PEs 
were quantified in human monocytes (Chapter 4) and human peritoneal lavages (Chapter 7). 
Furthermore, 12-H(p)ETE-PEs were quantified in murine macrophages using the air oxidised 
standard described above (Chapter 6). Finally, the synthesised 15-HETE-PE standard was 
added to human monocytes to investigate potential anti- or pro- inflammatory actions 
(Chapter 7).
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CHAPTER 4
CHARACTERISATION OF 15-H(d1£TE-PE METABOLISM FOLLOWING
ACTIVATION OF 15-LOX
4.1 Introduction
Products of 12/15-LOX may be involved in regulating inflammation, but the identities of the 
specific lipid products remain unknown (Kuhn & O’Donnell, 2006). Oxidation of AA by LOX 
generates HpETEs that contain a hydroperoxide group and these are believed to be rapidly 
reduced to hydroxides by GPx enzymes (M^Ginley & van der Donk, 2003, Hamberg & 
Samuelsson, 1974, Ursini & Bindoli, 1987). Peritoneal macrophages from mice lacking 12/15- 
LOX (12/15-LOX'7") show abnormalities in regulating cytokine production, both basally and 
following infection with S.epi (Dioszeghy et al, 2008). The addition of 12-HETE and 12-HpETE 
to 12/15-LOX"7" mice infected with S.epi, did not restore wild type (WT) phenotype (Dioszeghy 
et al, 2008). This suggests that alternative products formed by LOX may be responsible for its 
biological effects. While esterified products of 15-LOX known as 15-H(p)ETE-PEs have been 
identified in human monocytes, their metabolism has not been characterised (Maskrey et al, 
2007). Given that 12/15-LOX may have important implications in several inflammatory 
disorders, it is important to investigate what happens to 15-H(p)ETE-PEs following their 
generation. This may lead to the identification of products that are responsible for the effects 
exerted by 12/15-LOX.
A study by Maskrey et al (2007) concentrated on characterising the initial generation of 15- 
H(p)ETE-PEs in human monocytes and established several points concerning these lipids.
(1) Following activation, approximately 30% of l5-H(p)ETE is esterified.
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(2) Esterified 15-H(p)ETE is predominantly associated with PE phospholipids.
(3) Four 15-H(p)ETE-PEs are generated following monocyte activation (Scheme 2.1).
(4) H(p)ETE derived from human monocyte 15-H(p)ETE-PE consists mainly of the ‘S’ 
enantiomer.
(5) 15-H(p)ETE-PEs are formed by direct oxidation of AA-containing PE lipids (AA-PEs), and 
not by esterification of 15-H(p)ETE.
Following the discoveiy and structural characterisation of human monocyte 15-H(p)ETE-PEs by 
Maskrey et al (2007), the studies described in this chapter address the issue of how 15-H(p)ETE- 
PEs are metabolised following their generation. In addition, the quantification assay developed in 
Chapter 3 will be used for the first time, to directly quantify these novel phospholipids.
4.1.1 Aims
Establishing what happens to 15-H(p)ETE-PEs following their synthesis may have indicated 
how they are involved in complex immune processes. Therefore, the studies described in this 
chapter aimed to:
• Describe how 15-H(p)ETE-PEs are metabolised in human monocytes.
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4.2 Results
4.2.1 15-H(p)ETE-PEs increase following monocyte activation and are metabolised by 3 hours
following their synthesis.
The temporal generation of 15-H(p)ETE-PE generation by human monocytes was determined. 
Monocytes were activated for 10 to 180 minutes, and lipids reduced using SnCl2 before 
extraction. Importantly, this reduction step converts all 15-HpETE to 15-HETE, thus detected 
15-HETE-PEs is the total of esterified LOX products. Lipids were extracted then analysed by 
LC/MS/MS. 15-H(p)ETE-PEs increased significantly by 10 minutes following activation and 
then declined by 180 minutes (Figure 4.1). The results suggest that 15-H(p)ETE-PEs are 
metabolised following their synthesis.
4.2.2 15-H(p)ETE-PE metabolism does not involve hydrolysis o f 15-H(p)ETE, conversion o f the 
PE head group to PC or elongation o f  15~H(p)ETE.
There are several possibilities for the metabolism of 15-H(p)ETE-PEs, including cleavage or 
elongation of the Sn2 fatty acid, or conversion of the PE head group to PC or PS. To investigate 
whether the decrease in 15-H(p)ETE-PEs may have been due to cleavage of the sn2 fatty acid by 
PLA2, time-course samples were analysed by LC/MS/MS for free 15-H(p)ETE. The results 
showed that free 15-H(p)ETE increased by 10 minutes, but then remained the same throughout 
the time-course (Figure 4.2). Constant levels of free 15-H(p)ETE suggested either that free 15- 
H(p)ETE was not metabolised following its synthesis, or that free 15-H(p)ETE was 
simultaneously cleaved and re-esterified. To investigate this latter possibility, monocyte samples 
were spiked with free 15-HETE-ds then activated for time-points of 10 - 180 minutes. The lipids 
were then extracted and analysed by LC/MS/MS. 15-HETE-d8 levels did not change throughout
116
ng 
/1
 
m
ill
io
n 
ce
ll
s
60
30
■ 782/219 (18:0a/15-HETE-PE)
■ 766/219 (18:0p/15-HETE-PE)
■ 764/219 (18:1 p/15-HETE-PE) 
□ 738/219 (16:0p/15-HETE-PE)
10 20 30 60 90 120 180
Time (mins)
Figure 4.1. 15-H(p)ETE-PEs are metabolised to unknown products by 3 
hours. Human monocytes were activated with 10 pM A23187 for various time 
points followed by reduction with SnCl2. Lipids were extracted and analysed by 
LC/MS/MS (n = 3, mean ± SEM). *Students t-test, p < 0.05, with one-tailed 
Mann-Whitney test, the difference of each analyte is significant in comparison to 
its relative control.
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Figure 4.2 15-H(p)ETE remains stable following synthesis. Human monocytes 
were activated with 10 pM A23187 for various time points then reduced with SnCl2. 
Lipids were extracted and analysed by LC/MS/MS (n = 3, mean ± SEM). * Students 
t-test, p < 0.05, the difference is significant in comparison to the control sample.
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the time-course, which indicates that 15-H(p)ETE is unlikely to undergo simultaneous cleavage 
and re-esterification (Figure 4.3). To further confirm that 15-H(p)ETE is not being hydrolysed 
from 15-H(p)ETE-PEs, human monocytes were incubated with PLA2 inhibitors and a PAF-AH 
inhibitor, prior to activation. Levels of 15-H(p)ETE-PEs increased following activation, then 
returned to baseline by three hours (Figure 4.4), similar to the activated monocyte time-course 
shown in Figure 4.1. If hydrolysis of 15-H(p)ETE had been a method of 15-H(p)ETE-PE 
metabolism, inhibiting PLA2 enzymes have resulted in levels of 15-H(p)ETE-PEs remaining the 
same throughout the time-course following their synthesis, rather than declining to basal levels. 
Therefore, the metabolism of 15-H(p)ETE-PEs does not involve hydrolysis of 15-H(p)ETE by 
PLA2.
The decrease in 15-H(p)ETE-PEs seen in Figure 4.1 may have been due to conversion of the 
phospholipid head group from PE to PC or PS, by PE methyltransferase or PS synthase, 
respectively (Berg et al, 2002) (Schemes 4.1 and 4.2). In order to study conversion to PC, a 
18:0a/15-HETE-PC standard was synthesised. SAPC was oxidised using soybean LOX, followed 
by SnCl2 reduction and lipid extraction. The 18:0a/15-HETE-PC product was then analysed by 
MS to determine its m/z and elution time. LC/MS/MS analysis and product ion spectra were 
acquired in both positive and negative modes, which confirmed the identity and elution time of 
18:0a/l5-H(p)ETE-PC (Figure 4.5). 16:0p, 18:0p and 18:lp/15-H(p)ETE-PCs were also 
synthesised by oxidising a mixture of brain plasmalogen PC phospholipids using soybean LOX, 
but the product ion spectra were inadequate for identification and their elution times could not be 
confirmed. Consequently, monocyte samples were analysed for 18:0a/15-HETE-PC only.
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Figure 4.3 15-HETE-d8 is not esterified into phospholipids of human monocytes.
15-HETE-d8 was added to human monocytes prior to activation with 10 pM A23187. 
Samples were activated for various time-points followed by lipid extraction then 
analysis by LC/MS/MS (n = 3, mean ± SEM).
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Figure 4.4 15-H(p)ETE-PEs are not metabolised by PLA2 or PAF-AH enzymes. Human monocytes were activated with 
10 pM A23187 for 15 minutes and 3 hours following incubation with the PLA2 inhibitors, OOEPC, BEL and PACOCF3 or the 
PAF-AH inhibitor, MAFP. Samples were reduced with SnCl2 followed by lipid extraction and LC/MS/MS analysis (n = 3, 
mean ± SEM). * Students t-test, p < 0.05 with one-tailed Mann-Whitney test, the difference of each analyte is significant in 
comparison to its relative control.
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Scheme 4.1 Conversion of the phospholipid head group from 
phosphatidylethanolamine to phosphatidylcholine.
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Scheme 4.2 Conversion of the phospholipid head group from 
phosphatidylethanolamine to phosphatidylserine
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Figure 4.5 18:0a/15-H(p)ETE-PC standard was successfully synthesised. SAPC was 
oxidised using soybean LOX, then reduced with SnCl2 to form 18:0a/15-HETE-PC. The 
lipid product was extracted and its elution time and identity was confirmed by LC/MS/MS 
analysis (A) and product ion spectra (B) in both negative (i) and positive modes (ii).
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To investigate the generation of 18:0a/15-HETE-PC, human monocytes were activated using 
A23187 for up to 180 minutes followed by reduction, lipid extraction then analysis by 
LC/MS/MS. 18:0a/l 5-H(p)ETE-PC increased by 10 minutes then returned to basal levels by 
three hours, similar to 15-H(p)ETE-PEs, however, the signals were very weak indicating low 
abundance (Figure 4.6). This suggests that 18:0a/15-H(p)ETE-PC may be a minor product of 15- 
LOX and not formed following the conversion of the 18:0a/15-HETE-PE head group to PC. 
Since PE can also be converted to PS, samples were also analysed by LC/MS/MS for transitions 
equivalent to 15-HETE-PSs but the correct peaks could not be identified due to low abundance 
(data not shown), therefore conversion of the PE head group to PS cannot be excluded but is 
presumed unlikely. Overall, the results suggest that conversion of the 15-H(p)ETE-PE head 
group to PC or PS is not a likely route of their metabolism, at least to PC.
Elongation of the sn2 fatty acid (H(p)ETE) by the addition of C2H4 was also investigated as a 
possible route for 15-H(p)ETE-PE metabolism (Rosenthal & Hill, 1986). Theoretical transitions 
for 15-H(p)ETE-PE + C2H4  were calculated and then monocyte lipids were analysed by 
LC/MS/MS (Scheme 2.7). If 15-H(p)ETE was undergoing elongation, levels of 15-H(p)ETE-PEs 
+ C2H4  would be expected to rise after 1 0  minutes, corresponding with the decline seen for 15- 
H(p)ETE-PEs in Figure 4.1. However, over 180 minutes levels of 15-H(p)ETE-PE + C2H4 did 
not change significantly. A small increase was seen during the same timescale as activation but 
signals were weak, indicating low abundance. The results suggest that elongation of 15-H(p)ETE 
is not a route of 15-H(p)ETE-PE metabolism (Figure 4.7).
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Figure 4.6. Metabolism of 15-H(p)ETE-PE is unlikely to involve conversion of the PE 
head group to PC. Human monocytes were activated with 10 pM A23187 for various 
time points followed by reduction with SnCl2. Lipids were extracted and analysed by 
LC/MS/MS for 18:0/15-HETE-PC (n = 3, mean ± SEM). *Students t-test, p < 0.05 with 
one-tailed Mann-Whitney test, the difference is significant in comparison to the control 
sample..
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Figure 4.7. Metabolism of 15-H(p)ETE-PE is unlikely to involve chain elongation 
of H(p)ETE. Human monocytes were activated with 10 pM A23187 for up to 180 
minutes. Samples were reduced with SnCl2 followed by lipid extraction. Theoretical 
transitions with calculated mfz corresponding to an elongation of C2H4 to H(p)ETE 
portion were calculated and analysed by LC/MS/MS (n = 3, mean ± SEM).
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4.2.3 Products o f 15-LOX are not all endogenously reduced to 15-HETE-PEs.
Previous studies have shown that HpETE products of LOX are reduced to HETEs by GPx 
enzymes (Ursini et al, 1987). Therefore, to aid detection of 15-LOX products in human 
monocytes, lipid extracts were routinely reduced using SnCL, which stabilised all HpETE-PEs to 
more stable HETE-PEs. However, as the methods of 15-H(p)ETE-PE metabolism described 
above were excluded, it is possible that 15-HpETE-PEs were not endogenously reduced to 15- 
HETE-PE in human monocytes. It was previously shown that there is a loss of cytosolic 
glutathione in rat hepatocytes following activation with A23187 (Olafsdottir et al, 1988). 
Therefore, following A23187 activation of human monocytes, the amount of GPx present may 
be insufficient to reduce all of the products synthesised by LOX. If lipids were extracted from 
human monocytes with no prior reduction, then the detected 15-HETE-PEs would be due to 
endogenous reduction by GPx. Following SnCL treatment, detected 15-HETE-PEs are made up 
of both endogenous 15-HETE-PEs and additional lipid products of 15-LOX that can be 
chemically reduced to 15-HETE-PEs. Therefore, levels of 15-HETE-PEs would be higher in 
SnCb treated samples.
The amount of 15-HETE-PE generated endogenously in monocyte samples was investigated. 
Human monocytes were activated for up to 180 minutes, at each time-point half of each sample 
was immediately removed into lipid extraction buffer (non-reduced). The remaining half was 
reduced by SnCb prior to lipid extraction, then samples were analysed by LC/MS/MS. The 
results show that products of 15-LOX are not all endogenously reduced to form 15-HETE-PEs. 
Throughout the time-course, 27 to 38% of 15-LOX products were endogenously reduced to 15- 
HETE-PEs and levels remained constant following their initial synthesis (Figure 4.8). In samples 
reduced using SnCl2, 15-H(p)ETE-PEs increased by 15 minutes then declined by 180 minutes.
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As endogenous 15-HETE-PEs remained stable, the 15-H(p)ETE-PE decrease seen in reduced 
samples is likely to be due to the metabolism of a 15-HETE-PE precursor.
4.2.4 15-HpETE-PEs are unlikely to be the precursors o f 15-HETE-PEs that are metabolised in
time-course samples.
To identify lipids in human monocytes that can be reduced to form 15-HETE-PEs, the time- 
course samples generated for Section 4.2.3 were analysed by LC/MS/MS for transitions 
corresponding to possible 15-HETE-PE precursors. Since 15-LOX is reported to synthesise 15- 
HpETE, which is also known to form 15-HETE following reduction, 15-HpETE-PEs were 
possible precursors of 15-HETE-PEs ([M-H]" m/z 756, 780, 782 and 798 to a daughter ion of 
317) (Scheme 2.8) (Ursini et al, 1987). 15-HpETE-PEs were detected in non-reduced monocyte 
samples, but their levels were very low and in some cases, undetectable (as for 16:0p/15-HpETE- 
PE) (Figures 4.9B to 4.12B). If 15-HpETE-PEs were precursor lipids of 15-HETE-PEs 
synthesised following SnCl2 reduction, then the difference in 15-HpETE-PEs between reduced 
and non-reduced samples would be expected to correlate with the variation seen for 15-HETE- 
PEs. However, results from the quantification of 15-HpETE-PEs showed that their levels were 
too low to account for the differences in 15-HETE-PEs between reduced and non-reduced 
samples.
4.2.5 15-KETE-PEs are formed following 15-LOX activation and are metabolised to unknown 
products.
Free 15-ketoeicosatetraenoic acid (15-KETE) (also known as 15-oxoETE) has been detected in 
human monocytes and 12-KETE is reported to form 12-HETE following reduction (Falgueyret et
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al, 1990, Wei et al, 2007). Therefore, other potential lipid precursors of 15-HETE-PE include the 
carbonyl containing 15-KETE-PEs ([M-H]' m/z 736, 762, 764 and 780 to a daughter ion of 317) 
(Scheme 2.9). Therefore, the presence and identity of 15-KETE-PEs were investigated in human 
monocytes prior to their analysis in time-course samples. Monocytes were activated for 15 
minutes with A23187 then the lipids were extracted and analysed by LC/MS/MS. Product ion 
spectra were acquired at the apices of detected peaks (Figures 4.13 to 4.16 A). Product ion 
spectra of the particular peaks highlighted in Figures 4.13-16 contained fragments that are also 
seen in the product ion spectra of a 15-KETE standard, shown in a published study (m/z 113, 
203, 219, 255, 273 and 299, labelled in green) (Murphy et al, 2005). In particular, fragments 
typical of 15-KETE-PEs were seen in these product ion spectra, confirming their identity.
Next, monocyte time-course samples were analysed for 15-KETE-PEs. The results show that 15- 
KETE-PEs increased in non-reduced samples following activation, then declined by three hours 
(Figure 4.17). Consistent with the criteria of the 15-HETE-PE precursor, 15-KETE-PEs 
diminished following reduction, which corresponded to the increase in levels of 15-HETE-PEs. 
The results therefore suggest that 15-KETE-PEs form 15-HETE-PEs following reduction, and 
that they may be the lipids undergoing metabolism during time-course experiments.
4.2.6 18:0a/l 5-HpETE-PE forms 18:0a/15-KETE-PE following its addition to monocytes.
15-KETE-PEs are novel lipids and how they are synthesised by cells is not known. They may be 
formed by three pathways, (i) directly following the action of 15-LOX on AA-PE, (ii) following 
metabolism of the 15-HpETE-PE peroxyl group to a carbonyl, (iii) following enzymatic 
conversion of 15-HETE (Scheme 4.3) (McMurry, J, 2000, Bergholte et al, 1987, Wei et al,
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activated with 10 pM A23187 for various time points. Samples underwent lipid extraction either 
directly or following reduction with SnCl2. Lipids were analysed by LC/MS/MS for 15-KETE-PE 
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Scheme 4.3 Formation of carbonyl following the decomposition of a peroxyl group 
(adapted from McMurry J, 2000, with permsssion (04/12/2010).
2009). Previous studies have shown that free 12-HpETE and 5-HpETE can be converted 
enzymatically to 12- and 5-KETE respectively, thus supporting the second method of conversion 
(Piomelli et al, 1988, Zanni & Murphy, 2003). As a 15-HpETE-PE standard was available, 
studies investigated whether monocytes can convert exogenously added 15-HpETE-PE to 15- 
KETE-PE. 18:0a/l 5-HpETE-PE was added to human monocytes, followed by lipid extraction 
and analysis by LC/MS/MS. In cell-free buffer samples containing 18:0a/l5-HpETE-PE, 
18:0a/l 5-KETE-PE was also detected, as well as a small amount of 18:0a/l 5-HETE-PE (Figure 
4.18). This is likely to be due to the instability of 15-HpETE-PE standard, which may 
spontaneously degrade to these lipids in storage. However, 18:0a/l5-HpETE-PE added to human 
monocytes was fully metabolised, and corresponded with a significant increase in 18:0a/15- 
KETE-PE, and a small increase in 18:0a/l5-HETE-PE (Figure 4.18). The results suggest that 
monocytes can convert exogenously added 15-HpETE-PE to 15-KETE-PE.
4.2.7 15-KETE-PEs are metabolised to unknown products by three hours following their 
generation.
Results in non-reduced time-course samples shown in Figures 4.9-4.12 C suggested that 15- 
KETE-PEs are metabolised following their synthesis. The 15-KETE-PEs could be metabolised to 
two potential products, hydroxyeicosatrienoic acid-PEs (HETrE-PEs) (Scheme 2.10) ([M-H]' m/z 
738, 766, 768 and 784 to 321) and/or di-HETE-PEs (Scheme 2.11) ([M-H]‘ m/z 738, 780, 782 
and 798 to 335), therefore levels of these products were investigated in monocyte time-course 
samples described in Section 4.2.3. If 15-KETE-PEs were converted to these products, they 
would be expected to increase during the later time-points, corresponding to the decrease in 
detected 15-KETE-PEs. A large fold increase was seen following activation for di-HETE-PEs in
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Figure 4.18 18:0a/15-HpETE-PE can be converted to 18:0a/15-KETE-PE by 
monocytes. 18:0a/l5-HpETE-PE was added to human monocytes followed by 
immediate lipid extraction. Samples were analysed by LC/MS/MS for 18:0a/15-HpETE- 
PEs (A), 18:0a/15-KETE-PEs (B) and 18:0a/15-HETE-PEs (C) (n = 3, mean± SEM). To 
note, no samples were reduced by SnCl2.*Students t-test, p < 0.05, the difference of each 
analyte is significant in comparison to its relative control 1 4 3
non-reduced and reduced samples and for HETrE-PEs in reduced samples only. However, levels 
of di-HETE-PEs and HETrE-PEs remained constant throughout the time-course (Figure 4.19). 
The daughter ion used during LC/MS/MS analysis for di-HETE-PEs, m/z 335, is also the m/z of 
several other analytes, including several potential isomers of di-HETEs and leukotriene B4. The 
large increase following activation may be due to the analysis of multiple lipids with the same 
parent to daughter ion transition and retention time. Though, the results suggest that 15-KETE- 
PEs are not metabolised to HETrE-PEs or di-HETE-PEs as levels of these compounds do not 
increase throughout the time-course.
4.2.8 15-H(p)ETE-PEs are principally retained by monocytes while free 15-H(p)ETE is secreted 
following cellular activation.
Products of 12/15-LOX are suspected to be involved in regulating inflammation, possibly by 
acting as signalling molecules. Therefore, experiments were carried out to assess whether 15- 
H(p)ETE-PEs were secreted or retained by monocytes following their generation. Monocytes 
were activated for 15 minutes, then free and cell-associated 15-H(p)ETE-PEs were separated by 
centrifugation. Samples were reduced followed by lipid extraction and analysis by LC/MS/MS. 
15-H(p)ETE-PEs were mostly retained by monocytes following activation, conversely, free 15- 
H(p)ETE was primarily secreted (Figure 4.20). The results suggest that if 15-H(p)ETE-PEs are 
involved in signalling, then they may have autocrine or intracrine actions. However, as free 15- 
H(p)ETE were mostly secreted, it could have paracrine signalling properties.
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Figure 4.19 15-KETE-PEs are not metabolised to 15-HETrE-PEs or di-HETE- 
PEs. Monocytes were activated with 10 (iM A23187 for various time points. 
Samples underwent lipid extraction either directly or following reduction with 
SnCl2. 15-HETrE-PE (A) and di-HETE-PE (B) products for 16:0p (i), 18:lp (ii), 
18:0p (iii) and 18:0a (iv) phospholipids were analysed by LC/MS/MS (n = 3, mean ± 
SEM). * Students t-test, p < 0.05 with one-tailed Mann-Whitney test, the difference 
of each analyte is significant in comparison to its relative control.
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Figure 4.20. 15-H(p)ETE-PEs are retained by monocytes following their 
generation while free 15-H(p)ETE is secreted. Human peripheral blood monocytes 
were activated with 10 pM A23187 for 15 minutes. Lipids from the supernatant and 
cellular extracts were reduced then extracted and analysed by LC/MS/MS for 15- 
H(p)ETE-PEs (A) and 15-H(p)ETE (B) (n = 3, mean ± SEM). * Students t-test, p < 
0.05, the difference of each analyte is significant in comparison to its relative control.
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4.3 Discussion
The primary aim of experiments described in this chapter was to characterise the synthesis of 15- 
H(p)ETE-PEs in human monocytes and establish how they are subsequently metabolised. 
Following activation, 15-H(p)ETE-PEs in reduced samples reached maximum levels by 10 
minutes which then decreased by 180 minutes (Figure 4.1). The decrease in these lipids was 
suspected to be due to their metabolism. Several routes of metabolism were investigated and then 
excluded, including hydrolysis of 15-H(p)ETE-PE by PLA2 to release 15-H(p)ETE, conversion 
of the PE-head group to PC, and elongation of the sn2 fatty acid (H(p)ETE) by the addition of 
C2H4 (Figures 4.2-4.7). The results from these experiments suggested that 18:0a/l5-HETE-PC 
may also be a product of 15-LOX (Figure 4.6). This is supported by results published in Maskrey 
et al (2007), where a small amount of 15-HETE was shown to be esterified to PC in activated 
human monocytes. 18:0a/l 5-HETE-PC was not quantified in monocyte time-course samples as 
DMPE was used as an internal standard. The ionisation efficiencies of PC and PE are very 
different, PC compounds ionise more efficiently in positive mode but 15-HETE can only ionise 
in negative mode (Pulfer & Murphy, 2003). Therefore, 15-HETE-PCs were analysed in negative 
mode with reduced detection. The use of DMPC as an internal standard would account for this 
issue of ionisation and using the synthesised 18:0a/l 5-HETE-PC standard, this lipid could be 
quantified in human monocytes. However, conversion of the PE head group to PC was ruled out 
as a route for 15-H(p)ETE-PE metabolism as it did not follow the expected temporal pattern. 
Conversion of PE to PS was not excluded as the correct LC/MS/MS peaks could not be 
identified; this also suggests that there was no significant formation of PS-HETEs by 15-LOX 
(data not shown).
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The above mechanisms of metabolism were excluded, therefore, subsequent experiments 
investigated whether oxidised lipid products of 15-LOX were being effectively endogenously 
reduced to 15-HETE-PE by GPxs. Analysis of non-reduced time-course samples showed that 
endogenous 15-HETE-PEs accounted for approximately 30% of the total 15-HETE-PEs detected 
in SnCb reduced samples (Figure 4.8). The remaining 70% of 15-HETE-PEs were likely to be 
due to unidentified lipids that form 15-HETE-PEs following chemical reduction. Therefore, 
investigations were carried out to identify lipids synthesised by 15-LOX that can be reduced to 
form 15-HETE-PEs. 15-HpETE-PEs were possible lipid precursors of 15-HETE-PEs but very 
little was detected in monocyte time-course samples (Figures 4.9-4.12) (Schewe et al, 1986). 
Data in Figure 4.17 showed that 18:0a/15-HpETE-PE is very unstable and rapidly metabolised 
when added to human monocytes, which is consistent with such little detection of 15-HpETE-PE 
in human monocytes. Next, levels of 15-KETE-PEs were investigated in human monocytes. 
Results from time-course experiments showed that detected temporal pattern of generated 15- 
KETE-PEs were consistent with what would be expected from suspected lipid precursors of 15- 
HETE-PEs. Importantly, in non-reduced time-course samples 15-KETE-PEs increased by 15 
minutes following activation then declined, similar to levels of 15-HETE-PEs in SnCE reduced 
time-course samples. 15-KETE-PEs also diminished following reduction, corresponding to a 
simultaneous increase in 15-HETE-PEs. This suggests that 15-KETE-PEs are the likely 
precursors of 15-HETE-PEs but they are metabolised throughout the time-course to unknown 
products. Possible products of 15-KETE-PE metabolism include secondary oxidation products, 
this could be investigated in future experiments.
148
As there are no 15-KETE-PE standards, the identity of 15-KETE-PEs in monocyte samples was 
validated by comparing their product ion spectra to spectra of a 15-KETE standard as shown in a 
previous study (Murphy et al, 2005). The identity of 15-KETE-PEs could be confirmed by an 
alternative method. 15-KETE-PEs in non-reduced activated human monocytes could be isolated 
by RP-HPLC, followed by base hydrolysis or treatment with PLA2 enzymes to release the fatty 
acids. Free 15-KETE could then be identified by either MS analysis or HPLC, by comparing 
with a 15-KETE standard, available from Cayman Chemical. Hydrolysis using PLA2 enzymes 
may be more appropriate for this experiment as it specifically releases the sn2 fatty acid. This 
method is also considered to be a less ‘harsh’ than base hydrolysis, which may itself decompose 
the KETE-lipids (Chaitidis et al, 1998).
In this chapter it was proposed that 15-KETE-PEs are novel lipids formed following 15-LOX 
activation in human monocytes. However, the mechanism of their formation is unknown. They 
may be synthesised by two ways:
(i) Via metabolism of 15-HpETE-PEs synthesised by 15-LOX (as shown Scheme 4.3). 
18:0a/15-HpETE-PE added exogenously to monocytes was rapidly metabolised and coincided 
with an increase in 15-KETE-PE (Figure 4.17). Furthermore, 15-HpETE can be converted to 15- 
KETE in the presence of human prostacyclin and thromboxane synthases, therefore, 15-KETE- 
PEs could be formed directly from 15-HpETE-PEs (Yeh et al, 2007). In support of this route of 
metabolism, the direct conversion of HpETEs to KETEs, has also been described in murine 
macrophages and the nervous system of Aplysia (12-HpETE to 12-KETE) (Piomelli et al, 1988, 
Zarini & Murphy, 2003). It is also possible that HpETE could be converted to KETE non- 
enzymatically as shown in Scheme 4.4 (McMurry J, 2000).
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Scheme 4.4 The formation of 15-HpETE by 15-LOX-l
(adapted from Claesson et al, 2008 and Yeh et al, 2007, with permission (06/12/2010 
and 13/12/2010)).
(ii) Alternative routes have been reported for the synthesis of KETEs. Some studies report 
that KETEs can be generated enzymatically from HETE. For example, 15-KETE is formed after
15-hydroxyprostaglandin dehydrogenase (PGDH)-mediated oxidation of 15-HETE in R15L-cells 
and the same reaction is also carried out by PGDH isolated from rabbit lungs (Bergholte et al, 
1987, Wei et al, 2009). 5-HETE can also be converted to 5-KETE by 5-hydroxyeicosanoid 
dehydrogenase (5-HEDH) in neutrophils (Powell and Rokach, 2005). Importantly, a PGDH has 
been detected in human monocytes that is reported not only to convert lipoxin hydroxyl groups 
to carbonyls, but also, converts 15-HETE to 15-KETE (Wei et al, 2009, Romano M, 2006, 
Maddox et al, 1998). Therefore, it is possible that 15-KETE-PEs are generated following the 
metabolism of 15-HETE-PE.
(iii) 15-KETE-PEs may be synthesised directly by 15-LOX.
Under anaerobic conditions, soybean LOX is reported to synthesise 15-KETE instead of 15- 
HpETE (de Laclos & Borgeat, 1988). This supports the hypothesis that mammalian 15-LOX 
may also be able to synthesise 15-KETE. To investigate whether 15-LOX can directly generate 
15-KETE-PEs, an isolated rabbit 15-LOX could be used in an anaerobic reaction with pure 
SAPE and/or brain plasmalogen-PEs. Analysis of lipids generated would indicate whether 15- 
HpETE-PEs or 15-KETE-PEs can be direct products of 15-LOX.
Products of 12/15-LOX are believed to be involved in inflammation, possibly by acting as 
signalling molecules, therefore, it is important to identify these products and to determine how 
their effects are exerted (Kuhn & O’Donnell, 2006). 15-H(p)ETE-PEs (which herein includes the 
15-KETE-PEs) were retained by monocytes following LOX activation. This suggests that
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esterified products of 15-LOX may be involved in autocrine signalling. Free 15-KETE is also 
believed to have signalling properties. Previous studies report that 15-KETE is chemotactic and 
inhibits the proliferation of human vascular vein endothelial cells (HUVECs) and breast cancer 
cells (Sozzani et al, 1996, O’Flaherty et al, 2005, Wei et al, 2009). Furthermore, two 15-KETE 
analogs, 5-KETE and 15d-PGJ2 (15-deoxy-Ai2,i4-prostaglandin J2), regulate cell apoptosis and 
proliferation by acting as agonists of PPARy. 5-KETE and 15d-PGJ2 also affect interactions 
between macrophages and endothelial cells, which may have implications in particular 
inflammatory disorders including atherosclerosis and asthma (Li et al, 2004). 15-KETE-PEs may 
have similar properties which could be investigated in future experiments.
To conclude, the results in this chapter have indicated that approximately 30% of 15-LOX 
products are endogenously reduced to 15-HETE-PEs following 15-LOX activation in human 
monocytes. Furthermore, 15-KETE-PEs are generated following 15-LOX activation and are 
metabolised to unknown products. Many studies have described the attachment of lipid products 
to proteins via associations between carbonyl and amine groups, known as Schiff bases and 
Michael adducts. In particular, one study has shown that free 15-KETE and 5-KETE can form 
Michael adducts with glutathione (Lee et al, 2007). A covalent association with proteins could 
have accounted for the decline in 15-KETE-PEs throughout the time-course and was thus 
investigated in Chapter 5.
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CHAPTER 5
INCORPORATION OF [14C1 INTO PRODUCTS OF 15-LOX
5.1 Introduction
In the previous chapter, 15-KETE-PEs were shown to be synthesised in human monocytes 
following the activation of 15-LOX. 15-KETE-PEs were metabolised within 3 hours of their 
synthesis. This may have been due to the formation of covalent adducts with proteins, known 
as Schiff bases or Michael adducts. Schiflf bases are formed when a carbonyl group 
undergoes nucleophilic attack by a primary amine (Scheme 5.1) (McMurry et al, 2000). In 
particular, 15-KETE-PEs have a carbonyl group at C-15 of the sn2 fatty acid that could form 
a Schiff base as it has a defined 6+ and 6- charge separation. A second carbonyl group is 
located near the glycerol backbone, but this is unlikely to form a Schiff base as the negative 
charge is dissociated over the ester bond (Scheme 5.1) (McMurry et al, 2000). Alternatively, 
Michael adducts are formed when a primary amine attacks particular alkene bonds that are 
located near a carbonyl group, which are called a, p-un saturated ketones (McMurry et al, 
2000) (Scheme 5.2). The carbonyl group of sn2 fatty acid in 15-KETE-PEs is an a,p- 
unsaturated ketone, and the alkene bond is located between C-13 and C-14 (Scheme 2.9). The 
mechanisms for Schiff base and Michael adduct formation are shown in Schemes 5.3 and 5.4 
respectively.
Electrophilic lipids can form Schiff bases and Michael adducts with peptides and proteins. 
Examples include, 4-hydroxynonenal (HNE), malondialdehyde (MDA), 9,12-dioxo- 
dodecenoic acid (DODEs), isoketals, levuglandins and prostaglandins, which all bind 
covalently to proteins (Requena et al, 1997, Grimsrud et al, 2007, Vila et al, 2008, Aldini et
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Scheme 5.1 Positions in 15-KETE-PE susceptible to nucleophilic attack that 
form Schiff bases. A carbonyl group is susceptible to nucleophilic attack by 
primary amines present in lysine, or other PE/PS phospholipids (1). A carbonyl 
can also be attacked by an amine present within the same phospholipid (2). The 
amine of a PE/PS phospholipid head group can attack carbonyl groups of nearby 
compounds (3). 154
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Scheme 5.2 Positions in 15-KETE-PE susceptible to nucleophilic attack that 
can form Michael adducts. An alkene bond near a carbonyl group is susceptible 
to nucleophilic attack by a primary amines present in lysine, or other PE/PS 
phospholipids (1). An alkene bond can also be attacked by an amine present 
within the same phospholipid head group (2). The amine of a PS/PE phospholipid 
head group can attack an alkene bonds in nearby compounds (3). 155
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Scheme 5.4 Mechanism of Michael adduct formation by reaction of a primary 
amine group with an a, p-unsaturated ketone (adapted from McMurry et aly 
2000 with permission (04/12/2010)).
al, 2006, Williams et al, 2007, Bemoud-Hubac et al, 2004, Boutaud et al, 2001). 
Phospholipids can also form Schiff bases with proteins, as reported for oxidised products of 
l-palmitoyl-2-arachidonyl-sn-glycero-3-phosphatidylethanolamine (Ox-PAPE) and 1- 
palmitoyl-2-linoleoyl-glyceryl-phosphatidylcholine (Ox-PLPC) (Szapacs et al, 2008, Gugiu 
et al, 2008). Furthermore, PE and PS phospholipids can carry out nucleophilic attack due to 
the amine present in their head group. Thus, 15-KETE-PEs could form Schiff bases or 
Michael adducts within the same phospholipid, or could form phospholipid-phospholipid, or 
phospholipid-protein complexes (Schemes 5.1 and 5.2) (Jain & Sohet et al, 1984, Hazen et 
al, 1999, Wachel et al, 2006, Mattila et al, 2008, Bach et al, 2009a, Bach et al, 2009b).
The vast number of proteins and lipids in cells makes it a major challenge to identify which 
particular proteins form adducts with 15-KETE-PEs in human monocytes. Furthermore, as 
protein-lipid and lipid-lipid interactions have not been widely studied, the technologies 
designed to analyse these products are limited. Previous studies on other electrophilic lipids 
have investigated protein adduct formation using radioactive isotopes such as 14C and 3H 
(Kang et al, 1999, Horkko et al, 1997, Bull et al, 1996, Vandel Huevel et al, 1991, Rudolph 
et al, 2009). In these approaches, radiolabelled lipids are added to culture medium, then 
incorporated into cell membranes. Radiolabelled 15-KETE-PE or 15-HpETE-PE do not exist, 
however, [UC]-SAPE, [UC]-AA and [14C]-ethanolamine are available. In an attempt to 
establish whether products of 15-LOX form adducts with cellular proteins, these these 
substrates were utilised to induce cells to generate radiolabelled phospholipid oxidation 
products that could then be studied for protein adduct formation.
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5.1.1 Aims.
• To establish a method where 15-LOX in human monocytes could be induced to 
synthesise 14C radiolabelled products.
• To explore whether radiolabelled oxidised products of 15-LOX could form adducts 
with proteins.
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5.2 Results
5.2.1 Monocytes treated with [14C]-ethanolamine hydrochloride generated more [14C]-/5- 
H(p)ETE-PEs, in comparison to monocytes incubated with [14C]-AA or [14C]-SAPE.
[l4C]-ethanolamine hydrochloride, [14C]-AA or [14C]-SAPE may be used by cells to generate 
[,4C]-radiolabelled products of 15-LOX. However, due to variations in their size and 
hydrophobicity, the efficiency of their incorporation into membrane phsopholipids may vary. 
Human monocytes were incubated for 24 hours with 200 pM [14C]-ethanolamine 
hydrochloride (13.8 mCi/mmol), 200 pM [14C]-ethanolamine hydrochloride (112 
mCi/mmol), 10 pM [14C]-AA (57 mCi/mmol) or 1 pM [14C]-SAPE (56 mCi/mmol), to 
investigate which resulted in the largest generation of [14C]-15-H(p)ETE-PEs. After 
harvesting, monocytes were activated for 15 minutes using A23187, followed by reduction, 
then lipid extraction. The elution time of 15-H(p)ETE-PEs was confirmed by analysing 
samples by LC/MS/MS. Next, to isolate the 15-H(p)ETE-PEs, samples underwent RP-HPLC 
where fractions were collected at intervals of one minute. They were then analysed by 
scintillation counting to calculate the amount of [14C]-15-H(p)ETE-PEs present. As the 
monocyte samples were reduced, the [14C]-15-H(p)ETE-PEs detected are a combination of 
[l4C]-l5-HpETE-PEs, [14C]- 15-KETE-PEs as well as endogenous [,4C]-15-HETE-PEs. 
Monocytes incubated with [14C]-ethanolamine hydrochloride (112 mCi/mmol) generated the 
highest amount of [14C]-15-H(p)ETE-PEs (73.2 pmol), followed by monocytes incubated 
with [14C]-ethanolamine hydrochloride (13.8 mCi/mmol) (4.5 pmol), [14C]-AA (2.8 pmol) 
and lastly, [,4C]-SAPE (1 pmol) (Figure 5.1). Therefore, [14C]-ethanolamine hydrochloride 
(112 mCi/mmol) was used in all subsequent experiments. Scheme 5.5 shows how [14C]- 
ethanolamine is incorporated into PE.
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Figure 5.1 Comparison of different strategies used to generate [14C]-15-HETE- 
PEs. IL-4 induced human monocytes were incubated for 24 hours with either 200 
pM [14C]-ethanolamine hydrochloride (13.8 mCi/mmol), 200 pM [14C]- 
ethanolamine hydrochloride (112 mCi/mmol), 10 pM [14C]-AA or 1 pM [,4C]- 
SAPE. The monocytes were harvested, activated with A23187 then reduced. The 
lipids were extracted and analysed by LC/MS/MS. Samples underwent RP-HPLC 
where fractions were collected every 1 minute for times corresponding to the elution 
of 15-HETE-PEs. The fractions were then analysed by scintillation counting and the 
amount of [14C-] 15-HETE-PEs per 1 million cells was calculated (n=l).
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162
5.2.2 [I4C]-treated monocytes generate \^ aC\-AA-PEs and \14C]-15-H(p)ETE-PEs.
To characterise fully the generation of [14C]-AA-PEs and [14C]-15-H(p)ETE-PEs, IL-4 
treated human monocytes were incubated for 24 hours with [14C]-ethanolamine hydrochloride 
(112 mCi/mmol). Following their incubation with the radiolabel, human monocytes were 
harvested and activated with A23187 for 15 minutes, followed by reduction then lipid 
extraction. Sample analysis by LC/MS/MS confirmed that 15-LOX activation was not 
affected by incubation with [14C]-ethanolamine hydrochloride (Figure 5.2). LC/MS/MS 
transitions for [14C]-AA-PEs and [14C]- 15-HETE-PEs were also analysed, however, this 
approach was not useful, as they only have a mass increase of two in comparison to the 12C 
isomers they elute the same time as naturally occurring isotope peaks of the non-radiolabelled 
products (data not shown). Due to low incorporation of [14C], the correct peaks could not be 
identified by LC/MS/MS. However, MS analysis confirmed the elution times of the non- 
radiolabelled AA-PEs and 15-H(p)ETE-PEs in these samples (Figures 5.3A and 5.4A). An 
alternative method of analysing radioactivity is by scintillation counting. To calculate the 
amount of [14C]-AA-PEs and [14C]-15-H(p)ETE-PEs in control and activated monocytes, 
phospholipids were separated by RP-HPLC and fractions of both samples were collected at 
intervals of thirty seconds. Each fraction was then analysed by scintillation counting. 
Radioactivity traces of both unactivated and activated samples showed peaks corresponding 
to the elution times of AA-PEs and 15-HETE-PEs (Figures 5.3B and 5.4B). Following 
activation, levels of radioactive lipids eluting at the retention times of 15-HETE-PEs were 
seen to increase. This indicates that [14C]-ethanolamine hydrochloride was incorporated into 
membrane phospholipids, which was then oxidised by LOX to form H(p)ETE-PEs. As a 
known quantity of [14C]-ethanolamine hydrochloride was added to monocytes, the amount of 
[14C] incorporated into 15-H(p)ETE-PEs can be calculated as follows. The total amount of
163
ng 
pe
r 
1 
mi
llio
n 
ce
lls
30
■738/219 (16:0p/15-HETE-PE) 
□ 764/219 (18:1 p/15-HETE-PE) 
■ 766/219 (18:0p/15-HETE-PE) 
a  782/219 (18:0a/15-HETE-PE)
20
10
Control A23187 Control A23187
No incubation with [14C ] Incubated with [14C ]
Figure 5.2. There is no statistical difference in 15-HETE-PE generated by 
activated human monocytes following incubation with and without [14C]- 
ethanolamine hydrochloride. IL-4 stimulated human monocytes were incubated for 
24 hours with and without [l4C]-ethanolamine hydrochloride. Cells were harvested, 
activated with 10 pM A23187 for 15 minutes followed by reduction and lipid 
extraction (n=l). Samples were analysed by LC/MS/MS. No statistical difference 
was seen during comparison of 15-HETE-PE generation between both A23187 
treated samples using Students T-Test with one-tailed Mann-Whitney test.
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Figure 5.3 [14C]-AA-PEs are detected following incubation of monocytes with [,4C]- 
ethanolamine hydrochloride. IL-4 induced monocytes were incubated for 24 hours with 
[14C]-ethanolamine hydrochloride. Monocytes were harvested, followed by reduction then 
lipid extraction. The control sample was analysed by LC/MS/MS and the elution times of 
AA-PEs were recorded (A). During RP-HPLC, fractions were collected at intervals of 30 
seconds, which were then analysed by scintillation counting for the detection of [14C]-AA- 
PEs(B). 1 6 5
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Figure 5.4. [,4CJ-15-HETE-PEs are detected in activated monocytes following incubation 
with [14C]-ethanolamine hydrochloride. IL-4 induced monocytes were incubated for 24 hours 
with [14C]-ethanolamine hydrochloride. Monocytes were harvested, activated for 15 minutes 
with A23187, followed by reduction then lipid extraction. The activated sample was analysed 
by LC/MS/MS and the elution times of 15-H(p)ETE-PEs were recorded (A). During RP-HPLC, 
fractions were collected at intervals of 30 seconds, which were then analysed by scintillation 
counting for the detection of [14C]-15-H(p)ETE-PEs (B). As samples were reduced detected 
15-HETE-PEs and [14C]- 15-HETE-PEs also includes reduced 15-KETE-PEs and 15-HpETE- 
PEs.
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15-HETE-PEs was first quantified following analysis by LC/MS/MS (Figure 5.2). Next, the 
total of detected [14C]-15-H(p)ETE-PEs was calculated from the radioactivity traces of 
activated samples (Figure 5.4B). In this was, it was seen that 2.7% of 15-H(p)ETE-PEs were 
radiolabelled in activated monocytes, equivalent to 0.00036% of the total amount of 
radioactivity added.
5.2.3 [‘4 C]-ethanolamine hydrochloride is specifically incorporated into PE phospholipids.
[14C]-ethanolamine hydrochloride is incorporated into the PE pool, however, as shown in 
Schemes 4.1 and 4.2 (Chapter 4), PE can be converted to PC or PS. To assess which 
phospholipid classes contained the [14C] radiolabel, the control sample generated in section
5.2.2 underwent normal phase-HPLC (NP-HPLC). Scintillation counting of fractions from 
LC elution showed that [14C] was exclusively incorporated into PE phospholipids (Figure 
5.5). The total amount of PE in monocyte samples was calculated by UV using an egg PE 
standard (not shown) and the amount of radiolabelled PE was calculated following 
scintillation count analysis (Figure 5.5). 1.5% of the PE phospholipid pool was radiolabelled, 
this incorporation is equivalent to 0.02% of the total amount of radioactivity added.
5.2.4 Preliminary investigations support the association o f proteins with [! 4 C]-radiolabelled 
lipids synthesised by 15-LOX.
In human monocytes, 15-LOX has been shown to oxidise AA-PEs to synthesise 15-HpETE- 
PEs and 15-KETE-PEs (Chapter 4). Similarly, in monocytes incubated with [14C]- 
ethanolamine hydrochloride, [14C]-AA-PEs may be oxidised by 15-LOX to synthesise [14C]- 
15-HpETE-PEs and [14C]-15-KETE-PEs. Experiments were carried out to investigate
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Figure 5.5 [,4C]-ethanolamine hydrochloride is exclusively incorporated into the PE 
phospholipids. IL-4 induced monocytes were incubated for 24 hours with [14C]-ethanolamine 
hydrochloride. Following cell harvest, monocytes were reduced followed by lipid extraction. 
Samples were analysed by UV during NP-HPLC (A), fractions were collected at intervals of 
one minute, which were then analysed by scintillation counting (B).
168
whether radiolabelled oxidised products of 15-LOX could bind to proteins, and whether this 
could account for some of the decrease in 15-KETE-PEs as seen in Figure 4.17. IL-4 treated 
human monocytes were incubated for 24 hours with [14C]-ethanolamine hydrochloride, 
harvested then activated using A23187 for 15 minutes or 3 hours. At each time point, samples 
were split into three. One third was removed immediately into extraction solvent (non­
reduced), the remaining sample was split into two and either reduced for 10 minutes with 
SnCb or 1 hour with NaCNBth, followed by lipid extraction. Two different reductants were 
used as the strength of a reducing agent is believed to affect the stabilisation of adducts. For 
example, NaCNBH3 is less nucleophilic than reducing agents such as NaBFL* therefore, its 
rate of reduction rate is slower, allowing the stabilisation of both Schiff bases and Michael 
adducts (Baxter & Reitz, 2003). Strong reducing agents such as NaBH4 and SnCl2 reduce 
ketones to hydroxyl groups, thus stabilising Michael adducts only (Szapacs, et al 2008). 
Therefore, using SnCh and NaCNBFLj as reductants, the formation of both Schiff bases and 
Michael adducts can be investigated. Following lipid extraction, the aqueous phase of 
monocyte samples were used to investigate whether proteins had formed adducts with [14C]- 
labelled products of 15-LOX.
5.2.4.1 [14C]-radiolabelled lipid products of 15-LOX are likely to covalently bind with 
proteins following cell activation.
To investigate whether radiolabelled lipid products of 15-LOX bind to proteins, the aqueous 
phase of samples generated in 5.2.4 underwent TCA precipitation. They were then 
centrifuged for 15 minutes to separate protein-associated (pellet) and non-protein-associated 
(supernatant) compounds. The pellets and supernatants of samples were analysed by 
scintillation counting. The amount of radiolabelled lipids associated with proteins increased
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from control to 3 hours in all samples (Figure 5.6). The largest rise was seen between 0 
minutes and 3 hours for NaCNBH3 treated samples, where the percentage of [14C] associated 
with proteins increased from 6.5 to 11%. The percentage of radiolabel associated with the 
protein fraction increased in both SnCl2 and NaCNBEU treated samples, this is primarily due 
to the formation of Michael adducts between oxidised lipids and proteins/peptides. Therefore, 
covalent association of 15-KETE-PEs to proteins may account for the decrease in 15-KETE- 
PEs seen in time-course experiments (Chapter 4).
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Figure 5.6 Radiolabelled lipid products of 15-LOX bind with proteins following cell 
activation. IL-4 induced human monocytes were incubated with [,4C]-ethanolamine 
hydrochloride, following harvest, cells were activated for 15 minutes or 3 hours with A23187. 
Samples underwent lipid extraction immediately or were firstly reduced using SnCl2 or 
NaCNBH3. The aqueous fraction was subjected to TCA precipitation followed by 
centrifugation, to separate protein associated and non-protein associated compounds. Samples 
were then analysed by scintillation counting and their percentage of radioactivity was 
calculated in the protein associated (A) and non-protein associated (B) fractions (n = 3, mean 
± SEM). *Students t-test, p < 0.05, the difference of each analyte is significant in comparison 
to its relative unactivated control. 1 7 1
5.3 Discussion
To investigate whether products of 15-LOX could bind covalently with proteins, [l4C]- 
ethanolamine hydrochloride was used to generate radiolabelled AA-PEs, which were 
subsequently oxidised by 15-LOX. To ensure incorporation of the [14C] radiolabel, the 
presence of [14C]-AA-PEs and [14C]-15-HETE-PEs (which also contained reduced [l4C]-15- 
KETE-PEs and [14C]-15-HpETE-PEs) in human monocytes was firstly characterised. The 
results indicate that only a small proportion of [14C] is incorporated into membrane PE 
phospholipids (2.7%). Furthermore, only 0.00036% of the total [14C] radiolabel added to 
monocytes was present in the 15-H(p)ETE-PE pool. Thus, if [14C]- 15-KETE-PEs bind 
covalently to proteins, the amount of radiolabelled products would be even less, therefore 
identifying bound proteins using this method may be challenging. Using [14C]-ethanolamine 
hydrochloride with a higher specific activity may aid in identifying covalently bound 
products but, the [14C]-ethanolamine hydrochloride used in this chapter (112 mCi/mmol) has 
the highest specific activity available for this compound. Alternatively, incubating monocytes 
with a higher concentration of [14C]-ethanolamine hydrochloride could increase the amount 
of [14C] incorporated. However, a concentration of200 pM [14C]-ethanolamine hydrochloride 
was used and increasing it further could result in activating monocytes prior to the addition of 
A23187. The use of two alternative [14C] containing compounds, [14C]-AA and [14C]-SAPE 
was investigated in studies for this chapter. However, they were not incorporated into 
membrane phospholipids as efficiently as [14C]-ethanolamine hydrochloride. Other 
radiolabelled compounds include [3H]-ethanolamine hydrochloride and [3H]-AA, but [3H] is 
a weaker radioactive isotope than [14C] and is therefore not a suitable alternative to [14C]- 
ethanolamine hydrochloride.
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Schiff bases are reactive and require stabilisation prior to analysis (McMurry T, 2000, 
Tallman et al, 2006, Szapacs et al, 2008, Held et al, 1979). In particular, a mild reducing 
agent such as NaCNBH3 is required to stabilise Schiff bases. Conversely, SnCl2 is a strong 
reductant that will only stabilise Michael adducts (Isawa & Mukaiyama, 1987). In time- 
course experiments described in Chapter 4, 15-KETE-PEs declined by 3 hours following 
activation of 15-LOX. Levels of radiolabel in the protein-associated fraction increased by 3 
hours following activation in both SnCl2 and NaCNBH3 treated samples. The difference in 
protein-associated radiolabel between SnCl2 and NaCNBH3 treated samples represents the 
formation of Schiff bases. Therefore, the results suggest that lipid products of 15-LOX form 
primarily Michael adducts with proteins, which could account for the decline seen in 15- 
KETE-PEs. Previous studies support the formation of covalent bonds between lipids and 
proteins, which may also be important immunologically. For example, aminophospholipid 
antibodies specifically recognise and bind to oxidised cardiolipins and oxidised 1-palmitoyl- 
2-linoleyl-phosphatidylcholine (ox-PLPC) that have formed covalent bonds with proteins 
such as glycoprotein 1 (Horkko et al, 1996, Horkko et al, 1997). In addition, recent reports 
have shown that oxidised PS, PE and PG phospholipids form Schiff bases with antimicrobial 
peptides (Mattila et al, 2008, Yang et al 2008, Eberard et al, 2009, Wan et al, 2007). This 
evidence supports the association of oxidised phospholipids with proteins and peptides. In 
addition, lipid electrophiles can act as signalling mediators by forming Michael adducts with 
proteins. Examples include 15-deoxy-12,14-prostaglandin J2 (14-deoxy-PGJ2) to NFkB, and 
4-HNE to the inhibitor of icBa (IkB), heat shock factor (HSF), PPAR and MAPK (Rudoph & 
Freeman, 2009, Cemuda-Morollon et al, 2001, Ji et al, 2001, Coleman et al, 2007, Jacobs & 
Mamett, 2007, Zhang et al, 2006).
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Future work could include identifying peptides and/or proteins that bind to the oxidised 
phospholipids generated by 15-LOX. Proteins in samples could be separated by SDS-PAGE, 
the gels could then be cut and analysed by scintillation counting. This may show whether 
radiolabelled proteins are present and using a protein marker would give an indication of their 
size. Alternatively, proteins bound to oxidised phospholipids could be extracted using 
biotinylated phospholipid and fatty acid probes. Specifically, phospholipids tagged with 
biotin could be oxidised, allowed to bind to proteins then the biotin group could be used to 
extract the attached complexes from samples. The products could be digested using trypsin 
followed by identification using LC/MS/MS (Figure 5.7) (Tallman et al, 2006, Szapacs et al, 
2008). This technique has previously been used to identify 21 proteins that bind to ox-PLPC 
(Szapacs et al, 2008). In addition, a biotinylated probe has been used to investigate the 
binding of proteins to Ox-PAPE in aortic endothelial cells. In that study, 20 proteins were 
shown to bind Ox-PAPE-N-biotin, but as of yet, they have not been identified (Gugiu et al, 
2008). A biotinylated free acid HETE probe has been used for a similar purpose. Proteins 
attached to biotinylated 15-HETE were sequenced and the fragments identified corresponded 
to actin and the a-subunit of liver mitochondrial ATP synthase (Kang et al, 1999).
Several publications have investigated the formation of covalent bonds between proteins and 
lipid electrophiles or short chain aldehydes. Of particular interest are reports showing that 15- 
HpETE binds covalently to BSA in-vitro (Refsgaard et al, 2000, Liu & Wang, 2005). 
Furthermore, a precursor of 12-HETE, such as 12-HpETE or 12-KETE, is also suggested to 
bind to proteins in platelet microsomes (Wilson et al, 1979). In these publications, the 
adducts were either Schiff bases, Michael adducts, or formed following the metal ion 
catalysis of a peroxide, forming a peroxyl radical that can react directly with lysine residues 
(Refsgaard et al, 2000, Kato et al, 1992, Burcham et al, 1996, Esterbauer et al, 1991). All
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three types of adducts could potentially be formed between proteins and oxidised products of 
15-LOX in human monocytes.
Various proteins have been identified as targets of oxidised lipids. Among the most abundant 
proteins that bound to biotinylated ox-PLPC were albumin, alpha-1-antitrypsin, 
apolipoprotein Al, A2, A4 and E and complement C3 (Szapacs et al, 2008). Table 5.1 lists 
some metabolites derived from AA that covalently bind to proteins. This list includes 
examples of adducts that may be similar to complexes formed by products of 15-LOX. 
Importantly, both free and esterified 13-HpODEs, can covalently bond with amine groups of 
polypeptides, as well as to PE or PS, thus supporting that HpETE-PEs may be able to form 
similar adducts (Fruebis et al, 1992). PE and PS phospholipid head groups can also form 
Schiff bases with sugars and oxidised cholesterol products (Levi et al, 2008, Nakagawa et al, 
2005, Hazen et al, 1999, Wachel et al, 2006, Bach et al, 2009a & 2009b). Multiple esterified 
or free oxidised products of 15-LOX may be able to bind to one protein. For example, a 
particular report investigated the binding of a 13-HpODE decomposition product, 9,12-dioxo- 
10(E)-dodecenoid acid (DODE) with cytochrome C. This study showed that up to four 
DODE molecules could bind to one molecule of cytochrome C at one time (Williams et al, 
2007). This may be taken into consideration when investigating the binding of 15-LOX 
products to proteins. These studies show that free eicosanoids can certainly bind covalently 
with proteins, but as of yet, this has not been investigated for esterified eicosanoids generated 
by LOXs.
The biological role(s) of these adducts remains largely unknown. In one study, an IgM
monoclonal antibody known as E06 was shown to bind to Schiff base adducts formed
between oxidised phospholipids and lysine residues of apoB (Friedman et al, 2002). This is
proposed to prevent the uptake of ox-LDL by macrophages, and may therefore be important
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AA metabolite Bound Protein References
Levuglandin E2 
(LGE2)
Prostaglandin H synthase 
(PGHS)-l -2, 
histones andubiquitin
Lecomte et al ,1990, 
Boutoud et al, 2001, 
Iyer et al, 1989
Prostaglandin H2 (PGH2) albumin and unidentified Maclouf et al, 1980, 
Fizpatrick & Gorman 1977, 
Eling et al, 1977,
Anderson et al, 1979, 
Crutchley et al, 1979
Thromboxane A2 (TXA2) albumin and unidentified Maclouf et al, 1980, 
Fizpatrick & Gorman, 1977
Prostaglandin A, (PGA,) glutathione by glutathione -  
S-transferases
Ham et al, 1975 
Cagen et al, 1975 
Chaudhari et al, 1978 
Spearman et al, 1985
15-keto-PGF2a glutathione by glutathione -  
S-transferases
Ham et al, 1975, 
Cagen et al, 1975, 
Chaudhari et al 1978, 
Spearman et al, 1985
4-hydroxynonenal (HNE) albumin, heat shock proteins, 
fatty acid binding proteins, 
IkB, PPAR, MAPK and 
many others
Requena et al, 1997 
Aldini et al, 2006,
Vila et al, 2008, 
Grimsrud et al, 2007 
Ji et al, 2001,
Coleman et al, 2007, 
Jacobs & Mamett, 2007, 
Zhang et al, 2006
malondialdehyde (MDA) spectrin and Apoliprotein B, 
PE and PS headgroups
Requena et al, 1997, 
Jain & Shohet, 1984, 
Jain & Hochstein, 1980, 
Fogelman et al, 1980
9,12-dioxo-10(E)- 
dodecenoid acid 
(DODE)
Cytochrome C Williams et al, 2007
13-HpODEs 
(free and esterified )
PE head groups Fruebis et al, 1992
Isoletals PE head groups Bemoud-Hubac et al, 2004
Table 5.1. Metabolites of AA implicated in the formation of Schiff bases or Michael 
adducts i -
in atherosclerosis (Friedman et al, 2002). Therefore, there is evidence to support that covalent 
adducts formed by oxidised phospholipids, may have immunological importance.
In summary, hydroperoxides such as free HpODEs or HpETEs form Michael adducts with 
amines, polypeptides, PE and PS head groups, therefore it is likely that esterified HpETEs or 
KETEs synthesised by LOX may also form similar adducts. Furthermore, the formation of 
covalent bonds between oxidised products of LOX and proteins could account for the 
disappearance of 15-KETE-PEs seen in Chapter 4. To further investigate the association of 
radiolabelled products of 15-LOX with proteins initial studies could include using SDS- 
PAGE to separate protein adducts. This may indicate whether this line of investigation is 
worth pursuing. If so, then synthesis of a biotinylated AA-PE standard (for subsequent 
oxidation by LOX) may also be important to identify proteins/peptides that bind to esterified 
LOX products.
178
CHAPTER 6
CHARACTERISATION OF ESTERIFIED PRODUCTS GENERATED BY 
MURINE MACROPHAGE 12/I5-LOX
6.1 Introduction
The studies described in the previous chapter investigated products of 15-LOX in human 
monocytes. Analogous lipids generated by 12/15-LOX have also been detected in murine 
macrophages (Maskrey et al, 2007). Murine 12/15-LOX preferably oxygenates AA at C-12 and 
its highest expression is in resident peritoneal macrophages (Sun & Funk, 1996). Studies on 
C57/BL6 mice lacking 12/15-LOX (12/15-LOX"7') have shown that their peritoneal macrophages 
do not generate either free or esterified 12-HETEs (Sun & Funk, 1996, Maskrey et al, 2007). In 
these mice, total blood cells counts are normal and there are no differences in organ morphology 
(Sun & Funk, 1996). However, their macrophages show some immunological alterations, 
including decreased expression of CD-36 in response to IL-4, reduced expression of IL-12 
following LPS stimulation and impaired phagocytosis (Huang et al, 1990, Zhao et al, 2002, 
Miller et al, 2001).
12-HETE-PEs were identified in peritoneal macrophages, and their levels increased following 
activation with A23187 (Scheme 2.2) (Maskrey et al, 2007). These novel esterified products of 
12/15-LOX may have immunological significance and their absence may be responsible for at 
least some of the immune defects in macrophages from 12/15-LOX'7" mice. Therefore, it was 
important to characterise their generation and metabolism as part of characterising their function.
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The phospholipid composition of membranes is important and their trafficking between the inner 
and outer membrane leaflet can influence events such as apoptosis and phagocytosis. PS and PE 
are externalised in membranes during apoptosis in order to target cells for phagocytosis 
(Shiratsuchi et al, 1998). Also, there are studies suggesting that oxidation of PS is required prior 
to their extemalisation and for subsequent apoptosis of particular cell types (Tyurina et al, 2004a, 
Jain S, 1985). 12-H(p)ETE-PEs may play a similar function, since phagocytosis by 12/15-LOX'7' 
macrophages is impaired. Therefore, the extemalisation of 12-H(p)ETE-PEs was investigated in 
this chapter.
6.1.1 Aims
In light of the recent discovery of 12-HETE-PEs in murine macrophages, the studies described in 
this chapter have:
• Characterised the synthesis, and investigated the metabolism, of 12-H(p)ETE-PEs in 
murine peritoneal macrophages.
• Investigated their cellular location both basally and following macrophage activation.
• Considered the biological role of 12-H(p)ETE-PEs in murine macrophages. In particular, 
studies investigated whether 12-H(p)ETE-PEs were externalised following their 
synthesis.
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6.2 Results
6.2.1 12-H(p)ETE-PEs generated basally are cell-associated in peritoneal lavages.
The cellular location of 12-H(p)HETE-PEs was investigated in peritoneal lsavages of WT and 
12/15-LOX'7' mice. Cells were firstly pelleted by centrifugation to separate free and cell- 
associated 12-H(p)ETE-PEs. Next, the supernatant was ultra-centrifuged to separate free and 
vesicle-associated 12-H(p)ETE-PEs. Samples were reduced using SnCk, followed by extraction 
and analysis by LC/MS/MS. The results show that basal 12-H(p)ETE-PEs were entirely cell- 
associated, and that these lipids are not generated by 12/15-LOX"7' mice (Figure 6.1).
6.2.2 12-H(p)ETE-PEs increase in activated peritoneal lavages.
The levels of 12-H(p)ETE-PEs in control and A23187 activated peritoneal lavage samples were 
determined. Samples were activated and then the lipids reduced, extracted and analysed by 
LC/MS/MS. Control murine lavages contained approximately 5.5 ± 0.2 ng 12-H(p)ETE-PEs 
compared with 18.5 ± 1.03 ng free 12-H(p)ETE per mouse (mean ± SEM, n = 3). Following 
activation, 12-H(p)ETE-PEs increased to 98.8 ± 17 ng and free 12-H(p)ETE were 123 ± 11 ng 
per mouse (mean ± SEM, n = 3). The results show that 12-H(p)ETE-PEs and 12-H(p)ETE are 
present in control lavage samples and increase following activation (Figure 6.2).
6.2.3 12-H(p)ETE-PEs are primarily retained by macrophages following cellular activation.
In order to determine whether 12/15-LOX products are secreted following their generation, 
activated macrophages were separated from the total lavage by centrifugation. The lipids were 
reduced, extracted and analysed by LC/MS/MS. Following activation, 12-H(p)ETE-PEs were 
mostly cell-associated but were also present in the supernatant (Figure 6.3 A). In contrast, free
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Figure 6.1 Basal 12-H(p)ETE-PEs are cell-associated. Cells in murine peritoneal 
lavages were pelleted by centrifugation and the supernatant was then ultra-centrifuged. 
All samples were treated with SnCl2 to reduce the lipids, which were then extracted and 
analysed by LC/MS/MS (n = 3, mean ± SEM).
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Figure 6.2 12-H(p)ETE-PEs increase following activation in peritoneal lavages.
Murine peritoneal lavages were activated with 10 pM A23187 for 15 minutes, samples 
were treated with SnCl2 reduce the lipids, then underwent lipid extraction. 1 2 - 
H(p)ETE-PEs (A) and 12-H(p)ETE (B) were analysed by LC/MS/MS (n = 3, mean ± 
SEM). * Students t-test, p< 0.05, the difference of each analyte is significant in 
comparison to its relative control.
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Figure 6.3 12-H(p)ETE-PEs are primarily cell-associated following activation.
Peritoneal macrophages were isolated from murine lavages then activated with 10 pM 
A23187 for 15 minutes, lipids were reduced using SnCl2, extracted and analysed by 
LC/MS/MS for 12-H(p)ETE-PEs (A) and 12-H(p)ETE (B) (n = 3, mean ± SEM). 
* Students t-test, p< 0.05, the difference of each analyte is significant in comparison to 
its relative control.
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12-H(p)ETE was mainly secreted (Figure 6.3 B). Products of 12/15-LOX may be involved in 
cellular signalling, regulating events such as inflammation, therefore the results suggest that 12- 
H(p)ETE-PEs may have both para- and autocrine effects while 12-H(p)ETE may only have 
paracrine effects.
6.2.4 12S-H(p)ETE is present in the PE phospholipid fraction.
12-HETE is the primary free and esterified HETE isomer formed by murine 12/15-LOX but the 
chirality of esterified 12-HETE-PEs has not been determined (Maskrey et al, 2007). Therefore, 
experiments were carried out to confirm which HETE enantiomer is synthesised by murine 
12/15-LOX. Lavage samples activated using A23187 were reduced with SnCL followed by lipid 
extraction. The PE fraction was then isolated by NP-HPLC, and then the fatty acids released 
using base hydrolysis, extracted and analysed by LC/MS/MS. 12-H(p)ETE was the most 
prevalent H(p)ETE isomer present, however, 15-H(p)ETE was also detected, as confirmed using 
different isomer HETE standards (Figure 6.4 A-J). 12-H(p)ETE was isolated by RP-HPLC then 
analysed by chiral HPLC. Comparison with 12S- and 12R-HETE standards showed that 12S- 
H(p)ETE was the only enantiomer present (Figure 6.5). Therefore, the results indicate that 
murine 12/15-LOX forms some 15-H(p)ETE-PEs but largely synthesises 12S-H(p)ETE-PEs.
6.2.5 12-H(p)ETE-PEs are formed by direct oxidation o f membrane phospholipids. 
12-HpETE-PEs could be synthesised within the cells by two pathways. The first is by direct 
oxidation of membrane phospholipids (Scheme 6.1). Alternatively, LOX could oxidise free AA 
forming free 12-HpETE, which would then be re-esterified (Scheme 6.2). During this pathway, 
PLA2 hydrolysis involves the incorporation of oxygen from water into AA. Buffers can be
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Figure 6.4. 12-H(p)ETE is the main product in the PE fraction according to the peak 
apex. Murine peritoneal lavages were activated with 10 pM A23187 for 15 minutes, lipids 
were reduced using SnCl2 and extracted. The PE fraction was isolated by NP-HPLC, then 
fatty acids were released from phospholipids by base hydrolysis, extracted and analysed by 
LC/MS/MS. Murine generated HETEs were compared to HETE standards (A-J) (n=10). 186
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Figure 6.5. 12/15-LOX synthesises predominantly 12S-H(p)ETE. Murine 
peritoneal lavages were activated with 10 pM A23187 for 15 minutes, lipids were 
reduced using SnCl2 then extracted. The PE fraction was isolated by NP-HPLC, then 
fatty acids were released from phospholipids by base hydrolysis, extracted and 
analysed by LC/MS/MS. 12-H(p)ETE was isolated by RP-HPLC then analysed by 
chiral phase-HPLC .
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generated using ‘heavy’ water (H2 lsO), and thus, activation of cells in this buffer would result in 
incorporation of heavy oxygen (180) into AA, generating esterified and free HETEs with a mass 
increase of two. These products can subsequently be analysed by LC/MS/MS. During re- 
esterification, there is a 50% chance that the 180  label will be lost, and therefore, 50% of 12- 
H(p)ETE-PE will be labelled (Scheme 6.2). To determine if 12-HpETE-PEs are formed by direct 
oxidation or by re-esterification of 12-HpETE, macrophages were activated in krebs buffer made
151up with O water. The lipids were reduced then extracted. LC/MS/MS analysis showed that the 
isotope label was successfully incorporated into free 12-H(p)ETE (data not shown), however, 
180-labelled 12-H(p)ETE-PEs were not detected, indicating that 12-H(p)ETE-PEs are generated 
by direct oxidation of phospholipids (Figure 6.6).
6.2.612-H(p)ETE-PEs are metabolised within 3 hours to unknown products.
Next, the metabolism of 12-H(p)ETE-PEs from murine 12/15-LOX were investigated. Peritoneal 
macrophages were activated for a maximum of 180 minutes, at each time-point, half of each 
sample was removed immediately into lipid extraction buffer while the remaining half was 
reduced prior to lipid extraction. Lipids were then analysed by LC/MS/MS. 30% of 12/15-LOX 
products were endogenously reduced to 12-HETE-PEs throughout the time-course (non-reduced 
samples) (Figure 6.7). Endogenous 12-HETE-PEs declined throughout the time-course, almost 
returning to baseline by 180 minutes (Figure 6.7). Following SnCL treatment, detected 12- 
H(p)ETE-PEs are made up of both endogenous 12-HETE-PEs and additional lipid products of 
12/15-LOX that can be chemically reduced to 12-HETE-PEs. Therefore, levels of 12-H(p)ETE- 
PEs would be higher in SnCL treated samples. 12-H(p)ETE-PEs were also metabolised by 180 
minutes, however, the decrease in endogenous 12-HETE-PEs was not enough to account for the
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Figure 6.6 12-H(p)ETE-PEs are formed by direct oxidation of AA-PEs.
Macrophages from murine lavages were activated with 10 pM A23187 for 15 
minutes in krebs buffer generated with either with regular or 180  labelled water. 
Lipids were reduced using SnCl2 followed by extraction and LC/MS/MS analysis. 
Samples were analysed for label incorporation into 12-H(p)ETEs (A), 12-H(p)ETE- 
PEs (B) (n = 3, mean ± SEM). *Students t-test, p< 0.05, the difference of each 
analyte is significant in comparison to its relative control.
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Figure 6.7 12-H(p)ETE-PEs are metabolised by three hours to unknown products.
Macrophages isolated from mouse lavages were activated with 10 pM A23187 for various time- 
points. Lipids from all samples were extracted, half following SnCl2 reduction. Analysis of 18:0a 
(A), 18:0p (B), 18: lp (C) and 16:0p (D) 12-H(p)ETE-PEs was carried out by LC/MS/MS (n = 3, 
mean ± SEM). □ Non Reduced ■ Reduced. * Students t-test, p< 0.05, with Mann-Whitney test, 
the difference of each analyte is significant in comparison to its relative control.
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decrease in 12-H(p)ETE-PEs in reduced samples. The results suggest that both 12-HETE-PEs 
and a non-reduced lipid precursor, such as 12-HpETE-PEs or 12-KETE-PEs are metabolised in 
activated macrophages. In contrast, endogenous free 12-HETE increased following activation 
then remained stable throughout the time-course (Figure 6.8).
6.2.7 12-H(p)ETE-PEs are externalised in the plasma membrane o fW T macrophages following 
activation.
Previous studies have shown that extemalisation of PS and PE phospholipids is required to 
induce apoptosis in particular cell types prior to their phagocytosis (Shiratsuchi et al, 1998). 
Furthermore, oxidation of phospholipids may be required before they are externalised (Tyurina 
et al, 2004a, Jain SK, 1985). In order to determine whether 12-H(p)ETE-PEs are externalised to 
the outer leaflet of the membrane bi-layer following activation, peritoneal macrophages were 
incubated with sulfo-NHS-biotin, which binds to primary amine groups of PE and PS 
phospholipids on the exterior of cells. Samples were reduced and the lipids extracted. 
Phospholipids bound to biotin can be followed by MS as their m/z increases by 226 amu. 12- 
H(p)ETE-PEs were externalised following cellular activation of WT macrophages (Figure 6.9 
A). However, 12-H(p)ETE-PEs were not detected at all in macrophages from 12/15-LOX' 'mice. 
Macrophage samples were also analysed for the AA-PEs. In 12/15-LOX_/‘ macrophages, AA-PEs 
were externalised, which did not occur in WT cells (Figure 6.9 B). The results suggest that 
following activation of WT macrophages, 12-H(p)ETE-PEs are selectively externalised, and in 
the absence of 12/15-LOX, the un-oxidised lipids (AA-PEs) are externalised in their place.
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Figure 6.8 Endogenous 12-HETE remains stable following activation.
Macrophages from mouse lavages were activated with 10 pM A23187 for various 
time-points. Lipids were extracted and endogenous 12-HETE was analysed by 
LC/MS/MS (n = 3, mean ± SEM). * Students t-test, p< 0.05, the difference is 
significant in comparison to the control.
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Figure 6.9 12-H(p)ETE-PEs are externalised following activation in macrophage 
plasma membrane. Murine macrophages were activated with A23187 and externally 
exposed PE were biotinylated. Samples were then reduced using SnCl2, followed by 
lipid extraction and LC/MS/MS analysis. Levels of biotinylated 12-H(p)ETE-PEs (A) 
and AA-PEs (B) were determined before and after activation in WT or 12/15-LOX'7' 
peritoneal macrophages (n = 3, mean ± SEM). *Students t-test, p< 0.05, the difference of 
each analyte is significant in comparison to its relative control.
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6.3 Discussion
12-H(p)ETE-PEs generated by 12/15-LOX were recently identified by Maskrey et al (2007) in 
murine macrophages following A23187 activation. 12/15-LOX is suspected to play a role in 
inflammatory disorders such as atherosclerosis, however, the products responsible have not been 
identified. Following the discovery of 12-H(p)ETE-PEs, it is important to characterise their 
generation and metabolism, and establish how they may be involved in inflammatory disorders.
The results in this chapter have shown that macrophage 12-H(p)ETE-PEs are derived entirely 
from direct oxidation (rather than esterification of free 12-H(p)ETE), similar to 15-H(p)ETE-PEs 
in human monocytes (Figure 6.6) (Maskrey et al, 2007). Interestingly, this is different to platelet 
12-LOX esterified phospholipids, which are generated by esterification of 12-HETE (Thomas et 
al, 2010). This suggests that platelet 12-LOX and murine 12/15-LOX synthesise the same 
products but by a different mechanism. However, human 15-LOX and murine 12/15-LOX 
generate their products by the same mechanism. In addition, previous studies have shown that 
oxidised cholesterol ester products of rabbit reticulocyte 15-LOX are also the result of direct 
oxidation, this supports that 12/15-LOX enzymes synthesise their products using similar 
mechanisms (Belkner et al, 1998).
Following this, the metabolism of 12-HpETE-PEs in murine macrophages was investigated. The 
trend seen in reduced macrophage time-course samples was similar to results seen in Chapter 4 
for human monocytes, where the lipid precursors of 15-HETE-PEs were identified as 15-KETE- 
PEs and were the primary lipids metabolised in human monocytes (Figures 4.9- 4.12). The lipid 
precursor of 12-HETE-PE in mice may be 12-HpETE-PE or 12-KETE-PE but as of yet, this has
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not been investigated. If the products are identified as either of these lipids, product ion spectra 
and LC/MS/MS retention times require validation using standards. 12-HETE-PE and 12-HpETE- 
PE standards can be generated using air oxidation techniques (as described in Chapter 3), 
however, 12-KETE-PEs cannot be generated in this way and are not available commercially (Yin 
et al, 2008).
In time-course experiments, endogenous 12-HETE-PEs were metabolised by 180 minutes, this is 
different to results obtained from human monocytes where only the lipid precursors were 
metabolised (Figures 4.8 and 6.7). The metabolism of 12-HETE-PEs and their precursors may be 
via PLA2 cleavage of the sn2 fatty acid. However, levels of endogenous 12-HETE were stable 
throughout the time-course. This is similar to results in human monocytes where 15-HETE 
remained stable in time-course samples and hydrolysis by PLA2 was ruled out as a method of 15- 
HETE-PE and 15-KETE-PE metabolism. However, to exclude the metabolism of 12-H(p)ETE- 
PEs by PLA2 enzymes, experiments are required using inhibitors of PLA2 . 12/15-LOX 
translocates to the plasma membrane following activation, suggesting that 12-HpETE-PEs are 
likely to be synthesised from plasma membrane derived phospholipids (Miller et al, 2001). 
Studies in Chapter 5 determined that 15-H(p)ETE-PEs or 15-KETE-PEs may bind to proteins. It 
may therefore be relevant to investigate whether 12-H(p)ETE-PEs (or 12-KETE-PEs) can form 
covalent associations with membrane proteins. Covalent bonding could account for the decrease 
in the unidentified products of 12/15-LOX. The results suggest that 12/15-LOX products from 
mice may be metabolised differently to 15-LOX products generated by human monocytes. This 
may be related to the pro- versus anti-inflammatory effect of 12/15-LOX in mice and rabbits 
respectively. For example, 12/15-LOX is believed to be anti-atherogenic in rabbits but pro-
197
atherogenic in mice, suggesting that murine leukocyte 12-LOX and rabbit 15-LOX may not be 
functionally equivalent (Kuhn et al, 1994b, Neuzil et al, 1998, Sun & Funk, 1996, Shen et al, 
1996, Smith et al, 1993, Takata et al, 1994a). Future experiments could therefore compare the 
effect of 12-H(p)ETE-PEs and 15-H(p)ETE-PEs in both murine and rabbit models of 
atherosclerosis.
12-H(p)ETE-PEs are externalised by activated WT macrophages (Figure 6.9). This may indicate 
an involvement in apoptosis or interactions with other cells. The extemalisation of 12-H(p)ETE- 
PEs may also alter membrane fluidity, which could affect phagocytosis and migration. 
Movement of PE and PS phospholipids to the outer leaflet of plasma membranes is suggested to 
be a marker of cell death and is required for phagocytosis of apoptotic cells (Mimikjoo et al, 
2009, Fadok et al, 2001, Diaz et al, 1999, Shiratsuchi et al, 1998). Furthermore, oxidation of PS 
phospholipids has been described prior to their extemalisation, a process which was also 
essential for the phagocytosis of particular cells (Tyurina et al, 2004a, Jain SK, 1985). Therefore, 
externalised 12-H(p)ETE-PEs could be required for macrophages to carry out phagocytosis. In 
support of these studies, treatment of leukemia HL-60 cells with an anti-oxidant, to prevent the 
peroxidation of PS, also blocked PS extemalisation and phagocytosis (Tyurina et al, 2004b). 
Furthermore, hepatoma HepG2 cells are reported to undergo apoptosis when exposed to 
exogenous PE. Thus externalised 12-H(p)ETE-PEs in macrophage membranes may have a 
similar effect on cells that are targeted for phagocytosis (Yao et al, 2009).
12/15-LOX has been linked to cellular actions that require re-structuring of the cell membrane. 
Once such example is during phagocytosis, where macrophages from 12/15-LOX7' mice fail to
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properly phagocytose apoptotic thymocytes (Miller et al, 2001). The results in this chapter show 
that 12-H(p)ETE-PEs are externalised following cellular activation. This could alter membrane 
fluidity and explain how 12/15-LOX is involved in events such as phagocytosis. In addition, 
phosphorylation of F-actin during phagocytosis requires the activity of 12/15-LOX (Rice et al, 
1998, Tang et al, 1993, Liu et al, 1995, Honn & Tang et al, 1992, Honn et al, 1994, Miller et al, 
2001 & 2003, Tang & Honn, 1994, Kang et al, 1999). Actin is a major component of the 
cytoskeleton and its re-structuring is pivotal to actions requiring movement of cell membranes 
(Berg et al, 2002). Therefore, future experiments could include investigating if 12-H(p)ETE-PEs 
are involved in the phosphorylation of F-actin. Furthermore, as HETE is reported to form a 
complex with proteins thought to be subunits of actin, experiments could also show whether 12- 
H(p)ETE-PEs can bind to F-actin (Kang et al, 1999). 12/15-LOX is reported to translocate to the 
plasma membrane of macrophages and dendritic cells following activation (Andersson et al, 
2006, Miller et al, 2001, Zhu et al, 2003). This supports the action of 12/15-LOX on membrane 
phospholipids, where product generation may have a direct affect on membrane fluidity and 
structure. While studies show that 12/15-LOX, and therefore, 12-H(p)ETE-PEs, may be involved 
in re-structuring the cellular membrane, the importance of this is yet to be assessed. However, as 
12/15-LOX is only significantly expressed in peritoneal macrophages its role is likely to be 
specific to this subset of cells (Sun & Funk, 1996).
If 12/15-LOX, and therefore 12-H(p)ETE-PEs, are involved in actin polymerisation then they 
may also have an effect on cell migration. Over-expression of 12/15-LOX in endothelial cells 
transfected with the gene results in the up-regulation of VCAM-1, which increases the 
adhesiveness of cells’. A similar result was observed when endothelial cells were induced with
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IL-4, a cytokine used to induce 12/15-LOX in human monocytes (Lee et al, 2001, Vitta et al, 
1999). As discussed above, PE extemalisation alters the properties of a cell membrane, which 
may also affect the ability of cells to adhere to one another. Therefore, externalised 12-H(p)ETE- 
PEs may be involved in interactions between macrophages and endothelial cells. The up- 
regulation of VC AM by 12-H(p)ETE-PEs has not been investigated as of yet, but may be worth 
pursuing to determine the role of 12-H(p)ETE-PEs in migration and cell-cell interactions. In 
particular, migration assays comparing the attachment of 12/15-LOX"7' and WT macrophages to 
surface ligands expressed by epithelial cells, would investigate whether 12-H(p)ETE-PEs are 
involved in macrophage-epithelial interactions. In support that such cell-cell interactions may 
take place, oxidised PS phospholipids in macrophage membranes have been shown to interact 
with the CD-36 receptor of apoptotic cells undergoing phagocytosis (Greenberg et al, 2006). In 
particular, extemalisation of a decomposed hydroperoxide group from oxidised phospholipids 
may assist the physical contact of cells with pattern recognition receptors, known as the lipid 
whisker model (Figure 6.10) (Greenburg et al, 2008).
In addition to 12-H(p)ETE-PE extemalisation in murine macrophages, platelet 12-H(p)ETE-PEs 
are externalised following activation (Thomas et al, 2010). Interestingly, in a patient suffering 
from the bleeding disorder Scott Syndrome (where membrane lipid scrambling is impaired), 
platelet 12-HETE-PEs are not externalised following activation (Thomas et al, 2010). This 
suggests that scramblases are involved in 12-H(p)ETE-PE extemalisation. Lipid oxidation is also 
reported to affect aminophospholipid translocases and PS scrambling, causing the extemalisation 
of PS phospholipids (Tyurina et al, 2004a). However, little is known about the structure and 
mechanism of floppases and scramblases, and most of the current research investigating the
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Figure 6.10. Schematic representation of the lipid whisker model. Cell 
membranes of apoptotic cells have oxidised phospholipids with sn-2-oxidised 
fatty acid acyl chains protruding into the extracellular space. This conformation 
allows them to interact with scavenger receptors and other pattern recognition 
receptors on the surface of macrophages (reproduced from Greenburg et al, 
2008, with permission (12/11/2010)).
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extemalisation of lipids has concentrated on PS and not PE. The use of inhibitors for these 
transporters may determine how 12-H(p)ETE-PEs are moved to the outer-side of cell membranes 
(Bevers et al, 1999).
Results in this chapter have shown how 12-H(p)ETE-PEs are synthesised by 12/15-LOX in 
murine macrophages, however further investigation is required to fully understand how they are 
metabolised. In particular, the lipid precursor of 12-HETE-PEs requires identification. Results 
showing the extemalisation of 12-H(p)ETE-PEs suggest a novel mechanism by which 12/15- 
LOX products are involved in altering membrane properties.
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CHAPTER 7
CELLULAR UPTAKE OF 15-HETE-PE. ITS EFFECT ON CYTOKINE 
GENERATION AND ITS SYNTHESIS DURING HUMAN BACTERIAL INFECTION
7.1 Introduction
The generation of murine 12-HETE-PEs in acute inflammatory processes was recently 
characterised in three in-vivo models, (i) peritonitis in response to S.epi supernatant (SES),
(ii) live S.epi infection, or (iii) following OVA sensitization of the lung (Figures 7.1 and 7.2) 
(Morgan et al, 2009). Results showed that levels of 12-HETE-PEs were reduced in murine 
peritoneal lavages following SES and live S.epi infection, but raised in ova lung allergy. 
These results indicate that 12/15-LOX is regulated during both Thl and Th2 driven immune 
responses.
The presence of 15-HETE-PEs has not been investigated in human inflammatory disorders. 
Patients undergoing peritoneal dialysis as a treatment for renal failure are prone to bacterial 
infections, such as by S.epi. Lavage fluid taken from patients with suspected bacterial 
infections could be analysed by MS for 15-HETE-PEs, to determine whether levels of these 
phospholipids are altered during bacterial infection in humans.
Following their generation, 12- and 15-HETE-PEs remain cell-associated, which suggests 
that they may play a role in intracellular signalling (Chapters 4 and 6). This may include 
stimulating the synthesis of cytokines. As described in Chapter 3, a 15-HETE-PE standard
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Figure 7.1 12-HETE-PEs decrease in SES peritonitis during inflammation, then 
recover by day 7. 12-HETE-PEs from peritoneal lavages of SES-infected mice were 
profiled post infection at various times by LC/MS/MS (n = 5) (Reproduced from 
Morgan et al, 2009, with permission (12/11/2010).
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Figure 7.2 12-HETE-PEs decrease in live bacterial peritonitis, but are elevated in Ova 
lung allergy. (A) 12-HETE-PEs from peritoneal lavages of S.epi-infected mice were profiled 
post infection at various times by LC/MS/MS (n = 3 - 5). (B) 12-HETE-PEs were profiled in 
lung homogenate from Ova-sensitized mice after 6 days of Ova challenge (intranasally), using 
LC/MS/MS (n = 3, mean = ± SEM) (Reproduced from Morgan et al, 2009, with permission 
(12/ 11/2010).
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was synthesised, which can be used in biological experiments. Before investigating its effect 
on cytokine generation, studies were conducted to determine the best method for its delivery 
and incorporation into cultured cells. Three methods were tested.
(i) The lipids were added to cells in methanol solution.
(ii) Liposomes were used. These are well known as vehicles of different substances, they 
have been utilised in gene therapy, drug delivery and as immune adjuvants (Figure 7.3) 
(Griesenbach et al, 1998, Liu D, 1991, Abra RM, 1984, Gregoriadis et al, 1996, Bennett JE, 
1996). However, their application as lipid transporters has not been explored.
(iii) Albumin-lipid complexes were tested. Carrier proteins such as serum albumin can also 
transport substances across cell membranes. Albumin binds reversibly and with high affinity 
to a diverse selection of ligands, including fatty acids, drugs, metals, amino acids and heme 
containing compounds (Varshney et al, 2010).
The above methods were adapted for our own investigations, to introduce 15-HETE-PE to 
cells. Following the successful incorporation of 15-HETE-PE, experiments then investigated 
its biological function. Oxidised phospholipids are reported to affect cytokines generated by 
LPS stimulated cells (von Schlieffen et al, 2009, Erridge et al, 2007, Erridge et al, 2008, 
Walton et al, 2003). Therefore, the effect of 15-HETE-PE on cytokine generation was 
investigated in monocytes activated by LPS.
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Figure 7.3 Liposomes are vesicles of bilayer phospholipids used to transport 
various substances. (A) Liposomes are formed from a lipid bilayer which 
encapsulate aqueous solutions. (B) Liposomes can be adapted for use as carriers of 
many substances such as drugs and DNA.
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7.1.1 Aims
In studies described in this chapter aimed to:
• Assess which method resulted in the greatest incorporation of 15-HETE-PE into 
human peripheral monocytes, including the time and concentration of 15-HETE-PE 
required.
• Investigated the effect of exogenously added 15-HETE-PE on cytokine generation 
from human monocytes activated with LPS.
• Investigated whether levels of 12/15-LOX products differ in human peritoneal lavage 
samples from stable, ‘healthy’ patients and those with suspected bacterial infections.
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7.2 Results
7.2.1 Synthesis o f liposomes containing 15-HETE-PE.
Liposomes of l,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC) and 15-HETE-PE were 
generated using a freeze-thaw method and vesicles larger than 100 nm were removed by an 
extruder. The liposomes were analysed by MS to ensure incorporation of both DPPC and 15- 
HETE-PE. A negative ion Q1 scan revealed ions corresponding to DPPC [M-CH3]' {m/z 718) 
and a DPPC adduct [M+Cl]' (m/z 768) (Figure 7.4 A). Positive ion Q1 scans showed peaks 
corresponding to DPPC [M+Na]+ (m/z 756) and [M+H]+ (m/z 734) (Figure 7.4 B). 15-HETE- 
PE was not seen in the negative Q1 scan, which is likely due to high concentrations of DPPC 
causing ion suppression. However, LC/MS/MS analysis of the sample confirmed the 
presence of this lipid in the liposome preparations (Figure 7.5).
To confirm the identity of peaks seen in Q1 scans, product ion spectra were obtained. 
Negative product ion spectra of DPPC ions 718 and 768 showed similar fragmentation 
patterns, both containing a fragment of m/z 255, which corresponds to palmitic acid (Figure 
7.6 A and B). It should be noted that the chlorine adduct, m/z 768, is not seen in its product 
ion spectrum due to its complete fragmentation. A positive product ion spectrum of 734 
confirmed the presence of the PC head group (m/z 184) (Figure 7.6 C). A negative product 
ion spectrum of m/z 782 was also carried out to confirm the presence and identity of 15- 
HETE-PE. The spectrum contained all the typical fragments of 15-HETE-PE (m/z 283 
(stearic acid), 319, 219 and 175 (15-HETE)) (Figure 7.7). These results confirm that the 
generated liposomes exclusively contained DPPC and 15-HETE-PE.
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Figure 7.4 Confirmation that synthesised liposomes contain DPPC. Liposomes 
were made using a freeze thaw method then analysed by MS. Q1 scans of a 1 in 
1000 diluted liposome sample in negative mode (A) and positive mode (B) confirm 
presence of DPPC.
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Figure 7.5 Confirmation that synthesised liposomes contain 15-HETE-PE.
Liposomes were made using a freeze thaw method. A sample was analysed by 
LC/MS/MS to confirm the presence of 15-HETE-PE.
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7.2.2 The addition o f  15-HETE-PE in methanol achieved the largest incorporation into
human monocytes.
To incorporate 18:0a/15-HETE-PE into human monocytes, three methods were used: 
liposomes, carrier proteins and methanol solvent. Isolated human monocytes, devoid of 
12/15-LOX expression, were incubated in medium with 1 pM 15-HETE-PE for up to 24 
hours. At each time-point, lipids from the medium were extracted, fresh medium was then 
added to the adhered cells which were scraped, followed by lipid extraction. All samples 
were analysed by LC/MS/MS analysis and 15-HETE-PE was quantified. Following its 
addition to cells in methanol, the percentage of cell-associated 15-HETE-PE increased from 
2.0% at 1 hour to 2.6% by 24 hours (Figure 7.8 A). Following an incubation period of 24 
hours, the incorporation achieved with liposomes or BSA was 1.6 and 1.8% respectively. At 
all time-points, the greatest incorporation of 15-HETE-PE was achieved following its 
addition in methanol. However, after the initial uptake by 1 hour, subsequent percentage 
increases in cell-associated 15-HETE-PE were not significant (p = >0.05). The concentration 
of 15-HETE-PE declined in the medium of cell samples when using the BSA and methanol 
methods, which corresponded to increases in cell-associated 15-HETE-PE (Figure 7.8 B). 
When comparing the combined concentration of 15-HETE-PE in cells and medium, 60-85% 
of the initial 15-HETE-PE concentration is unaccounted for. This suggests that 15-HETE-PE 
may decompose when stored at temperatures of 37 °C or it readily precipitates onto the 
plastic sides of tissue culture wells. A higher concentration of 15-HETE-PE was detected in 
the medium of liposome samples in comparison to BSA and methanol methods, suggesting 
that liposome complexes may reduce its decomposition and precipitation. The results indicate
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Figure 7.8 The addition of 15-HETE-PE in methanol resulted in the largest 
incorporation. 1 pM 15-HETE-PE was added to monocytes either in methanol (■), DPPC 
liposomes (•) or in BSA solution (J^  for various time-points. Lipids were extracted from 
both media and cells and analysed by LC/MS/MS. The percentage of 15-HETE-PE was 
calculated: A) % cell associated 15-HETE-PE (B) % 15-HETE-PE present in the media.
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that the addition of 15-HETE-PE in methanol gives the greatest incorporation into human
monocytes, although overall incorporation was very low.
7.2.3 Incorporation o f 15-HETE-PE into human monocytes is dose-dependent.
To determine the optimum concentration of 15-HETE-PE required for incorporation, 
monocytes were incubated for 1 hour, with 0.4 to 40 pg (1 to 100 pM) 15-HETE-PE. Lipids 
from cells and the surrounding medium were extracted then analysed by LC/MS/MS. The 
uptake of 15-HETE-PE was dose-dependent up to incubation with 20 pg (50 pM) 15-HETE- 
PE, but above this, incorporation began to plateau (Figure 7.9). The concentration of cell- 
associated 15-HETE-PE increased from 0.005 to 1.45 pg following incubation with 0.4 to 40 
pg respectively (Figure 7.9 A). The actual incorporation following incubation with 40 pg 
(100 pM) was greater than at 20 pg (50 pM) but the overall percentage of incorporation 
declined from 6.2 to 3.7% (Figure 7.9 B). This suggests that the addition of 15-HETE-PE at 
concentrations of above 50 pM were approaching the maximum concentration for lipid 
uptake using this method. Therefore, concentrations of 50 and 100 pM 15-HETE-PE were 
used to investigate their effect on cytokine generation in LPS treated human monocytes.
7.2.4 Cytokine generation is dose-dependently reduced by 15-HETE-PE.
Next, the effect of 15-FIETE-PE on cytokine generation was investigated. Human monocytes 
were incubated for 24 hours in tissue culture wells containing media with 50 or 100 pM 15- 
HETE-PE or the un-oxidised lipid, SAPE, in the presence or absence of LPS. Incubation for 
24 hours was required as cytokine levels do not typically increase until several hours
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Figure 7.9 Incorporation of 15-JfETE-PE is dose-dependent. Human monocytes 
were incubated for one hour with increasing concentrations of 15-HETE-PE. Cell- 
associated lipids were extracted and analysed by LC/MS/MS. The amount of cell- 
associated 15-HETE-PE was calculated (A) and also the overall percentage of 
incorporation (B).
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following cell stimulation (Janeway et al, 2005). Following 24 hours, the medium from each 
well was transferred to eppendorf tubes and centrifuged to remove cellular debris. Medium 
was then analysed for generation of cytokines by ELISA. In control samples, no cytokine 
generation was seen following the addition of 15-HETE-PE or SAPE, however, LPS 
stimulated a strong generation of G-CSF, IL-lp, IL-6, TNF-a and IL-10 (Figures 7.10-7.14). 
The addition of 15-HETE-PE to un-stimulated monocytes resulted in decreased generation of 
G-CSF, IL-lp, IL-6, IL-8 and MCP-1 (Figures 7.10-7.12 & 7.15-7.16), however, this was not 
dose-dependent. In addition, it may not be specific to 15-HETE-PE as IL-lp, IL-6 and MCP- 
1 generation was also deceased following treatment with 50 pg SAPE. The addition of 15- 
HETE-PE to LPS-stimulated monocytes resulted in dose-dependent inhibition of G-CSF, IL- 
ip, IL-6 and TNF-a, while SAPE was without effect (Figures 7.10-7.13). IL-10 was also 
dose-dependently reduced following the addition of 15-HETE-PE. However, a similar result 
was seen in response to SAPE, suggesting that inhibition of IL-10 generation was not specific 
to 15-HETE-PE (Figure 7.14). LPS failed to stimulate the synthesis of IL-8 and RANTES, 
and levels did not significantly change following the addition of 15-HETE-PE or SAPE 
(Figures 7.15 & 7.17). MCP-1 generation was reduced by LPS, a response that was further 
reduced by both 15-HETE-PE and SAPE (Figure 7.17). The results indicate that 15-HETE- 
PE down-regulates LPS stimulated generation of G-CSF, IL-ip, IL-6 and TNF-a, and may 
also down-regulate generation of G-CSF, IL-ip, IL-6, IL-8 and MCP-1 in un-stimulated 
cells.
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Figure 7.10 LPS stimulated G-CSF is dose-dependently reduced by 15-HETE-PE. Control and LPS
stimulated monocytes were incubated with 50 and 100 pM 15-HETE-PE or SAPE for 24 hours. The media
supernatant was analysed by ELISA for cytokine generation (n = 3, mean ± SEM). *Students t-test, p< 0.05.
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Figure 7.11 LPS stimulated IL-ip is dose-dependently reduced by 15-HETE-PE. Control and LPS stimulated
monocytes were incubated with 50 and 100 pM 15-HETE-PE or SAPE for 24 hours. The media supernatant was
analysed by ELISA for cytokine generation (n = 3, mean ± SEM). * Students t-test, p< 0.05.
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Figure 7.12 LPS stimulated IL-6 is dose-dependently reduced by 15-HETE-PE. Control and LPS stimulated
monocytes were incubated with 50 and 100 jliM  15-HETE-PE or SAPE for 24 hours. The media supernatant was
analysed by ELISA for cytokine generation (n = 3, mean ± SEM). * Students t-test, p< 0.05.
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Figure 7.13 LPS stimulated TNF-a is dose-dependently reduced by 15-HETE-PE. Control and LPS 
stimulated monocytes were incubated with 50 and 100 pM 15-HETE-PE or SAPE for 24 hours. The media 
supernatant was analysed by ELISA for cytokine generation (n = 3, mean ± SEM). * Students t-test, p< 0.05.
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Figure 7.14 LPS stimulated IL-10 is not specifically reduced by 15-HETE-PE. Control and LPS stimulated
monocytes were incubated with 50 and 100 pM 15-HETE-PE or SAPE for 24 hours. The media supernatant was
analysed by ELISA for cytokine generation (n = 3, mean ± SEM). * Students t-test, p< 0.05.
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Figure 7.15 IL-8 generation decreases following the addition 15-HETE-PE to unstimulated monocytes.
Control and LPS stimulated monocytes were incubated with 50 and 100 pM 15-HETE-PE or SAPE for 24 hours.
The media supernatant was analysed by ELISA for cytokine generation (mean ± SEM, n=3).
Figure 7.16 MCP-1 generation decreases following the addition 15-HETE-PE to unstimulated monocytes.
Control and LPS stimulated monocytes were incubated with 50 and 100 |uM 15-HETE-PE or SAPE for 24 hours. 
The media supernatant was analysed by ELISA for cytokine generation (n = 3, mean ± SEM). * Students t-test, 
p< 0.05.
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Figure 7.17 RANTES is not affected by the addition of LPS or 15-HETE-PE. Control and LPS stimulated
monocytes were incubated with 50 and 100 pM 15-HETE-PE or SAPE for 24 hours. The media supernatant was
analysed by ELISA for cytokine generation (mean ± SEM, n=3).
7.2.5 Levels o f 15-HETE-PEs in control and bacterial-infected human peritoneal lavages are 
variable.
The generation of HETE-PEs during bacterial infections in humans has not been investigated. 
Lavage samples from patients undergoing peritoneal dialysis (stable controls) and individuals 
with suspected bacterial infections underwent lipid extraction and LC/MS/MS analysis. As 
part of routine diagnosis, bacterial cultures of patient lavage samples assessed whether they 
had bacterial infections and also identified the type of bacterium. Small levels of 15-HETE- 
PEs were detected in lavage fluid of stable control patients that were comparatively increased 
in the presence of particular gram-positive bacterial infections (P1-P3) (Figure 7.18). The 
results are contrary to that reported in studies of a mouse model S.epi infection, which is also 
a gram-positive bacterium, where 15-HETE-PE decreased following infection (Figures 7.1 
and 7.2 A). Infection with Haemolytic Streptococci a (P2) showed the greatest increase of 15- 
HETE-PE, followed by infection with Coryneform (P3) and a small increase was seen in 
response to Haemolytic Streptococci (3 (PI). 15-HETE-PEs were not raised following 
infection by the gram-negative bacteria, Proteus Vulgaris and Klebsiella (P4 and P5). 
Increases in 15-HETE-PE were also seen in N3 and N4, namely samples from cases where 
bacterial infection was initially suspected but tested negative during diagnosis by bacterial 
cultures. This suggests that these patients may have been infected with a bacterium outside 
the scope of routine bacterial cultures or had undergone an alternative immune challenge. To 
date, samples testing positive for bacterial infection have all been caused by different 
bacterial types, therefore only one sample has been collected for each identified bacterium. 
Furthermore, patients identified as ‘stable controls’ have underlying health conditions and are 
therefore not ‘true’ naive controls as used in murine disease models. Thus, the results are
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Figure 7.18 15-HETE-PE may be generated in response to infection by particular 
gram-positive bacteria. Lipids were extracted from lavage samples of patients 
undergoing peritoneal dialysis- stable controls, or patients with suspected bacterial 
infection. Samples were analysed by LC/MS/MS for 15-HETE-PE. Formal 
identification of infected bacteria: PI: Haemolytic Streptococci (3 (gram +ve), P2: 
Haemolytic Streptococci a (gram +ve); P3: Coryneform (gram +ve), P4: Proteus 
Vulgaris (gram -ve); P5: Klebsiella (gram -ve).
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preliminary, merely indicating whether 15-HETE-PEs may be raised or decreased in response 
to particular bacteria. When multiple samples showing the same trend have been collected, 
the significance of these results can be verified.
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7.3 Discussion
As 15-HETE-PEs may be involved in regulating immune responses, the investigations 
described in this chapter were aimed at incorporating 15-HETE-PE into human monocytes in 
order to investigate their effect on cytokine generation (Morgan et al, 2009). The addition of 
15-HETE-PE in methanol was the most effective method for incorporation into monocytes, 
and concentrations of 50 and 100 pM 15-HETE-PE resulted in the highest percentage uptake. 
1.2 and 1.45 pg of 15-HETE-PE (per one million monocytes) was cell associated following 
incubation with 50 and 100 pM 15-HETE-PE respectively (Figure 7.9A). In comparison, 2.5 
ng of 15-HETE-PE is generated endogenously per one million monocytes (Figure 4.8). 
Incubating cells with lipid concentrations of 100 pM may not seem physiological, however, 
only a small percentage of 15-HETE-PE becomes cell-associated (6.2% for 50 pM). While 
levels of incorporation are low, depending on the location of lipid uptake, the local membrane 
concentration of 15-HETE-PE may be high. In Chapter 4, 15-H(p)ETE-PEs synthesised by 
15-LOX were shown remain within monocytes, thus following local generation, they may 
also be present in high levels. In Chapter 5, the incorporation of three radioactive compounds 
into monocytes was compared - ethanolamine, AA and SAPE. The results showed that the 
smallest compound, ethanolamine was the one most successfully incorporated. Therefore, so 
little incorporation of 15-HETE-PE may be due to its structure and amphipathic nature. 
Numerous research groups investigating the biological function of phospholipids are using 
concentrations in the high pM range for their experiments, some of which use a mixture of 
oxidised phospholipids (Asai et al, 2009, von Schlieffen et al, 2009, Treede et al, 2009, 
Ferrante & Ferrante, 2005). In these studies, the addition of high concentrations was required 
to cause an effect. Furthermore, preliminary experiments for this chapter involved incubating
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human monocytes with nM concentrations of 15-HETE-PE and SAPE, but neither lipid 
affected the generation of LPS stimulated cytokines (data not shown). The results indicated 
that the lipids were not taken-up sufficiently by cells to exert an effect. Therefore, as so little 
is actually incorporated, incubating cells with high concentrations of lipid is required to 
ensure biological effect. However, as the percentage of incorporation was less following 
incubation with 100 pM than that achieved with 50 pM, there may be an upper limit for lipid 
incorporation. In addition, 100 pM was the highest concentration investigated as increasing 
the concentration further would risk cell lysis. The greatest amount of lipid incorporation 
took place within the first hour and did not increase significantly at following time-points. 
The most suitable method for introducing lipids to human monocytes, was successfully 
identified and experiments also established the amount of cell-associated 15-HETE-PE at 
each of the investigated time-points and concentrations.
The next aim was to assess the effect of 15-HETE-PE on cytokine generation. 15-HETE-PE 
treatment of un-stimulated monocytes resulted in down-regulation of G-CSF, IL-1 (3, IL-6, IL- 
8 and MCP-1. Furthermore, release of G-CSF, IL-1 p, IL-6 and TNF-a was dose-dependently 
reduced by 15-HETE-PE. These cytokines are considered to be pro-inflammatory and are 
involved in wound repair. In particular, IL-6, TNF-a and IL-1 p are up-regulated during the 
acute-phase response and are key elements in early healing events (Singer & Clark, 1999, 
Janeway et al, 2005). While wound repair requires the initial presence of these cytokines, 
prolonged presence of IL-1 p, TNF-a and IL-6 can have detrimental effects on tissue (Mast & 
Schultz, 1996, Howells GL, 1995). For example, their elevation is reported in chronic
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conditions such as atherosclerosis and rheumatoid arthritis (Touitou & Kone-Paut, 2008, 
Ishihara & Hirano, 2002, Kleeman et al, 2008, Kirii et al, 2003, Kamari et al, 2007, Bode et 
al, 1999, Ahmed et al, 2000, Niemand et al, 2003, Tamuzzer & Schultz, 1996, Wallace & 
Stacey, 1998). G-CSF is foremost a growth factor, produced by endothelial cells and 
macrophages. It is suspected to play a key role in regulating the number and activity of 
circulating neutrophils during an inflammatory response (Liesechke et al, 1994, Bronchud et 
al, 1988, Metcalf D, 2008, Morstyn et al 1988). G-CSF has also been linked to the expression 
of TNF-a and IL-ip, in a process known as the colony-stimulating factor (CSF)- network 
(Hamilton JA, 2008, Campbell et al, 1991, Leizer et al, 1990). Up-regulation of these 
cytokines by LPS in our samples is consistent with their pro-inflammatory functions. The 
down-regulatory effect of 15-HETE-PE on this small selection of cytokines supports an anti­
inflammatory role for 15-LOX in human monocytes, consistent with its anti-atherosclerotic 
effect in rabbits (Serhan et al, 2003). Products of 12/15-LOX oxidised at the C-12 position of 
AA are frequently shown to be pro-inflammatory in mice, while products oxidised at C-15 
are often anti-inflammatory (Sasson & Eckel, 2006, Shen et al, 1996, Smith et al, 1993, 
Takata et al, 1994a). Additional evidence to support this includes the down-regulation of LPS 
stimulated TNF-a following the addition of 15-HpETE to mono mac 6 cells (Ferrante et al, 
1997, Ferrante & Ferrante, 2005). Furthermore, the treatment of cultured monocytes and a 
J774A.1 cell line with 12-HETE, resulted in the increased expression of IL-6 and TNF-a 
mRNA, a pro-inflammatoiy effect (Wen et al, 2007). Importantly, reduced generation of G- 
CSF, IL-ip, 11-6 and TNF-a will reduce the number of neutrophils and pro-inflammatory 
signals present at an inflammatory site. This may be significant in chronic conditions such as
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atherosclerosis and rheumatoid arthritis, where an original beneficial inflammatory response 
becomes harmful over time and attenuates any damage undertaken by cells.
Significantly, the effect of cytokine generation following LPS stimulation is specific to 15- 
HETE-PE and not its un-oxidised precursor SAPE, indicating that the action of 12/15-LOX is 
required. Several articles have recently been published regarding LPS-stimulated cytokines 
and the effect of oxidised phospholipids on their generation, in particular oxidised PC. The 
incubation of human umbilical vein endothelial cells with air-oxidised PC, PE, PG, PS and 
PA phospholipids, have been shown to reduce expression of E-selectin (von Schlieffen et al, 
2009). Multiple oxidised-PC lipids (1-palm itoy 1-2-arachidonoyl-.v«-glycero-3-
phosphocholine (OxPAPC), l-palmitoyl-2-azelaoyl-s,w-glycero-3-phosphocholine (PAzPC), 
1 -palmitoyl-2-glutaroyl-5«-glycero-3-phosphocholine (PGPC), l-Palmitoyl-2-(5,6-epoxy
isoprostane E2)-.v«-glycero-3-phosphocholine (PEIPC), l-Palmitoyl-2-(5- oxovaleroyl)-s«- 
glycero-3-phosphocholine (POVPC)), and other oxidised phospholipids (oxidised 1- 
palmitoyl-2-arachidonoyl-s«-glycero-3-phosphoglycerol (OxPAPG), oxidised l-palmitoyl-2- 
arachidonoyl-sw-glycero-3-phosphate (OxPAPA), oxidised 1 -palmitoyl-2-arachidonoyl-vrc- 
glycero-3-phosphoserine (OxPAPS), and oxidised l-palmitoyl-2-arachidonoyl-sw-glycero-3- 
phosphoethanolamine (OxPAPE)) reduce LPS-stimulated TNF-a, IL-1 a and IL-(3 (von 
Schlieffen et al, 2009, Erridge et al, 2008). This is consistent with results reported in this 
chapter. The inhibition of LPS signalling by oxidised phospholipids has recently been 
reviewed by C. Erridge (2009), who describes at what stage oxidised phospholipids are likely 
to exert their effect (Figure 7.19). Oxidised phospholipids may block LPS signalling by (i) 
inhibiting the binding of LPS to LPS binding protein (LBP), (ii) blocking the association of 
LBP to membrane bound CD-14 (mCD-14) or, (iii) following the association of LBP to
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Figure 7.19 Locations where LPS signaling may be inhibited by oxidised 
phospholipids. Oxidised phospholipids inhibit the binding of LPS to LBP (i), 
mCD14 (ii), and MD2 (iii), preventing signaling via TLR4. Intracellular signalling 
is unaffected (reproduced from Erridge, C. 2009, (12/11/2010) with permission).
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soluble CD-14 (sCD-14), its association to the MD2 subunit of TLR4 can be blocked 
(Erridge et al, 2007, Erridge et al, 2008, Walton et al, 2003). Although mechanisms for 
HETE-PE inhibition of cytokine generation have not yet been investigated, they may include 
some of these. It is also important to note, as generation of particular cytokines was seen in 
the absence of LPS stimulation there is likely to be an additional, if not an alternative 
pathway, by which 15-HETE-PE may exert its effect.
The results have shown that IL-10 generation is also dose-dependently inhibited by 15- 
HETE-PE, but the response was non-specific as the un-oxidised lipid was also diminished. 
The lack of effect on IL-8 and RANTES generation and the reduction in MCP-1 following 
LPS-activation is inconsistent with reported literature. Not only has LPS been shown to 
stimulate the generation of these cytokines in human monocytes, LPS stimulated IL-8 
generation is reduced following the addition of oxidised-PAPC (Sica et al, 1999, Erridge et 
al, 2007). These inconsistencies may have been due to sample degradation following multiple 
episodes of freeze-thawing.
In order to gain a broader view of events that are affected by 15-HETE-PE, a larger range of 
cytokines require analysis. A method suitable for this purpose is a FACS based technique 
known as luminex that allows the simultaneous analysis of approximately 30 cytokines. 
12/15-LOX regulates additional cytokines to those reported in this results chapter, for 
example, 12/15-LOX up-regulates a subunit of IL-12, IL-12p40 (Middleton et al, 2005). But 
it is unknown whether 15-HETE-PEs are involved in this process. 12/15-LOX is critical for 
the production of IL-12 in LPS stimulated murine macrophages, and stimulation of IL-12p40
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by LPS is defective in 12/15-LOX'' mice (Zhao et al, 2002, Middleton et al, 2005). 
Furthermore, peritoneal macrophages from 12/15-LOX"/_ mice show altered expression of 
several cytokines. For example, they generate less CCL5/RANTES but more IL-1, GM-CSF, 
IL-3 and IL-17 in comparison to WT cells (Dioszeghy et al, 2008). In addition, 12/15-LOX' ' 
macrophages stimulated with SES generate more GM-CSF, but less IL-12p40, IL-12p70 and 
RANTES (Dioszeghy et al, 2008). These studies and results in this thesis support a role for 
12/15-LOX in the regulation of multiple cytokines. Future work could include comparing the 
effect of 15- and 12-HETE-PE on these cytokines in human monocytes and murine 
macrophages. However, currently, 18:0a/12-HETE-PE is only available within an isomer 
mixture of HETE-PEs, as discussed in Chapters 3 and 6. Carrying out studies investigating 
the addition of 15- and 12-HETE-PE to the same cell model may show whether they exert 
different effects. This may define more clearly the pro- or anti- inflammatory role of 12/15- 
LOX in humans and mice.
The data from human peritoneal lavage samples suggest that 15-HETE-PEs may be generated 
in response to immune challenges from particular gram-positive bacteria. However, each 
sample that tested positive for bacteria showed very different concentrations of 15-HETE- 
PEs. The number of patient samples must be significantly increased to validate this data; such 
small numbers of samples make it difficult to draw any other conclusions. There are several 
drawbacks in the analysis of this data, such as the way it was analysed and how the results 
have been expressed. In particular, levels are expressed in nmol/per total lavage, but 
normalising according to the number of macrophages would be considered more correct 
(Figure 7.18). Where possible, FACS analysis was carried out on samples to determine the
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number of macrophages, but they varied vastly between samples. Also, only two control 
samples could be analysed by FACS and both showed very different results. Due to this, the 
data expressed this way was skewed with no correlation whatsoever. The data has therefore 
been presented in a way in which one conclusion at least may be drawn, that 15-HETE-PEs 
were raised in response to some gram-positive bacteria, in comparison to die control samples.
These samples were from patients with underlying health conditions rather than healthy 
individuals, and for the patients with identified bacterial infections, it is not known at what 
stage of the bacterial infection they were at when the lavage was carried out. In addition, it 
cannot be certain that the ‘stable control patients’ and patients that tested negative for 
bacterial infections had any other underlying infections. For example, 15-HETE-PEs were 
raised in two of the samples that tested negative for screened bacteria, but due to what? 
Investigating the generation of 12-HETE-PE in response to various gram-positive and 
negative bacteria using mouse models may show whether different bacteria cause a different 
profile generation of 12-HETE-PE.
In summary, a method was described for inducing low level incorporation of 15-HETE-PE 
into human monocytes. The effect of 15-HETE-PE on cytokine generation was then 
investigated. Generated IL-lp, IL-6, TNF-a and G-CSF were down-regulated following the 
addition of 15-HETE-PE, suggesting that 12/15-LOX products may have anti-inflammatory 
properties in human monocytes.
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CHAPTER 8
ULTRA-STRUCTURAL ANALYSIS AND PHOSPHOLIPID PROFILING OF 
PERITONEAL MACROPHAGES FROM WT AND 12/15-LOX'7' MICE
8.1 Introduction
Phospholipids are major constituents of membrane structures and changes in their 
composition may affect cellular/organelle formation as well as their function. 12/15-LOX 
may play a role in membrane function as macrophages from 12/15-LOX' ' mice are unable to 
carry out phagocytosis as efficiently as WT macrophages (Miller et al, 2001). This may be 
due to alterations in actin phosphorylation and polymerisation, which ultimately alters the re­
organisation of the cytoskeleton (Kang et al, 1999, Rice et al, 1998, Tang & Honn, 1997).
In Chapter 6, 12/15-LOX was shown to be involved in altering the phospholipid membrane 
composition by generating oxidised PEs which are externalised. Changing the lipid profile of 
membranes may alter their physical properties and could therefore affect cellular processes 
that require re-organisation of the membrane, such as migration and phagocytosis, events that 
have previously been linked to 12/15-LOX (Miller et al, 2001 & 2003, Kang et al, 1999, Rice 
et al, 1998, Tang & Honn, 1997). In one study, cells devoid of 12/15-LOX had increased 
cellular deposition of cholesterol esters, which were alternatively degraded in cells where 
12/15-LOX was present (Belkner et al, 2005). 15-LOX 1 has been linked to the oxidation of 
cholesteryl arachidonate, which could be a method of metabolising cholesterol esters 
(Belkner et al, 1991). Importantly, an excess of lipids in cells may have implications on 
cellular membrane composition and structure. Differences in phospholipid levels between 
WT and 12/15-LOX'7' macrophages have not been investigated, but this could be done using 
MS. Furthermore, altered phospholipid composition may cause ultra-structural differences,
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which could be observed by electron microscopy (EM). EM allows the visualisation of entire 
cell structures as well as the organelles, all of which are defined by phospholipid membranes.
8.1.1 Aims
MS was used to assess any differences in phospholipid profile between WT and 12/15-LOX'7' 
macrophages, and whether they could account for any physiological differences seen during 
EM analysis.
• To determine if there were ultra-structural differences between peritoneal 
macrophages from WT and 12/15-LOX'7" mice.
• To characterise the phospholipid and cholesterol ester profiles of peritoneal 
macrophages from WT and 12/15-LOX'7' mice.
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8.2 Results
8.2.1 Peritoneal macrophages from 12/15-LOX7‘ mice show ultra-structural abnormalities 
consistent with a lysosomal storage disease.
To compare the ultra-structure of WT and 12/15-LOX"7' peritoneal macrophages, lavages 
from naive mice were pooled, pelleted and prepared for analysis by transmission EM (as 
described in section 2.2.12). The general structure of macrophage cell populations from three 
separate pooled preparations is shown in Figures 8.1 to 8.3. Figure 8.1 shows whole 
macrophages from WT mice. Highlighted by black arrows are healthy-looking mitochondria, 
defined by their small, compact size and defined cristae. In contrast, mitochondria from 
12/15-LOX"7" macrophages appear swollen and granular (Figure 8.2). 12/15-LOX"7" 
macrophages also contain a large number of vacuoles (yellow arrows) and suspected 
lysosomal storage bodies that appear as dark inclusions (red arrows); some of these 
inclusions have double membranes which are an indication of autophagosomes (blue arrows). 
Vacuoles and suspected lysosomal storage bodies can also be seen in WT macrophages but in 
fewer numbers. The same structures are seen in enlarged pictures of WT and 12/15-LOX'7" 
macrophages (Figure 8.3). Structural analysis of 12/15-LOX"7" macrophages suggest that their 
physiology is consistent with cells showing symptoms of lysosomal storage disease (LSD). 
The lack of visual ‘swirls’ which are usually associated with such disorders, indicate that this 
may be a secondary condition, rather than a primary LSD.
8.2.2 Statistical analysis suggests that glycerophospholipidprofiles ofW T and 12/15-LOX ' 
macrophages may account for their structural differences.
In order to determine whether the structural differences seen between WT and 12/15-LOX7
macrophages could be due to altered phospholipid composition, macrophages were isolated
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Figure 8.1 EM analysis of WT peritoneal macrophages. Peritoneal lavage samples 
from WT mice were fixed and prepared for EM analysis. Sections were analysed by TEM 
at x10,000 magnification. Arrows indicate areas of particular interest, including healthy 
mitochondria (black), and few lysosomal storage bodies (red) and vacuoles (yellow).
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Figure 8.2 Analysis of 12/15-LOX 7' peritoneal macrophages suggests the presence of LSD.
Peritoneal lavage samples from 12/15-LOX'7' mice were fixed and prepared for EM analysis. 
Sections were analysed by TEM at x10,000 magnification. Arrows indicate areas of particular 
interest, including abnormal mitochondria (black), and numerous autophagosomes (blue), 
lysosomal storage bodies (red) and vacuoles (yellow).
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12/15-LOX-'-
Figure 8.3 Close inspection of macrophages suggest the presence of LSD in 12/15-LOX'7’ 
mice. Peritoneal lavage samples from WT and 12/15-LOX’7" mice were fixed and prepared for 
EM analysis. Sections were analysed by TEM at x20,000 magnification. Arrows indicate areas 
of particular interest, including healthy mitochondria (in WT) (black), abnormal mitochondria 
(in 12/15-LOX'7') (green), and numerous autophagosomes (blue), lysosomal storage bodies 
(red) and vacuoles (yellow). 243
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from peritoneal lavage samples by adhesion followed by lipid extraction. Samples were 
analysed by LC/MS/MS for many phospholipids commonly found in membranes, including 
PE, PC, PI, PG, PA and PS. Very few of the analysed phospholipids showed an individual 
statistical difference between WT and 12/15-LOX'7' (Figures 8.4 to 8.9). For the PE, PS, PG 
and PI phospholipids that were statistically different following T-test analysis (P= <0.05), the 
highest levels were seen in 12/15-LOX'7' macrophages. Conversely, individual PC 
phospholipids that showed a statistical difference were all greater in WT macrophages. 
However, one-way ANOVA analysis with a Tukey post hoc test to compare all pairs of 
phospholipid data sets from WT and 12/15-LOX*7" phospholipids showed that combined 
levels of detected PE, PS and PG phospholipids were significantly higher in 12/15-LOX'7' 
macrophages in comparison to macrophages from WT mice (P=<0.05). Conversely, analysis 
by one-way ANOVA with a Tukey post hoc test showed that combined levels of PC 
phospholipids were significantly higher in WT macrophages (P=<0.05). The results suggest 
that different glycerophospholipid profiles may contribute to the ultra-structural differences 
between WT and 12/15-LOX'7' macrophages.
8.2.3 Combined levels o f cholesterol esters are higher in 12/15-LOX^ peritoneal 
macrophages.
In addition to differences in glycerophospholipid profiles of WT and 12/15-LOX'7' 
macrophages, alternative lipids, such as cholesterol esters, may also be involved in the 
structural abnormalities. Importantly, 15-LOX is reported to oxidise cholesteryl arachidonate, 
and in the absence of 12/15-LOX, there is increased cellular deposition of cholesterol esters 
(Belkner et al, 2005). Therefore profiles of cholesterol esters were investigated in WT and 
12/15-LOX"7' macrophages. Samples of macrophages isolated by adhesion from WT and
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Figure 8.4 Differences between the PE phospholipid profiles of WT and 
12/15-LOX'7- macrophages are significant following ANOVA analysis.
Peritoneal macrophages from WT and 12/15-LOX'7- mice were isolated by 
adhesion prior to lipid extraction. PE phospholipids were analysed by LC/MS/MS 
(n=8, mean ± S.E.). * Students t-test, p<0.05. The overall difference in PE 
phospholipids between WT and 12/15-LOX data sets is significant following 
analysis by one-way ANOVA with a Tukey post hoc test, p<0.05.
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Figure 8.5 Differences between the PC phospholipid profiles of WT and 12/15-LOXA 
macrophages are significant following ANOVA analysis. Peritoneal macrophages from 
WT and 12/15-LOX‘/_ mice were isolated by adhesion prior to lipid extraction. PC 
phospholipids were analysed by LC/MS/MS (n=8, mean ± S.E.). ^Students t-test, p<0.05. 
The overall difference in PC phospholipids between WT and 12/15-LOX data sets is 
significant following analysis by one-way ANOVA with a Tukey post hoc test, p<0.05.
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Figure 8.6 Differences between the PS phospholipid profiles of WT and 
12/15-LOX7' macrophages are significant following ANOVA analysis.
Peritoneal macrophages from WT and 12/15-LOX"7" mice were isolated by 
adhesion prior to lipid extraction. PS phospholipids were analysed by direct 
injection MS/MS (n=8, mean ± S.E.). *Students t-test, p<0.05. The overall 
difference in PS phospholipids between WT and 12/15-LOX data sets is 
significant following analysis by one-way ANOVA with a Tukey post hoc test, 
p<0.05.
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Figure 8.7 There are few significant differences between the PI phospholipid 
profiles of WT and 12/15-LOX 7' macrophages. Peritoneal macrophages from 
WT and 12/15-LOX 7'm ice were isolated by adhesion prior to lipid extraction. PI 
phospholipids were analysed by LC/MS/MS (n=8, mean ± S.E.). *Students t-test, 
p<0.05.
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Figure 8.8 Differences between the PG phospholipid profiles of WT and 
12/15-LOX7- macrophages are significant following ANOVA analysis.
Peritoneal macrophages from WT and 12/15-LOX'7' mice were isolated by 
adhesion prior to lipid extraction. PG phospholipids were analysed by LC/MS/MS 
(n=8, mean ± S.E.). * Students T-Test, p<0.05. The overall difference in PG 
phospholipids between WT and 12/15-LOX data sets is significant following 
analysis by one-way ANOVA with a Tukey post hoc test, p<0.05.
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Figure 8.9 There are few significant differences between the PA phospholipid 
profiles of WT and 12/15-LOX_/‘ macrophages. Peritoneal macrophages from 
WT and 12/15-LOX'7" mice were isolated by adhesion prior to lipid extraction. PA 
phospholipids were analysed by LC/MS/MS (n=8, mean ± S.E.).
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12/15-LOX'7' mice were analysed by LC/MS/MS for cholesterol esters. In 12/15-LOX 7' 
macrophages there were small increases in cholesterol esters, when the levels of 
phospholipids were combined the increases were significant in comparison to levels detected 
in WT, following analysis by a one-way ANOVA with a Tukey post hoc test (p=<0.05). 
Therefore, these differences may also contribute to the ultra-structural abnormalities seen in 
12/15-LOX'7' macrophages (Figure 8.10).
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Figure 8.10 Differences between the cholesterol ester profiles of WT and 12/15- 
LOX'A macrophages are significant following ANOVA analysis. Peritoneal 
macrophages from WT and 12/15-LOX"7' mice were isolated by adhesion prior to 
lipid extraction. Cholesterol esters were analysed by LC/MS/MS (n=8, mean ± S.E.). 
The overall difference in cholesterol esters between WT and 12/15-LOX data sets is 
significant following analysis by one-way ANOVA with a Tukey post hoc test, 
p<0.05.
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8.3 Discussion
To investigate structural differences between WT and 12/15-LOX7 macrophages, murine 
peritoneal samples were analysed by EM. Multiple differences were identified between them, 
including abnormal mitochondria, multiple lysosomal storage bodies and suspected 
autophagosomes, which are all consistent with LSDs. Lysosomes, are small vesicular 
organelles, their primary function being to merge with late endosomes, to absorb and re- 
disperse their content (Mullock et al, 1998, Bright et al, 2007, Kiselyov & Muallem, 2007). 
The process of endosomal degradation is carried out by numerous lipid and protein 
hydrolases. Mutations in these enzymes result in a build-up of undigested proteins, lipids and 
sugars that can be seen as dark inclusions during EM analysis, known as lysosomal storage 
bodies (Kiselyov & Muellem, 2007, Ponder & Haskins, 2007). Numerous dark inclusions 
were seen in 12/15-LOX'7' macrophages that are likely to be lysosomal storage bodies.
Lysosomes play an important role in autophagy, which is defined as “a cells’ digestion of its 
own organelles and cytoplasmic content” (Meijer & Codogno, 2004, Cuervo et al, 2005). 
This process involves the formation of autophagic vesicles, which encapsulate organelles 
destined for destruction (Figure 8.11) (Kiselyov & Muellem, 2007). Autophagy is required 
for the rapid clearance of oxidised proteins and organelles, and is thought to mediate a 
specialised form of cell death that is distinct from necrosis and apoptosis (Sherz-Shovsal & 
Elazar, 2007, Gozuacik & Kimchi, 2004). Both lysosomes and autophagy are important 
regulators of mitochondrial health by mediating mitochondrial turnover. The mitochondria 
seen in 12/15-LOX 7' macrophages appear swollen and granular, consistent with signs that 
they are ‘old’ and damaged, long overdue to undergo autophagy. The phenotype of cells 
showing signs of LSD resembles that of aged cells, abnormally structured mitochondria and 
the presence of lysosomal storage bodies are typical of this condition (Kiselyov & Muellem,
E n d ocy tosis  at the E xocytosis  at th e
p lasm a m em brane ; y  y  p lasm a m em b ra n e
I
C j  Recycling endosome
Early endosome
Late endosome
Autophagic
vacuole
LysosomeGolgi
Figure 8.11. The endocytic pathway, lysosomes and autophagy. Endocytosed material 
enters endocytic vesicles (early endosomes). The material is sorted and if designated for 
destruction, it is transported to late endosomes which fuse with lysosomes for digestion and 
absorption. Autophagy is also driven by lysosomes which fuse with autophagic vacuoles 
(reproduced from Kiselyov & Muallem, 2008, with permission (04/12/2010)).
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2007). There are several common dysfunctions leading to LSDs: 1) Mis-sorting by enzymes 
resulting in secretion of material, rather than their targeted digestion by lysosomes. 2 ) 
Endocytosed material is not broken down due to defective lysosomal enzymes or supporting 
proteins. 3) Hydrolysed products are not effectively secreted from lysosomes. 4) pH 
regulation within lysosomes is defective (Kiselyov & Muallem, 2008).
When autophagy is prevented, mitochondria become damaged, due to the oxidative nature of 
reactions that take place within this organelle. For example, during cellular signalling 
mitochondria are important in buffering Ca2+ concentrations. During these buffering events, 
much of the damage caused to mitochondria is due to reactive oxygen species that are 
generated by components of the oxidative chain (Bruce et al, 2004, Peterson OH, 2004, 
Brookes et al, 2004, Giorgio et al, 2005, Kiselyov & Muellem, 2007). Usually, damaged lipid 
and protein components trigger mitochondrial-dependent cell death, where cells undergo 
fragmentation followed by engulfment by autophagic vacuoles (Brookes et al, 2004, Giorgio 
et al, 2005, Kiselyov & Muellem, 2007). Blocking autophagy leads to an accumulation of 
aged, partially dysfunctional and fragmented mitochondria, making host cells more 
susceptible to mitochondrial-mediated damage (Figure 8.12) (Ravikumar et al, 2004, Boya et 
al, 2005, Settembre et al, 2008, Jennings et al, 2006, Zhao et al, 2003). There is an increased 
number of shortened mitochondria with enlarged christae that lose their ability to function as 
Ca2+ buffers during signalling, thus making cells in cases of LSD more sensitive to the pro- 
apoptotic effects of Ca2+ (Jennings et al, 2006, Kiselyov et al, 2007). A progressive increase 
in autophagic vacuoles is in accordance with disproportionate organelle damage and 
degradation, recognised as ‘autophagic stress’ (Kiselyov et al, 2007).
In 12/15-LOX'7' macrophages, autophagosomes were distinguished as inclusions with double 
membranes. Confirming the identity of autophagosomes needs to be carried using antibodies
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Figure 8.12 Fragmentation of mitochondria in LSDs. A: In normal cells, fragmented 
mitochondrial debris are removed from the cytoplasm by autophagy and are destined for 
degradation by lysosomes. B: In LSD-affected cells, autophagy is suppressed through 
unknown mechanisms; fragmented mitochondria accumulate while the mitochondria that 
remain have altered functional capacities (reproduced from Kiselyov K, 2007, with 
permission (04/12/2010)).
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for monodancylcadaverine, autophageic light chain 3 (LC-3), and lysosome associated 
membrane protein-1 and -2 (LAMP-1 and LAMP-2), followed by analysis by confocal 
microscopy (Kiselyov & Muellem, 2007, Klionsky DJ, 2005, Miedel et al, 2008). Primary 
LSDs are commonly associated with the observation of ‘swirls’ in cells, but these were 
absent in 12/15-LOX7 macrophages (Alroy & Ucci, 2006). The lack o f ‘swirls’ suggests that 
the dark inclusions, identified as storage bodies, are not the primaiy storage compartment for 
this undigested material. To confirm whether these dark inclusions were at one point part of 
the endocytic pathway, cells can be loaded with colloidal gold, which can then be processed 
for analysis by EM (Miedel et al, 2008).
There are many known LSDs, all resulting in the accumulation of undigested material, 
whether they are lipids, proteins or carbohydrates, in vacuole and/or non-vacuole inclusions. 
The identification of storage bodies in the cytoplasm of peripheral blood mononuclear cells 
(PBMCs) and skin biopsies is an invaluable tool for the diagnosis of LSDs (Wisniewski KE, 
1986). In particular, glycerosphingolipids and cholesterol have been shown to accumulate in 
a diverse collection of LSDs (Futerman & Van Meer, 2004). In some disorders, a build up of 
undigested lipids leads to an increase in lipid rafts, disturbing the dynamics of lysosomal 
membranes, in particular, their ability to bind with autophagosomes (Sobo et al, 2007). This 
is of interest as 12/15-LOX is an enzyme that oxidises lipid membranes, and therefore its 
absence may lead to the accumulation of undigested products. A lipid LSD is indicated by the 
presence of swirls, however, they were not observed in macrophages from 12/15-LOX 7' 
mice, this and the presence of vacuoles and inclusions indicate that it may be a protein 
storage disorder.
To speculate the cause of this LSD I can extrapolate from the knowledge gained during the 
experiments described in these chapters, as well as information from published articles. In
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Chapter 6 , it was shown that in the absence of 12/15-LOX there are no 12-HETE-PE 
products. If these lipids are involved in events downstream of their synthesis, then their 
absence will affect other cellular processes. In addition, in Chapter 5 it was demonstrated that 
15-HETE-PEs may form Schiff bases or Michael adducts with proteins. It is possible that this 
process is required for the removal of particular protein/peptides. This could account for the 
presence of storage bodies in 12/15-LOX'7' macrophages. However, as the combined levels of 
cholesterol esters, PE, PS and PG phospholipids were raised in 12/15-LOX'7' macrophages, 
the storage bodies may be due to a lipid excess. Identification of the contents within the 
storage bodies may indicate the type of LSD present.
A growing number of reports show that extemalisation of oxidised phospholipids, such as 12- 
HETE-PEs in murine macrophages (as described in Chapter 6 ), is required as a signal for the 
phagocytosis of apoptotic cells (Shiratsuchi et al, 1998, Yao et al, 2009). 15-LOX can also 
oxidise organellar preparations of mitochondria, rough and smooth ER, golgi and 
peroxisomes in-vitro (Van Leyen et al, 1998). Thus, oxidation of organelle membranes may 
also be required to signal their destruction or recycling via pathways such as autophagy. 
12/15-LOX is generally considered to be a soluble cytosolic protein, however, when it 
integrates into membrane lipids it takes on properties of an integral membrane protein 
(Vijayvergiya et al, 2004). During this, 12/15-LOX produces pore-like structures in the 
membranes that can be seen by EM (Vijayvergiya et al, 2004). Following the integration of 
12/15-LOX, membranes become permeable and the lumenal contents are released. 
Significantly, incubation of 15-LOX with AA containing lipid liposomes also leads to vesicle 
permeablisation (van Leyen et al, 1998, Maccarrone et al, 2001b, Walther et al, 2004, 
Vijayvergiya et al, 2004). However, pore like structures were not seen in WT or 12/15-LOX'7' 
cells, but 12/15-LOX may still be involved in autophagy as a previous study has shown that
15-LOX inhibitors retard the breakdown of reticulocyte mitochondria (Grullich et al, 2001). 
Also, over-expression of 15-LOX leads to the collapse of mitochondrial pH gradient 
(Vijayvergiya et al, 2004). Importantly, 15-LOX has been linked to the degradation of 
mitochondria in maturing reticulocytes and in differentiating lens fibres (Schewe et al, 1975, 
Schewe et al, 1977, Bassnett & Beebe, 1992, Basnett & Mataic, 1997, Dahm et al, 1997). In 
addition, 15-LOX may also be involved in the degradation of peroxisomes, which is also 
suggested to occur by autophagy (Yokota et al, 2001). There may be a relationship between 
LOX and mitochondrial function in particular cells, but as 12/15-LOX'7' mice appear normal 
and the enzyme is only expressed in a small subset of leukocytes, it is unlikely to play a 
major role in mitochondrial regulation. In support of this, it is important to note that both 
abnormal and healthy mitochondria were present in 12/15-LOX'7' macrophages. If 12/15- 
LOX is involved in mitochondrial autophagy, possibly in the fragmentation process prior to 
its incorporation into endosomes, it may account for the aged and deformed state of some 
mitochondria in 12/15-LOX'7'macrophages.
Cells from many distinct LSDs have very similar degenerative phenotypes, suggesting that 
regardless of the underlying genetic cause of the disorder, they all share common downstream 
mechanisms (Kiselyov et al, 2007). A frequent observation in these disorders is the poor 
condition of particular tissues, including the spleen, liver and thyroid (Beltroy et al, 2005). In 
a study carried out by colleagues of the O’Donnell group (Cardiff, UK), WT and 12/15-LOX 
7' mice were sacrificed at 30 weeks, and particular organs, including the liver and spleen were 
extracted and weighed. No significant difference was seen on weight comparisons of these 
organs and it is yet to be seen whether they differ in overall phospholipid content (not 
shown). Muscle and adipose tissue samples were also taken for EM and histological analysis.
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The results from this study may support the aforementioned conclusion that the disorder in 
12/15-LOX"7' macrophages is indicative of a LSD.
Lipid profiling of 12/15-LOX"7" macrophages concluded that the combined levels of PE, PS 
and PG phospholipids and cholesterol esters were higher, while combined levels of PC were 
lower, in comparison to levels in WT macrophages. Therefore, an excess of cholesterol esters 
and/or PE, PS and PG phospholipids may account for the undigested material in lysosomal 
storage bodies. Alternatively, if 12/15-LOX products are confirmed as forming Schiff base 
and/or Michael adducts with proteins or peptides in WT cells, then it may be investigated as 
to whether the same proteins/peptides are the stored material in 12/15-LOX"7' macrophages. 
Previous studies have reported 12/15-LOX"7" macrophages show defective migration and 
phagocytosis of apoptotic thymocytes (Miller et al, 2001 & 2003). As stated above, combined 
levels of PEs and PSs, which are on the inside of the plasma membrane, were increased in 
12/15-LOX"7' macrophages, while levels of PCs, which are on the outside, were decreased 
(Figures 8.4-8.6). The phospholipid composition of membranes is integral to their function, 
therefore, these changes may contribute to the altered capability of 12/15-LOX"7" 
macrophages to migrate and carry out phagocytosis.
To conclude, this chapter has described the possible identification of LSDs in 12/15-LOX"7" 
mice using EM analysis methods. Further investigations will clarify the mechanisms by 
which this condition comes about, taking us a step nearer to understanding the primary role of 
12/15-LOX in macrophages.
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CHAPTER 9
GENERAL DISCUSSION
The studies described herein have investigated the metabolism and biological function of 
particular LOX products, 12-H(p)ETE-PEs and 15-H(p)ETE-PEs, generated by murine 
macrophages and human monocytes respectively. Furthermore, to accurately quantify 15- 
H(p)ETE-PEs, a new quantification assay was developed, for which, a pure 15-H(p)ETE-PE 
standard was synthesised (Chapter 3). Previous studies have suggested that 12/15-LOX is 
involved in inflammation. Therefore, experiments were carried out to investigate how 12- and 
15-H(p)ETE-PEs may be involved in inflammatory processes. In particular, studies 
investigated the effect of a synthesised 15-H(p)ETE-PE standard on cytokines generated by 
LPS stimulated human monocytes (Chapter 7).
Direct quantification of phospholipids is important for accurate data. Up to now, many 
studies have been carried out using mixtures of ox-PLs, which were quantified either by 
‘calculated estimation’ based on the amount of initial substrate used, or by detecting the total 
amount of peroxide products (Watson et al, 1997, Podrez et al, 1999, Podrez et al, 2002, Von 
Schlieffen et al, 2009, Cherepanova et al, 2009, Walton et al, 2003, Leitinger et al, 1999). 
Alternatively, ox-PLs have been quantified indirectly, such as quantification of fatty acids 
following base hydrolysis (Maskrey et al, 2007, Morgan et al, 2009). These methods of 
phospholipid quantification are not as accurate as directly quantifying individual molecular 
phospholipid species. This issue was addressed in Chapter 3, where a new method was 
developed to directly quantify 15-H(p)ETE-PEs following analysis by LC/MS/MS (Section 
3.2.4). For this assay, a pure 15-H(p)ETE-PE standard was required therefore, it was 
synthesised by adapting a method described by Brash et al (1987) (Scheme 3.1.).
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The new method of quantification accounts for discrepancies in ionisation efficiency between 
the internal standard (DMPE) and the analyte in question, but it cannot account for any 
differences in extraction efficiency. Currently, DMPE is the closest lipid in structure to the 
HETE-PEs that does not exist in human monocytes or murine macrophages. Therefore, it is 
the most suitable internal standard for HETE-PE quantification. Nevertheless, to account for 
variations during extraction, deuterated 12- and 15-HETE-PEs are required as internal 
standards. The structure of deuterated HETE-PEs would be more similar to native HETE-PEs 
and their extraction efficiency would be identical, thus providing greater accuracy during 
quantification. However, due to the complexity of the structures, synthesising deuterated 
HETE-PEs may be challenging.
Similar quantification assays have now been used to quantify alternative HETE-PE isomers 
and phospholipids containing LA and DHA following the synthesis of appropriate standards 
(O’Donnell et al, unpublished). Future directives could include synthesising 15-KETE-PE 
standards to enable the quantification of these lipids in human monocytes and to investigate 
their fimction and metabolism. The adaptation of a method described by Brash et al (1987) to 
synthesise 15-H(p)ETE-PEs, and the subsequent use of these lipids to directly quantify 15- 
H(p)ETE-PEs in biological samples has been an central part of this thesis. Importantly, this 
assay could be used by other research groups to quantify many alternative lipids analysed by 
MS.
Studies report that 15-LOX has anti-inflammatory effects in rabbits, while 12/15-LOX is pro-
inflammatory in mice (Kuhn & Chan, 1997, Feinmark & Comicelli, 1997, Comicelli &
Trivedi, 1999, Cathcart & Folcick, 2000, Witter & Hersberger, 2007). Therefore, experiments
were carried out to investigate the effect of 18i0a/l 5-HETE-PE on human monocytes
(Chapter 7). 18:0a/l 5 -HETE-PE had an anti-inflammatory effect on monocytes by down-
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regulating LPS stimulated TNF-a, IL-ip, IL- 6  and G-CSF generation (Figures 7.11-7.14). As 
monocytes were shown to synthesise 15-KETE-PEs it will also be relevant to investigate 
whether these lipids also down-regulate cytokine generation (Chapter 4). However, a 15- 
KETE-PE standard is not yet available. The addition of 12-HETE-PEs to LPS-stimulated 
murine macrophages may confirm whether 12/15-LOX has a pro- or anti-inflammatory effect 
on cytokines in mice. Furthermore, treating human monocytes with the murine isomer, 
18:0a/12-HETE-PE, may show whether the position of oxidation alters its biological action. 
However, these experiments would require a pure 12-HETE-PE standard, which is also not 
available. Meanwhile, a standard of mixed 18:0a/HETE-PE isomers may be used in 
preliminaiy work investigating the effect of HETE-PEs on induced inflammation in animal 
models. For example, atherosclerotic mouse/rabbit models, or mice infected with live S.Epi. 
or SES, could be treated with either the HETE-PE isomer mix or the 18:0a/l5-HETE-PE, to 
investigate whether their effects are different. The results described herein contribute to 
evidence previously published suggesting that 15-LOX in humans and 12/15-LOX in mice 
may have opposing effects. The future experiments described above will be important in 
determining whether this is the case, and thus, may aid in the development of therapies for 
inflammatory conditions, such as atherosclerosis.
The synthesis of 15-H(p)ETE-PEs in human monocytes was previously described by
Maskrey et al (2007), therefore, the temporal generation of 12-H(p)ETE-PEs was
investigated in murine macrophages (Chapter 6 ). The results described herein show that
products of human monocyte 15-LOX and murine macrophage 12/15-LOX are synthesised
similarly. However, generated 15-HETE-PEs and 12-HETE-PEs may be metabolised
differently. In human monocytes, novel lipids were identified as 15-KETE-PEs, which form
15-HETE-PEs following chemical reduction (Figures 4.13-4.17). 12/15-LOX may generate
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the equivalent murine phospholipids, 12-KETE-PEs, future studies could investigate this. The 
mechanism of 15-KETE-PE synthesis is unknown, they may be formed directly by LOX, 
following metabolism of the peroxide (15-HpETE-PE), or enzymatic conversion of 15- 
HETE-PE (Scheme 4.3). Under anaerobic conditions, soybean LOX is reported to synthesise 
15-KETE in place of 15-HpETE, therefore, 15-LOX could also directly synthesise KETE- 
PEs (de Laclos & Borgeat, 1988). This could be investigated using an isolated rabbit 15- 
LOX. Similar experiments could be carried out to examine whether 12/15-LOX directly 
synthesises 12-KETE-PEs or 12-HpETE-PEs, however, murine 12/15-LOX has not been 
isolated as of yet. Alternative LOX isomers may synthesise KETE-PE lipids, which may have 
important effects in their respective sites of generation, and thus, may also be investigated in 
the future.
Following their synthesis, 15-KETE-PEs are metabolised to unknown products. Several 
pathways of metabolism have been rejected, including conversion of the PE head group to PC 
and elongation of the sn2 fatty acid (HpETE/KETE). To investigate potential products 
formed following 15-KETE-PE synthesis, time-course samples were analysed by precursor 
scans for the snl fatty acids (16:0p, 18:lp, 18:0p and 18:0a) and also, for the PE-head group. 
However, no compounds containing fragments with these m/z were identified (data not 
shown). Therefore, work was carried out to investigate whether products of 15-LOX could 
bind covalently with proteins (Chapter 5). The results suggest that phospholipids oxidised by 
15-LOX may form Michael adducts with proteins. As these covalently bound products 
increase by 3 hours, they could account for the 15-KETE-PE decrease seen in time-course 
samples (Figure 5.6). Thus, the results herein contribute to previous evidence reporting the 
formation of protein-lipid bonds. Future work could include identifying protein targets of 
phospholipids oxidised by 15- and 12/15-LOX. To begin, experiments could investigate
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proteins that have been previously identified in association with ox-PLs (Horkko et al, 1996, 
Horkko et al, 1997, Mattila et al, 2008, Yang ef a/ 2008, Eberard et al, 2009, Wan et al, 
2007, Gugiu et al, 2008, Szapacs et al, 2008).
12/15-LOX may be involved in processes that require alteration of the cell membrane, such 
as migration or phagocytosis. Results in Chapter 6  showed that 12-HETE-PEs were 
preferentially externalised instead of their un-oxidised counterparts (AA-PEs) in activated 
murine macrophages (Figure 6.9). Phospholipid extemalisation may alter membrane fluidity 
therefore allowing processes such as phagocytosis and/or migration to occur. Thus, the results 
described herein explain how the absence of these ox-PLs may lead to the abnormal 
phagocytotic ability of 12/15-LOX'7' macrophages (Miller et al, 2001). Interestingly, in 
particular cell types, phospholipid oxidation is required prior to their extemalisation 
(Mimikjoo et al, 2009, Fadok et al, 2001, Diaz et al, 1999, Shiratsuchi et al, 1998, Tyurina et 
al, 2004a, Jain SK, 1985). Externalised ox-PLs may have an alternative immunological 
function. For example, externalised ox-PCs and ox-cholesterols have been identified as 
ligands for receptors such as CD-36, which may have important consequences in 
atherosclerosis (Greenberg et al, 2006, Podrez et al, 2003). Externalised HETE-PEs could 
also act as ligands for similar receptors. Future work could include investigating whether 15- 
H(p)ETE-PEs and 15-KETE-PEs are externalised in human monocytes, this may clarify 
whether the actions of 15-H(p)ETE-PEs are similar to 12-H(p)ETE-PEs synthesised by 
murine macrophages. 12-H(p)ETE-PEs are externalised in human platelets, thus it may be of 
interest to investigate whether products of alternative LOX isoforms are externalised in their 
respective cell types (Thomas et al, 2010). To support a role for 12/15-LOX in membrane 
function, future work could include migration assays, which may show whether cell 
movement is directly affected by 12/15-LOX, and therefore, 12- and/or 15-H(p)ETE-PEs.
Phospholipid oxidation by 12/15-LOX may be a method of changing the properties of 
cellular membranes, thus, inhibiting oxidation may alter membrane function. 15-LOX is 
reported to oxidise various cell membranes, which include the mitochondria, rough and 
smooth ER, golgi, peroxisomes and plasma membranes (Van Leyen et al, 1998, Schewe et al, 
1975, Schewe et al, 1977, Yokota et al, 2001). Therefore, in the absence of 12/15-LOX, the 
functional properties of multiple organelle membranes, in addition to the plasma membrane, 
may be altered. Ultra-structural analysis of peritoneal macrophages from 12/15-LOX'7' mice 
showed that their macrophages have abnormalities consistent with LSDs, which may be due 
to variations in total cellular lipid content (Chapter 8 ). However, the nature of the ultra- 
structural abnormalities suggests the presence of a secondary protein LSD (Figure 8.2 & 8.3). 
Particular aspects of interest regarding the altered ultra-structure of 12/15-LOX'7' 
macrophages was firstly, the presence of lysosomal storage bodies and secondly, the 
abnormal mitochondria. Further work is required to determine whether the absence of 12/15- 
LOX is responsible for these malformations. In addition, the undigested material within 
lysosomal storage bodies requires identification. If it is identified as protein, then it is 
possible that products of 12/15-LOX act by targeting these proteins for destruction in WT 
macrophages via the formation of Michael adducts. Furthermore, the lysosomal storage 
bodies may have been part of the autophagy system. If this is confirmed, 12/15-LOX may 
then be linked to mitochondrial maintenance and turnover. Therefore, 12/15-LOX may play a 
role in altering the properties of membranes within macrophages, which may be via oxidation 
and extemalisation of phospholipids. The structural abnormalities of 12/15-LOX'7' 
macrophages reported in Chapter 8  have not been seen previously. EM could be used to 
investigate whether the absence of LOX causes structural abnormalities in cells containing 
different isoforms of LOX. In particular, it may be of interest to develop a rabbit 15-LOX'7' as
the enzyme may be more functionally equivalent to human 15-LOX, in comparison to murine 
12/15-LOX.
The generation of HETE-PEs in humans following bacterial infection has not previously been 
investigated. Therefore, as part of a long-term study, lavage samples from patients with 
suspected bacterial infections were analysed for the presence of 15-H(p)ETE-PEs. The results 
suggested that 15-H(p)ETE-PEs may be raised following infection by gram-positive bacteria. 
However, the number of patient samples needs to be increased in order to confirm these 
preliminary results. In addition, lavage samples from patients that are commencing peritoneal 
dialysis as a treatment for renal failure are required, they may provide a better indication of 
15-H(p)ETE-PE levels in patients that are free from infection. Data gathered during this long­
term study may contribute to understanding the role of 15-H(p)ETE-PE in human 
inflammatory conditions. Previous work carried out by our group has shown that 12-HETE- 
PE synthesis is altered following bacterial infection and in OVA lung allergy (Morgan et al, 
2009). Until more data from human studies can be gathered, short term studies involving 
animal models are invaluable. In particular, as rabbit and human leukocyte LOX both oxidise 
AA at C-15, future work could include investigating the effect of 15-H(p)ETE-PEs in rabbits 
with inflammation induced by bacteria.
In the experiments described herein, human monocytes and murine macrophage samples 
were activated using calcium ionophore (A23187). While this agonist is frequently used it is 
not physiological. Experiments using a physiological agonist may more closely simulate 
events that take place in-vivo. Therefore, investigations were carried out attempting to 
activate human monocytes and murine macrophages via their surface IgG and IgE receptors 
(von Bubnoff et al, 2002). However, HETE-PEs were not synthesised consistently (data not
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shown). Multiple experiments showed conflicting results, therefore, there remains no 
physiological agonist for 12/15-LOX in human monocytes and murine macrophages. 
However, finding a physiological agonist will be important for future experiments 
investigating products and the effects of 12/15-LOX.
To conclude, the data described herein has provided a platform to further investigate the 
function of esterified products generated by 15- and 12/15-LOX. Future studies may 
determine if products of 12/15-LOX are involved in inflammatory disorders such as 
atherosclerosis, and whether their effects are pro- or anti-inflammatory. In particular, if 
products of 12/15-LOX have anti-inflammatory effects then future studies may investigate 
the potential therapeutic benefit of 15-H(p)ETE-PEs, and their use as treatments for 
inflammatory conditions.
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